Korea Innovative PHARMACEUTICAL Company

Korea Innovative PHARMACEUTICAL Company

2021

This brochure illustrates a project promoted by Korean pharmaceutical companies and with support from the Korean government, to enter global markets. You’ll meet the Korean pharmaceutical industry as a reliable partner for global collaboration.

Contents

02 Current Status of Korean Pharmaceutical Market

09 Introduction of Korean Innovative Pharmaceutical Company Certification System

11 Information of Korean Innovative Pharmaceutical Company 57 Supplement

Korea Innovative PHARMACEUTICAL Company

2021

This brochure illustrates a project promoted by Korean pharmaceutical companies and with support from the Korean government, to enter global markets. You’ll meet the Korean pharmaceutical industry as a reliable partner for global collaboration.

Curr

ent

Stat

us o

f Ko

rean

P

harm

aceu

tica

l Mar

ket

□ (Market size) Korean pharmaceutical market passed the $20.8 billion mark in 2019. Its growth

has been driven by leading Korean companies, which have been releasing new global drugs

and achieving technology exports.

ㅇ Pharmaceuticals exports have increased at a CAGR of 15.2% for the past five years (2015-2019), fueled

especially by increases in Korean drugs entering into global markets.

<Current status of Korean pharmaceutical market>(unit: million dollar, %)

Category 2015 2016 2017 2018 2019Year-on-year growth rate

CAGR(`15~`19)

Market size 16,992 18,711 19,515 20,995 20,840 Δ0.7 5.2

Production 14,989 16,197 18,006 19,168 19,128 Δ0.2 6.3

Exports 2,946 3,118 4,071 4,671 5,193 11.2 15.2

Imports 4,948 5,633 5,579 6,498 6,905 6.3 6.9

Trade balance Δ2,002 Δ2,514 Δ1,508 Δ1,827 Δ1,712 Δ6.3 Δ3.1

* Source: Press release by the Ministry of Food and Drug Safety (2020)

ㅇ Among the world’s top 100 pharmaceutical companies, 2 korean companies are included.

* ‘19 drug sales and global ranking (Informa Pharma Intelligence Outlook2021, Scrip100): GC Pharma (93th place, $ 1,176

million), Kwang-Dong Pharmaceutical (96th place, $ 1,063 million)

ㅇ The Korean biologics market is valued around $2,229 million (2019), accounting for 10.2% of the entire

pharmaceutical market, which is lower than the international level (29% in 2019).

- Yet it has very high growth potential, with its production and export values rising greatly at a CAGR of 9.4%

and 12.2% respectively, for the last five years (2015-2019).

- Biosimilars in particular are expected to become a next-generation growth engine as 20 of the 27 drugs

approved in Korea were developed by Korean companies.

* With the focus on biopharmaceutical pharmaceutical companies such as Samsung Biologics and Celltrion, the world’s

largest biopharmaceutical production facility is being built and in operation (production capacity of 554K liters, more than

70 companies)

<Current status of Korean biopharmaceutical market>(unit: million dollar, %)

Category 2015 2016 2017 2018 2019Year-on-year growth rate

CAGR(`15~`19)

Market size 1,449 1,577 1,975 2,026 2,229 10.0 11.4

Production 1,520 1,729 2,301 2,372 2,175 Δ8.3 9.4

Exports 809 1,063 1,368 1,559 1,283 Δ17.7 12.2

Imports 738 911 1,042 1,213 1,337 10.2 16.0

Trade balance 71 152 326 346 Δ53 Δ115.5 -

* Source: Press release by the Ministry of Food and Drug Safety (2020)

Current Status of Korean Pharmaceutical Market

2

Current Status of Korean Pharm

aceutical Market

□ (Current status of businesses) 612(95.7%) of 639 pharmaceutical companies in Korea reported

production records for 2019, indicating an average production of 46 items per company.

<Current status of Korean pharmaceutical companies>(unit: number, %)

Category 2015 2016 2017 2018 2019CAGR

('15~'19)

Number of manufacturers 586 635 623 616 639 2.2

Manufacturers with production records 597 599 588 571 612 0.6

Number of items 25,890 26,397 26,293 26,239 28,363 2.3

Drug product 17,907 18,546 19,291 19,539 20,703 3.7

Drug substance 7,983 7,851 7,002 6,700 7,660 Δ1.0

Number of sellers 24,693 25,862 24,951 26,233 26,817 2.1

* Source: Press release by the Ministry of Food and Drug Safety(2020)

□ (Current status of R&D) Striving to enhance competitiveness to the level of advanced countries

by launching new drugs developed in Korea in overseas markets through the continuous

expansion of R&D investments

ㅇ The total R&D investment by the pharmaceutical companies listed in Korea (312 companies) was $2,537 million

in 2020, which accounts for 7.9% of the total sales.

- The R&D investment by the top 10 companies was $1,002 million, which is more than half of the total amount

of R&D investment by all the listed pharmaceutical companies, reaching 9.5% of the total sales.

- The total R&D expenditure of domestic listed innovative pharmaceutical companies (41 companies) accounted

for 52.6% of total listed companies and the proportion of R&D expenses was 11.0%.

<R&D investment of major Korean pharmaceutical companies>(unit: million dollar, %)

Category 2016 2017 2018 2019 2020

R&D investment

Listed companies 1,580 1,980 2,051 2,273 2,537

Top 10 companies 642 896 744 757 1,002

Innovative PharmaceuticalCompany

924 923 1,077 1,112 1,334

Ratio to sales

Listed companies 7.0 7.8 7.3 7.8 7.9

Top 10 companies 10.6 12.3 9.4 8.9 9.5

Innovative PharmaceuticalCompany

10.3 9.4 10.1 10.3 11.0

* Source: Korea Health Industry Development Institute (KHIDI)

3

Curr

ent

Stat

us o

f Ko

rean

P

harm

aceu

tica

l Mar

ket

□ (Current status of new drug development) A total of 32 new drugs were developed as of

September 2021 by these efforts of Korean pharmaceutical companies.

* 1999-2014: 21 new Korean drugs were developed → 2015-2021: 11 new Korean drugs were developed.

<New drugs developed since 2015>

Company Product Efficacy/Effectiveness Approval Date

Crystal Genomics Inc. Acelex Capsule Treatment for osteoarthritis February 5, 2015

DongWha Pharm. Co., Ltd. Zabolante tablet Antimicrobial agent (antibiotics) March 20, 2015

Dong-A ST Co., Ltd.

Sivextro tablet

Antimicrobial agent (antibiotics) April 17, 2015

Sivextro injection

Suganon tablet Antidiabetic drug October 2, 2015

Hanmi Pharmaceutical Co., Ltd. Olita tablet Cancer drug (lung cancer) May 13, 2016

Ildong Pharmaceutical Co., Ltd. Besivo tablet Hepatitis B treatment May 15, 2017

CJ Healthcare K-Cab Tab gastroesophageal reflux disease (GORD) July 5, 2018

Yuhan Corporation Leclaza tablet NSNLC(Non-Small Cell Lung Cancer) January 18, 2021

Celltrion, Inc.Regkirona injection

(CT-P59)COVID-19 February 5, 2021

Hanmi Pharmaceutical Co., Ltd. Rolontis injection Neutropenia March 18, 2021

□ (Overseas market entry) Korean companies are creating high value-added through the

expansion of their global market shares by launching domestically-developed new drugs in

the global market and increasing licensing-out to overseas markets.

ㅇ 16 Korean drugs have obtained approval in the US and EU since 2014, putting sales to developed markets into

high gear.

- SK Biofarm independently proceeded to the third phase of clinical trials and released it to the United States

following new drugs developed in Korea, such as Excopre (‘19), which was approved by the FDA.

4


aceutical Market

<Current status of domestically-developed drugs in terms of approval at home and abroad>

Company Trade NameReference Drug(Manufacturer)

Efficacy/Effectiveness

Approved in Korea

Approved Overseas

EMA FDA

Dong-A ST Co., Ltd.

Sivextro New drug Oxazolidinone antibiotic Apr 17, 2015 Mar 2015 Jun 2014

Daewoong Pharmaceutical Co.

Ltd.

MeropenemMerrem

(AstraZeneca)Carbapenem antibiotic Apr 14, 2010 - Dec 2015

NabotaBotulinum toxin

(Allergan)Glabellar wrinkles Nov 2013 - Jan 2019

Celltrion Inc.

Remsima injection*

Remicade(Johnson & Johnson)

Rheumatoid arthritis(RA),

ulcerative colitis, etc.Jul 20, 2012 Aug 2013 Apr 2016

Truxima*Rituxan(Roche)

RA, chronic lymphocytic leukemia,

non-Hodgkin’s lymphoma, etc.

Nov 16, 2016 Feb 2017 -

Herzuma*Herceptin(Roche)

Breast cancer Jan 2014 Feb 2018 Dec 2018

LinezolidZyvox(Pfizer)

Tuberculosis, Wide range of

antibiotics- - Apr 2019

TEMIXYSZeffix (GSK),

Viread (Gilead)AIDS - - Nov 2018

Samsung Bioepis Co., Ltd.

Benepali (EU)* Eticobo (US)

Etoloce (Korea)

Enbrel(Amgen)

RA, psoriasis, etc. Sep 7, 2015 Jan 2016 Apr 2019

Flixabi (EU)*Renflexis (US)*Remaroche

(Korea)

Remicade(Johnson & Johnson)

RA, ulcerative colitis, etc.

Dec 4, 2015 May 2016 Apr 2017

Imraldi (EU)*Hadlima (US)*

Adalloce (Korea)*

Humira(AbbVie)

RA, Crohn's disease, inflammatory bowel

diseases, etc.Sep 20, 2017 Aug 2017 July 2019

Ontruzant(EU)*Samfenet(Korea)*

Herceptin(Roche)

Breast cancer Nov 9, 2017 Nov 2017 Jan 2019

Avincio(EU)* Avastin((Roche) Anticancer - Aug 2020 -

SK Chemicals AFSTYLA New biologic Antihemophilic drug Jan 2020 Jan 2017 May 2016

SK Biopharmaceuticals

Sunosi New drug Sleep disorder - Jan 2020 Mar 2019

XCOPRI® New drug Epilepsy - - Nov 2019

* Source: Korea Health Industry Development Institute (KHIDI) (The * mark for the trade name indicates biosimilars.)

5

Curr

ent

Stat

us o

f Ko

rean

P

harm

aceu

tica

l Mar

ket

ㅇ Large-scale license agreements with global pharmaceutical companies are accelerating exports of technologies

developed by Korean pharmaceutical companies.

* A total of 17 worth maximum $9,569 million in 2020

<License agreements signed by Korean pharmaceutical companies in 2020>

Contract date

Company ProductExported

toPartner

Contract Value

2020

JanDaewoong

Pharmaceutical Co. Ltd.Fexuprazan

(GERD treatment)Mexico Moksha8 $50 million

AprilLegoChem Biosciences,

Inc.ADC source technology

(ConjuALL)England Iksuda Therapeutics $407 million

MayLegoChem Biosciences,

Inc.LCB73

(anti-ROR1 ADC)England Iksuda Therapeutics $227 million

June

Pharmabcine Inc.Nose neoplasm treatment

(New drug candidate substance)US Wincal Biopharm Private

MecoxcuremedM002-A

(COVID-19 treatment)Europe

Tube Pharmaceuticals GmbH

Private

Alteogen, Inc. ALT-B4 -One of the top 10

global pharmaceutical companies

$3,865 million

Aug

Hanmi Pharmaceutical Co. Ltd.

LAPSGLP/GCG(NASH treatment)

US MSD $870 million

Daewoong Pharmaceutical Co. Ltd.

Fexuprazan(GERD treatment)

Brazil EMS $72.58 million

Yuhan CorporationYH12852

(Functional gastrointestinal disease treatment)

USProcessa

Pharmaceuticals$410.5 million

Sept SCM Lifescience High purity mesenchymal stem cell Russia Pharmimex JSC Private

Oct

OliX PharmaceuticalsOLX301D

(subretinal fibrosis, Wet age-related macular degeneration)

France Thea Open Innovation $197 million

SK BiopharmaceuticalsCenobamate

(Epilepsy treatment)Japan

Ono Pharmaceutical Co., Ltd.

$48.16 million

Voronoi, Inc.VRN07

NSNLC(Non-Small Cell Lung Cancer candidate substance)

US ORIC Pharmaceuticals $621 million

ABLBio, lnc.LCB71/ABL202

(ADC anticancer drug candidate substance)

ChinaCStone

Pharmaceuticals$363.5 million

Nov Isu Abxis Co., Ltd.ISU305

(paroxysmal nocturnal haemoglobinuria treatment)

RussiaJSC Pharmasyntez-

NordPrivate

Dec

Genexine, Inc.GX-P1

(immunosuppressant)US Turret Capital $1,500 million

LegoChem Biosciences, Inc.

LCB67(ADC anticancer drug candidate

substance)US Pyxis Oncology $2,994 million

* Source: IR data of the companies

6


aceutical Market

ㅇ Based on its technological competitiveness and quality drugs, the pharmaceutical industry in Korea has taken

a stride in strengthening its ability to develop innovative drugs in a short period of time, including R&D, clinical

trials and drug manufacturing. Impressive growth made in the last few years suggests that Korea based

pharmaceutical companies are ready to take a leap forward as global players.

□ (Pipeline) Development of innovative medicines and strong pipelines across various

therapeutic areas

ㅇ The local pharmaceutical industry began manufacturing both finished products and drug substances in the

1960s, and developed new processes in the 1980s. Following the early phase of drug development in the late

1980s, Korean pharmaceutical industry began to develop innovative drugs in the 2000s. Since then, Korean

pharmaceutical industry has been successfully developing one of the most innovative and incrementally modified

drugs.

ㅇ Since the introduction of the chemical compound patent system in 1987, the number of innovative drugs

introduced in the country has also increased at a very fast pace. Korea has seen development of innovative

drugs across various therapeutic areas, from “Sunpla Injection”a treatment for stomach cancer developed by SK

Pharmaceuticals in 1999 to “Rolontis injection”a treatment for Neutropenia developed by Hanmi Pharmaceutical

in 2021. So far, Korean pharmaceutical companies have developed therapies in an array of areas including

oncology, antibacterial, gastritis, respiratory infections, duodenal ulcer, diabetic foot ulcer, erectile dysfunction,

hepatitis B and hypertension.

ㅇ Launch of innovative drugs(Total of 32)

7

Curr

ent

Stat

us o

f Ko

rean

P

harm

aceu

tica

l Mar

ket

□ (Clinical Trials) Clinical trials grew dramatically from both qualitative and quantitative

perspectives

ㅇ Already on a clear growth track with its high level of clinical trial capabilities and reliable data, Korea is emerging

as a core clinical trial destination in the pharmaceutical market in Asia. Korea-based 32 major healthcare

organizations, including Seoul National University Hospital, Samsung Seoul Medical Center and Asan Medical

Center, have won global certifications for their clinical study environment helping the country to build a clinical

infrastructure on a global level. With this advanced infrastructure, Korea ranked 6th in the world for global clinical

trial protocol market share in 2020, moving two level up from the 8th at the previous year. Its share in global

clinical trials increased from 3.25% in 2019 to 3.68% in 2020. The number of domestic clinical trials came to 799

in 2020, up nearly 11.9% compared to 714 in 2019.

ㅇ The number of multinational regional clinical trials (MRCTs) conducted by multinational pharmaceutical companies

in Korea has also increased sharply since the country introduced International Conference on Harmonization

Good Clinical Practice (ICH GCP) in 2000. Especially, Pfizer formed a partnership with Korea as part of its global

clinical program in 2008, selecting 4 of its 9 global Core Research Sites (CRSs) in Korea.

ㅇ The platform technologies developed through the ‘Smart Clinical Trial Platform’program are widely adopted by

Korean hospitals and contribute to achieving higher clinical trial efficiency of Korea. Active use of the EMR data in

conducting feasibilities and matching patients with the complex inclusion/exclusion criteria would greatly improve

efficiency together with a more streamlined and transparent clinical trial authorization process by Korean health

authorities.

□ (Manufacturing) High level of competitiveness and ability to generate rich pipelines of

innovative drugs

ㅇ Pharmaceutical companies in Korea have been working to ensure that their drug manufacturing facilities meet

rigorous global standards. To reflect global trends, the guidelines on Good Manufacturing Practices(GMP)

changed from dosage forms to prior approval of individual items in 2008. As the guidelines shifted from

management of dosage forms to that of individual items based on a step-by-step process through 2010, the

quality assurance system for domestically manufactured drugs reached a global level.

ㅇ In addition, Korea has the ability to conduct drug R&D for compounds and commercial technologies, including

organic synthesis, agents and global clinical trials. This ability was gained through development of generics

and incrementally modified drugs. Korea is also a leader in the pharmaceutical biological technology area. With

fruitful results from R&D including development of the world’s first stem cell therapy and xenotransplantation of

pancreatic ducts, Korea is in an advantageous position to be a leader in promising future industries. The level of

therapeutic technologies in cardiac surgery and management, and cervical cancer in Korea is the best among

other OECD countries, according to OECD Health Data 2009.

ㅇ Korea pharmaceutical industry is shifting its focus from the domestic market to the global market, and the world

now pays attention to Korean pharmas as successful partners.

8

Introduction of Korean Innovative Pharmaceutical Company Certification SystemPublic-private Partnership for Development of

Pharmaceutical Industry Contributing to Global Health1

Korea aspiring to transforming itself into one of the top seven pharmaceutical powerhouses

Korea has designated the pharmaceutical industry as one of the future growth engines, In order to foster the industry,

the Korean government has been placing emphasis on enhancing growth potential through far-reaching policy

measures, ranging from technology innovation to promoting market transparency, boosting global competitiveness

of companies, and establishing infrastructure for sustainable development, Moreover, with knowledge and capacity

mustered, the government, industry, medical society, and academic community are devoting themselves to make a

leap forward into global markets. Under the circumstance where the Korean population has been aging rapidly, the

Korean government has keen interest in the pharmaceutical industry, which serves as a foundation for the quality of

life of the public, The government introduced “Accreditation of Innovative Pharmaceutical Company” in 2012, and will

reinforce its efforts to support the industry every year with a view to reinventing the nation into one of the top seven

pharmaceutical titans.

Introduction of Promotion and Support of Innovative Pharmaceutical Company 2

2-1. What Company Can Be an Innovative Pharmaceutical Company?

Special Act on Pharmaceutical Industry Promotion and Support (enacted in March 2011) serves as the legal

foundation to designate innovative pharmaceutical companies verified to possess high R&D capacity for new drug

development and to be globally competitive, Those companies are expected to play a leading role in developing the

domestic pharmaceutical industry into a future growth engine.

In particular, ‘innovative pharmaceutical company’ is the government’s ambitious pharmaceutical industry fostering

policy adopted as a concept that refers to a company that has been recognized as having superior capability in

new drug development as well as overseas expansion based on the ‘Special Act on Fostering and Supporting

the Pharmaceutical Industry’. To scope with the rapid changes in the environment surrounding the pharmaceutical

industry, such as during price cuts and effect of the Korea-US FTA, the Ministry of Health and Welfare aims to

support the ‘innovative pharmaceutical company’ with research, development and overseas advancement capability

as the core of ‘2012 Pharmaceutical Industry Competitiveness Enhancement Plan’, which was arranged together

with the related ministries in January 2012, to foster Specialized Pharma which is specialized in specific medical

conditions, Global Genenric Pharma which does mass production of generics, or Global Major Pharma which is

at the level of advanced multinational corporations, and to lead the advanced pharmaceutical ecosystem led by 3

global corporations. This is a big sketch that government has envisioned.

Above all, ‘innovative pharmaceutical company’ was accepted as a very honorable medal to select the

companies that play a leading role in fostering domestic pharmaceutical industry as future growth engine industry.

Moreover, ‘innovative pharmaceutical company’ will be the scale to read the will of the government to cultivate the

pharmaceutical industry in the future since it is the only carrots proposed by the government, which has consistently

been in whipping, including the introduction of the rebate dual punishment system and implementation of the batch

drug price cut.

Introduction of Korean Innovative Pharmaceutical Company Certification System

9

Intro

duct

ion of

Kor

ean I

nnov

ative

Ph

arma

ceut

ical C

ompa

ny C

ertif

icatio

n Sys

tem

2-2. What are the Criteria for Selecting an Innovative Pharmaceutical Company?

In order to be selected as an innovative pharmaceutical company, it was necessary to have a research and

development investment or facilities of a certain scale or more. Inother words, the R&D expenditure relative to

average gross drug salws in the last 3 years has had to meet the requirements as follows: 1) companies with an

annual sales of more than KRW 100 billion would have a R&D cost of at least 5%, 2) companies with less that KRW

100 biliion would have a R&D cost of more that 7% or an absolute amount of more than KRW 5 billion, and 3) for US

or EU GMP facilities, a R&D cost relative to sales would be at least 3%.

2-3. Accreditation Process

The Accreditation Screening Committee conducted written and verbal evaluations on candidate pharmaceutical

firms which met the requirements (Article 2 of the Enforcement Decree of the Special Act: investment volume over

a certain level), In the evaluations, the committee assessed candidate companies based on specific requirements,

such as R&D performance in the past, company’s capacity, vision and investment plan, ethical business practice,

etc, The results of the evaluations delivered by the screening committee were finalized after the review carried out

by the Committee for Pharmaceutical Industry Promotion and Support, which is chaired by the Minister of Health and

Welfare.

2-4. Composition of Designated Innovative Pharmaceutical Companies

• General pharma firms [32]: 32 leading firms that have marked high scores in terms of R&D investment as well

as researchers, manufacturing facilities, patent and license-out, and overseas market advancing plus ten SMEs

that have built on expertise in specialized areas such as development of incrementally modified drugs

• Bio venture companies [10]: firms with relatively low sales but highly competitive technology and creative

business models

• Multinational pharma firms [3]: one local company of an MNC considered outstanding in terms of R&D investment

(in early clinical trials), local production performance, overseas market advancing, etc.

2-5. List of Companies Certified as Innovative Pharmaceutical Companies [45](June, 2021)

Category Name of Company

General pharma firms [32]

BMI Korea, Boryung Pharm, Bukwang Pharm, Celltrion, Chong Kun Dang Pharm, Dae Hwa Pharm, Daewon Pharm, Daewoong Pharm, Dongkoo Bio&Pharm, Dongkook Pharm, Dongwha Pharm, GC Pharma, Genuonesciences, Handok, Hanlim Pharm, Hanmi Pharm, HK inno.N, Hyundai Pharm, Ildong Pharmaceutical, Isu Abxis, JW Pharm, Korea United Pharm, LG Chem, Pharma Research, Pharmicell, Samyang holdings, Shin Poong Pharm, SK Chemicals, ST Pharm, Taejoon Pharm, Yuhan, Yungjin Pharm

Bio venture companies [10] ABL Bio, Alteogen, BC World Pharm, Corestem, CrystalGenomics, Genexine, Helixmith, Medytox, Olix Pharma, Tego Science

Multinational pharma firms [3] AstraZeneca Korea, Janssen Korea, Korea Otsuka Pharm

10

1) ABL Bio, lnc.

2) Alteogen, Inc.

3) AstraZeneca Korea

4) BCWORLD PHARM. CO., LTD.

5) BMI Korea Co., Ltd.

6) Boryung Pharmaceutical Co., Ltd.

7) Bukwang Pharmaceutical Co., Ltd.

8) Celltrion, Inc.

9) Chong Kun Dang

10) Corestem, Inc.

11) CrystalGenomics, Inc.

12) Daehwa Pharmaceutical Co., Ltd.

13) Daewon Pharm. Co., Ltd.

14) Daewoong Pharmaceutical Co., Ltd.

15) DongKoo Bio & Pharma Co., Ltd.

16) Dongkook Pharmaceutical Co., Ltd.

17) DONGWHA PHARM

18) GC Pharma

19) Genexine, Inc.

20) GENUONE Sciences Inc.

21) HANDOK, Inc.

22) HANLIM PHARM. CO., LTD.

23) Hanmi Pharmaceutical Co., Ltd.

24) Helixmith

25) HK inno.N

26) HYUNDAI Pharm.

27) Ildong Pharmaceutical Co., Ltd.

28) ISU ABXIS Co., Ltd.

29) Janssen Korea Ltd.

30) JW Pharmaceutical

31) Korea Otsuka Pharmaceutical Co., Ltd.

32) KOREA UNITED PHARM. INC.

33) LG Chem, Ltd.

34) Medytox, Inc.

35) OliX Pharmaceuticals, Inc.

36) PharamResearch Products Co., Ltd.

37) Pharmicell Co., Ltd.

38) Samyang Holdings Corporation

39) Shin Poong Pharm. Co., Ltd.

40) SK Chemicals Co., Ltd.

41) ST PHARM Co., Ltd.

42) Taejoon Pharmaceutical Co., Ltd.

43) Tego Science, Inc.

44) Yuhan Corporation

45) Yungjin Pharm Co., Ltd.

Information of Korean Innovative Pharmaceutical Company

ABL Bio is a leader in bispecific antibody therapeutics for immuno-oncology and neurodegenerative diseases. ABL owns a productive set of innovative bsAb platforms and pipelines. It discovered ABL001, the first bsAb to start clinical trials in the country and ABL503, the first bispecific in Korea to start trials in the U.S. ABL also developed ‘Grabody-B,’ a bsAb platform maximizing BBB penetrance and is applicable to various CNS targets, including Parkinson’s disease.

Lead Candidates

Product Use Progress

ABL001(NOV1501) a bispecific antibody therapeutics for solid tumor currently in Phase 1b/2 clinical trials in South Korea

ABL503 a bispecific antibody for solid tumor currently in Phase 1 clinical trial in U.S.

ABL111 a bispecific antibody for pancreatic, gastric cancer currently in Phase 1 clinical trial in U.S.

ABL501 a bispecific antibody for solid tumor expected to begin Phase 1 clinical trial in South Korea

ABL301 a bispecific antibody therapeutics for Parkinson’s disease preclinical stage

R&D Pipeline

www.ablbio.com/en

South Korea’s leading biotech developing bispecific antibody-based innovative thera-peutics for the treatment of cancer and neurological diseases.

CEOSang Hoon Lee

Location2nd Floor, 16 Daewangpangyo-Ro 712 Beon-Gil, Bundang-Gu, Seongnam-Si, Gyeonggi-Do, 13488, South Korea

SpecialtyBispecific Antibody, Immuno-oncology Therapeutics, BBB Shuttle Platform Technology

Tel/Fax/E-mailT. +82-31-8014-7032F. +82-31-8018-9836E. [email protected]

Technology Transfer/LicensingWeonkyoo YouR&D/Head of R&DT. +82-31-8018-9803E. [email protected]

Overseas export/Overseas OfficeBryan KangStrategy&Planning/Head of DepartmentT. +82-31-8018-9825E. [email protected]

etcHee Jun ParkStrategy&Planning/Senior ManagerT. +82-31-8014-7032E. [email protected]

CONTACT US

ABL Bio, lnc.

Investor Relations 2021 │ 1

245.168.25

77.73.70

251.175.40

77.73.74

146.146.146

62.176.54

169.206.5

252.215.145

208.19.26

75.73.74

1.70.129

230.156.161

236.180.183

164.164.164

202.199.201

255.239.213

238.238.238

ABL Bio Pipeline

PROGRAM INDICATION EARLY DISCOVERY

LATE DISCOVERY PRE-CLINICAL PHASE Ⅰ PHASE Ⅱ / Ⅲ

Angiogenesis ABL001 (Anti-VEGF/DLL4 BsAb)

Solid Cancer

Antibody-Drug Conjugate (ADC)

ABL20X Cancer

Immuno-Oncology

(4-1BB)) ABL10X Cancer

(PD-L1) ABL50X Cancer

I/O mAb ABL40X Cancer

Neurology ABL301 (ɑ-Synuclein / IGF1R)

Parkinson’s Disease

12

Info

rmat

ion

of K

orea

n In

nova

tive

Ph

arm

aceu

tica

l Com

pany

www.alteogen.com

“Novel Biologics for Better Life”

CEOSoon Jae Park

Location62, Yuseong-daero 1628 beon-gil, Yuseong-gu, Daejeon, 34054, Korea

Specialty1. NexMab™ Technology for site-

specific ADC conjugation2. NexP™ Technology for long-acting

biobetter recombinant therapeutics3. Hybrozyme™ Technology for

the novel human recombinant Hyaluronidase.

4. Biosimilars – Leading biosimilar technology


Technology Transfer/LicensingHee Ho ChoBD/ManagerT. +82-70-7721-8755E. [email protected]

etcMin Suk Lee, Ph.D.Strategic Planning/Senior Vice PresidentT. +82-42-384-8780E. [email protected]

CONTACT US

Alteogen, Inc.

ALTEOGEN, located in Daejeon, South Korea, is a biotech venture company established in 2008. ALTEOGEN has developed proprietary NexPTM, NexMabTM and HybrozymeTM platform technologies for long-acting biobetters, site-specific conjugated ADC and novel recombinant human hyaluronidase, respectively. ALTEOGEN aims to transform and improve care for the lives of those who are suffering from serious diseases, in search of therapies with our cutting-edge science and technology. ALTEOGEN was listed on KOSDAQ in 2014.

Main Products

Product type Code name indication specific indication Development

Stage

Novel Biologics

(Biobetter)

Recombinant fusion protein ALT-P1 Growth hormone deficiency Growth hormone deficiency Phase 2

Antibody drug conjugate ALT-P7 Oncology Breast cancer Phase 1

Recombinant protein

ALT-B4 Subcutaneous Absorption Accelerator Oncology Pre-clinical

ALT-BB4 stand-alone Hyaluronidase Oncology Phase 1

BiosimilarALT-L9 Ophthalmic diseases Wet Age Macular Degen-

eration Phase 1

ALT-LS2 Oncology Breast cancer Pre-clinical

R&D Pipeline

StageProject Research Process Dev. Pre-clinic Phase 1 Phase 2 Phase 3

Long-ActingBiobetter

ALT-P1(NexPTM-hGH)

ALT-B8 (Long-acting GLP1-Fc-FGF19)

(NASH)

NexMabTM

(ADC)ALT-P7

(HM2-MMAE)(Breast/Gastric cancers)

Biosimilars

ALT-LS2(Herceptin® SC biosimilar)

(Breast/Gastric cancer)

ALT-L9(Eylea® biosimilar)

(wAMD)

Hyaluronidase(HybrozymeTM)

ALT-B4(SC drug Delivery)

ALT-BB4(Standalone)

* Biosimilars are exempted from Phase 2 study

Adult Phase 2 in Korea

Phase 1 completed in Korea Global Phase 3 planned*

Licensees proceed to Phase 1 Clinical Study

Pediatric Phase 1 in India

Phase 1 completed in Korea

13

Information of Korean Innovative

Pharmaceutical Com

pany

www.astrazeneca.com

We push the boundaries of science to deliver life-changing medicines.

CEOJuno Kim

Location21F ASEM Tower, 517 Yeongdong-daero, Gangnam-gu, Seoul, Korea

SpecialtyOncology, Cardiovascular, Renal & Metabolism, and Respiratory and Immunology

Tel/Fax/E-mailT. +82-2-2188-0800F. +82-2-2188-0852 E. [email protected]

Technology Transfer/LicensingYunkyong KimBusiness Development/BD DirectorT. +82-2-2188-0800

CONTACT US

AstraZeneca Korea

AstraZeneca Korea is a science-led biopharmaceutical business delivering life changing medicines to patients through innovative science and excellence in development and commercialization. It focuses on the discovery, development and commercialisation of prescription medicines, primarily for the treatment of diseases in three main therapy areas – Oncology, Cardiovascular, Renal & Metabolism ,and Respiratory and immunology.

Main Products R&D Pipeline

Oncology

IRESSA (Non-small cell lung cancer)TAGRISSO (Small cell lung cancer, Non-small cell lung cancer)Imfinzi (Non-small cell lung cancer)Lynparza (Ovarian Cancer, Breast Cancer)Faslodex (Breast Cancer) Calquence (Chronic lymphocytic leukemia)

Cardiovascular and Metabolism

Forxiga (Type 2 diabetes, Chronic heart failure) Brilinta (Acute coronary syndrome)

Respiratory andImmunology

Symbicort (Asthma, COPD)Daxas (COPD)Fasenra (Asthma)

14

Info

rmat

ion

of K

orea

n In

nova

tive

Ph

arm

aceu

tica

l Com

pany

BC World Pharm. Co., Ltd.(BCWP) has expertise in formulation and process development to provide quality generics. BCWP is not only certified as Korea Innovative pharmaceutical company, but also designated as Advanced Technology Center. In 2019, Carbapenem injections facility has been completed its construction in Wonju city. Starting with the commercialization of Carbapenem product, BCWP is preparing to enter global market such as US and Japan. Accordingly, the inspections for cGMP and PMDA are scheduled in this year.

Main Products

Therapeutic class Products Remarks

Antibiotics (Carbapenem) Meropenem Inj., Imipenem+Cilastatin Inj., Ertapenem Inj., Etc Launched

Anti-Infectives Vancomycin Inj., Metronidazole Gel., Etc. Launched

Anti-TB Rifampicin+Isoniazid+Pyrazinamide+Ethambutol Tab. Launched

Anti-Hyperlipidemia Atorvastatin Tab., Rosuvastatin Tab. Launched

Anti-Hypertensive Nicardipine HCl Inj., Amlodipine+Valsartan Tab., Etc Launched

Gastrointestinal Agents Rebamipide Tab., Etc Launched

Narcotics Fentanyl Sublingual Tab., Fentanyl Inj., Remifentanil Inj., Morphine Inj., Etc. Launched

Well-being Product Glutathione Inj., Zinc sulfate hydrate Inj., Ascorbic Inj., Multipotent Inj. (Zn, Cu, Se, Cr, Mn, F, Fe, I, Mo), Etc. Launched

R&D Pipeline

Category Item Indications Stage

Injection

BCWP_D001 Anti-cancer Pre-clinical



BCWP_D007 Parkinson’s disease Pre-clinical

BCWP_D008 Osteoarthritis pain of the knee Formulation

BCWP_D009 Anti-psychotic Pre-clinical

BCWP_D010 Anti-psychotic Phase 1



Oral Dosage Form

BCWP_E008 Anti-Parkinson Formulation

BCWP_C003 Anti-hyperlipidemia Phase 1

BCWP_G1904 Antihistamine Formulation

BCWP_G1905 Antispasmodic Formulation

en.bcwp.co.kr

Esteemed Global Healthcare Group focusing on R&D

CEOSung Han Hong

LocationGyung Bilding, 78, 22-gil Gaepo-ro, Gangnam-gu, Seoul, Republic of Korea

Specialty1. Incrementally Modified Drugs 2. Drug Delivery System (DDS) 3. Generic


Technology Transfer/LicensingLena JungGlobal business/BD ManagerT. +82-2-2182-0420E. [email protected]

Overseas exportDavid KimBusiness Unit/DirectorT. +82-2-2182-0432E. [email protected]

CONTACT US

BCWORLD PHARM. CO., LTD.

15


Pharmaceutical Com

pany

http://koreabmi.godohosting.com/index.php

Specialized pharmaceutical company aiming to improve people’s quality of life in the aging society

CEOKwang in,Lee/Koo,Woo

Location11, Cheomdan-7-gil, Jeju-si, Jeju-do, South Korea

Specialty1. Regenerative osteoarthritis

treatment 2. Cosmeceutical drug 3. Edema treatment & drug dispersion

agent4. Hemophilia treatment

Tel/Fax/E-mailT. +82-31-426-4780~3F. +82-31-426-5225E. [email protected]

[email protected]

Technology Transfer/Licensing Kyoengwoo Min Business Development/DirectorT. +82-31-429-4781E. [email protected]

Overseas exportNogil ParkInt’l Sales&Marketion/DirectorT. +82-70-8891-6627E. [email protected]

CONTACT US

BMI Korea Co., Ltd.

BMI Korea is a manufacturer of pharmaceutical formulations & medical devices in South Korea. Based on novel experiences, know-hows & technologies from generics to biopharmaceuticals for more than a decade, we have been developing & manufacturing various formulations (including Oral Solids & Solutions). Our specialty is in sterile formulations (Liquid vial, Lyophilized vial, Prefilled syringe) & aesthetic products and these days expanding into the biopharmaceutical area.

Main Products

Project Indication Efficacy/Effectiveness

Hirax (Liquid vial)

Hyaluronidase 300/750/1500/2000/5000 IU

- Enhances permeation of subcutaneous or intramuscular injections, local anesthetics and subcutaneous infusions.

- Promotes resorption of excess fluids and blood in the tissuesHidr

(vial/Pre-filled syringe)Sodium Polydeoxyribonucleo-tide 5.625mg/3ml - Treatment for wounds and tissue restoration caused by skin grafts

BM Hyal (Pre-filled syringe)

Sodium Hyaluronate 10mg/ml - Treatment of osteoarthritis of the knee and periarteritis of shoulder

Hyalprotec (Pre-filled syringe)

Sodium Hyaluronate 15mg/ml

- Cataract, keratotransplantation, glaucoma, etc.- Ophthalmic surgical adjuvant

Immualpha Thymosin Alpha11.6mg/ml

- Adjuvant therapy for influenza vaccination in elderly patients with reduced immune function

R&D Pipeline

TA Project IndicationDevelopment stage

discovery preclinic phase1 phase2 phase3 approved

GenericHirax

Edema, drug dispersion & absorption

HiDr Tissue regenera-tion

Biosimiar(Orphan)

Hileukin Metastatic renal cell carcinoma

BMI2007 Hemophilia

New drug

Hitox Glabellar wrin-kle etc

BMI1009 Osteoarthritis

BMI2004Edema, drug dispersion & absorption

16

Info

rmat

ion

of K

orea

n In

nova

tive

Ph

arm

aceu

tica

l Com

pany

Boryung Pharmaceutical was founded in 1963 with the vision of “Lifetime Care Company” with the spirit of coexistence and co-prosperity that contributes to human health.Boryung Pharmaceutical is focusing R&D for new anticancer drugs, and also developing “improved new drugs” such as treatments for cardiovascular and metabolic diseases, and produce the high-quality medicines in Yesan campus where the recently constructed as smart factory with cutting edge technology .Anti-hypertensive medicine “Kanarb”, Boryung Pharm's first commercialized new drug, is the No. 1 sales position in Korea and has been contracted for out license to about 40 countries around the world. In addition, Boryung Pharmaceutical has focused the “anti-cancer drugs” as a one of future growth engines and make full effort for R&D and investment. For the better future, the company is expanding product portfolio by acquiring brand medicine and developing improved new drugs, while expanding and reinforcing R&D capabilities and pipeline through open innovation.

Main Products

Product (Ingredient) Use Exporting Countries Remarks

Kanarb (Fimasartan) Hypertension

13 Latin countries, Russia, 4 Southeast Asian countries,

10 African countriesLaunched

Dukarb(Fimasartan+Amlodipine) Hypertension 25 Latin countries,

4 Southeast Asian countries Launched

Tuvero(Fimasartan+Rosuvastatin)

Essential hypertension and dyslipidemia 25 Latin countries Launched

Kanarb plus(Fimasartan+HTCZ) Hypertension 13 Latin countries, 8 African

countries Launched

Dukaro(Fimasartan+Amlodipine+Rosuvastatin) Hypertension and dyslipidemia Launched

Akarb(Fimasartan+Atorvastatin) Hypertension and dyslipidemia Launched

Gelfos M(Colloidal Aluminum Phosphate, Magne-

sium hydroxide, Simethicone)Gastric antacid China, Taiwan Launched

Besto(Lafutidine) Gastric ulcer Launched

R&D PipelineProject Discovery Preclinical Phase I Phase II Phase III Launch approved

NCE

BR2002 Lymphoma

BR2006 Cancer

BR2007 Cancer

IMD

BR1006 HypertensionDyslipidemia

BR1007 CKD

BR1008 HypertensionDyslipidemia

BR1010 Hypertension

BR4002 Alzheimer’s disease

Lifetime Care Company

CEOJae-hyun Ahn, Sam-soo Lee

Location136, Changgyeonggung-ro, Chongro-ku, Seoul

SpecialtyHypertension NCE, Oncology NCE, Cardiovascular disease IMD

Tel/Fax/E-mailT. +82-2-708-8000F. +82-31-491-5340

Technology Transfer/LicensingMim Park R&D strategy & BD Team/ManagerT. +82-2-708-8371E. [email protected]

Overseas exportJung_Min ChoiGS 1 Team/Head of Global SalesT. +82-2-740-4106E. [email protected]

etcHee_Young KimAdministration/General ManagerT. +82-31-491-2271E. [email protected]

CONTACT US

Boryung Pharmaceutical Co., Ltd. www.boryung.co.kr/eng

17


Pharmaceutical Com

pany

Bukwang, founded in 1960, is dedicated to bringing novel and outstanding medicines to the public.As in-house developed products, Levovir® was developed as the 4th new drug in the world for the treatment of hepatitis B and licensed-out to Asia. Dexid® was developed for the treatment of diabetic polyneuropathy, and has been exporting to Southeast-Asia.With the aim of improving health of human-being, Bukwang is pursuing the development of innovative novel drugs and actively investing in R&D.

Main Products

Product (ingredient/formulation) Indication Exporting countries Remarks

Levovir®capsule (Clevudine) Chronic hepatitis B virus infec-tion Philippines Launched

Dexid®tablet (R-thioctic acid tromethamine) Diabetic neuropathy East-Asian countries Launched

R&D Pipeline

TA Project Indication CategoryDevelopment phase

Discovery Preclinical Phase I Phase II Phase III

CNS Lurasidone Schizophrenia/biopolar depression

Chemical

Metabolism MLR-1023 T2DM

CNS JM-010 Dyskinesia

Anti-Infection Clevudine COVID-19

Oncology SOL-804 Prostate cancer

Immunology BKC-1501A Immune disorders

Metabolism BK-1701 Anti-diabetes/Obe-sity

CNS USP8 Program Neurodegeneration

I-O AhR inhibitor Cancers

CNS PKR inhibitor Neurodegeneration

www.bukwangpharm.com

Dedicated to delivering new and value-added products to patients for improving global health and well-being

CEOHee-Won Yoo

Location7, Sangdo-ro, Dongjak-gu, Seoul, Korea

Specialty1. CNS Small molecules2. Metabolic disorder Small

molecules3. Oncology Small molecules

(including IMDs)


Overseas exportYoung-wook ChangBD/ManagerE. [email protected]

CONTACT US

Bukwang Pharmaceutical Co., Ltd.

18

Info

rmat

ion

of K

orea

n In

nova

tive

Ph

arm

aceu

tica

l Com

pany

www.celltrion.com/en-us/home/index

A global pharmaceutical company that promotes health and welfare for all

CEOWoo Sung Kee

Location23 Academy-ro, Yeonsu-gu, Incheon

Specialty1. Biosimilars2. New Drugs3. Small Molcules

Tel/Fax/E-mailT. +82-32-850-5000E. [email protected]

Technology Transfer/LicensingJong Won JungStrategic Planning Department/Asst. ManagerT. +82-32-850-8425E. [email protected]

CONTACT US

Celltrion, Inc.

Celltrion, Inc. is a leading Korean biopharmaceutical company that launched the world’s very first antibody biosimilar product, Remsima®. As one of the first companies to chart the Korean biopharmaceutical sector, Celltrion pioneered many previously unexplored areas and evolved into one of the leaders in the biosimilar development and manufacturing sector with numerous milestone achievements. The company now plans to keep the momentum and continue the legacy as it ventures into new business areas such as small molecule pharmaceuticals and Ubiquitous-healthcare system with unique Celltrion approaches.

Main Products

1. Bio pharmaceutical

Product Reference Product INN IndicationsYuflyma Humira Adalimumab Rheumatoid Arthritis , IBD, Lymphoma

Regkirona - Regdanvimab COVID-19

Remsima SC - Infliximab Rheumatoid Arthritis, Ankylsoing Spondylitis, Ulcerative Colitis,Crohn's Disease, Psoriasis, psoriatic arthritis

Remsima Remicade Infliximab Rheumatoid Arthritis, Ankylsoing Spondylitis, Ulcerative Colitis,Crohn's Disease, Psoriasis, psoriatic arthritis

Truxima Rituxan Rituximab Non-Hodgkin's Lymphoma, Chronic Lymphocytic Leukemia, Rheumatoid Arthritis, Granulomatosis with Polyangiitis, Microscopic Polyangiitis

Herzuma Herceptin Trastuzumab HER2-Positive Metastatic Breast Cancer, Early Breast Cancer,Metastatic Gastric Cancer

2. Chemical pharmaceutical

Product Ingredient IndicationsTemyxis Lamivudine, Tenofovir AIDS (Acquired Immune Deficiency Syndrome)

Linezolid Linezolid Pneumonia, Skin and Skin Structure Infections,Vancomycin-resistant Enterococcus faecium Infections

3. COVID-19 Test Kit

Product IndicationsCelltrion DiaTrust™ COVID-19 Ag Rapid Test COVID-19

R&D Pipeline

1. Antibody Biosimilars

Project Original INN Indications StatusCT-P39 Xolair Omalizumab Asthma, Urticaria Phase 1·3CT-P16 Avastin Bevacizumab Metastatic Colorectal Cancer, Metastatic Breast Cancer, NSCLC Phase 3CT-P41 Prolia Denosumab Osteoporosis, Bone Loss Phase 1CT-P43 Stelara Ustekinumab Psoriasis, Crohn's disease, Ulcerative colitis Phase 3CT-P42 Eylea Aflibercept Diabetic Macular Edema Phase 3

2. New Antibodies

Project Indications StatusCT-P27 Pandemic·Seasonal influenza Phase 2CT-P59 COVID-19 Phase 3

3. IMDs

Project Indications StatusCT-G20 Cardiomyopathy Phase 1

Remsima Truxima Herzuma

19


Pharmaceutical Com

pany

www.ckdpharm.com/en/home

Chong Kun Dang Pharmaceutical Corp. (CKD) was established in 1941 with a goal of supplying the best quality medicines. In 1968, CKD received US FDA approval for Chloramphenicol. Remarkably, CKD is one of the first Korean pharmaceutical companies to establish Research Center in early 1970's to accelerate the development of novel technologies and therapeutics. As a result, CKD has successfully launched two novel therapeutics, Camtobell for anti-cancer and Duvie for type 2 diabetes, and world’s first NESP biosimilar, Nesbell.

Main Products

Brand Name Ingredients Notes

Oncology Camtobell Inj Belotecan Our New Drugs

Type 2 diabetes Duvie Tab Lobeglitazone Our New Drugs

Anemia for chronic kidney disease Nesbell Inj Darbepoetin-α Our Biosimilar

Antihypertensive drugs Dilatrend Tab Carvedilol

Immunology Tarcrobell Cap Tacrolimus

Antihyperlipidemic agent Lipilou Tab Atrovastain

R&D Pipeline

VALUABLE COMPANY, CREATIVE COMPANY, BEAUTIFUL COMPANY

CEOYOUNG JOO KIM

Location8 Chungjeong-ro, Seodaemun-gu, Seoul, Korea

Specialty1. Anticancer New Drugs 2. Antidiabetic New Drugs 3. Autoimmune Diseases


Technology Transfer/LicensingRachel Eunjin ShimBusiness Development Team/Team ManagerT. +82-2-2194-0414E. [email protected]

Overseas exportIl Hyeong CheongGlobal Business Planning Team/Team ManagerT. +82-2-2194-0423E. [email protected]

CONTACT US

CHONG KUN DANG

PIPELINE

∞ Biologics / * In-licensed product

CV & METABOLIC DISEASE

ONCOLOGY

IMMUNOLOGY

OTHERS

DISCOVERY PRECLINICAL PHASE I PHASE II PHASE III LAUNCH

Diabetes (PPAR-γ agonist)

Dyslipidemia (CETP inhibitor)

Atrial fibrillation (HDAC6 inhibitor)

SLE, Dermatomyositis (anti-INFα) COVID-19 (HDAC6 inhibitor)

∞

Neurodegenerative Disease (HDAC6 inhibitor)

CNS

Duvie

Camtobell

CKD-516

CKD-581

CKD-314

CKD-504

CKD-943**

CKD-11101

Ovarian Cancer, SCLC (Camptothecin analogue)

Liver Cancer (A3 adenosine receptor agonist)

Colorectal Cancer (VDA)

Multiple Myeloma (Pan-HDAC inhibitor)

NSCLC, Colorectal Cancer (Bi-specific antibody)

∞

CKD-702

CKD-508

∞

CKD-943*

New Chemical Drugs/Biologics

Anemia (Darbepoetin-α) Ophthalmology (Ranibizumab) Pain, Uremic Pruritus (Opioid κ receptor agonist) Rare Disease (Charcot-Marie-Tooth, CMT) (HDAC6 inhibitor)

CKD-510

CKD-971*

CKD-950*

CKD-701

CKD-510

20

Info

rmat

ion

of K

orea

n In

nova

tive

Ph

arm

aceu

tica

l Com

pany

CORESTEM is a bio-pharmaceutical company specializing in research and development of personalized stem cell therapies for incurable disease. We developed the world’s first stem cell therapeutic product for ALS (Amyotrophic Lateral Sclerosis), name of NEURONATA-R® Inj, received the permission of medicines by Korea’s Ministry of Food and Drug Safety in July 2014 and began commercialized medication to patients in February 2015. CORESTEM leads the market in meeting patient expectations beyond national, ethical, and economic limitations through ongoing research into incurable diseases.In order to maximize therapeutic efficacy and provide the best healing value, we are developing treatments by selecting the most suitable stem cells and internal technologies required for commercialization. In addition to ALS treatments, we have a pipeline for various diseases such as lupus and multiple system atrophy, and we plan to dominate the market by focusing on the development of treatments for rare and intractable diseases based on the successful development of ALS stem cell treatments. CORESTEM will be a company that offers new treatment options for incurable diseases.

Main Products

Product Ingredient Use

Neurological Disease NEURONATA-R® Inj Autologous bone marrow derived

mesenchymal stem cellMitigation of amyotrophic lateral sclerosis

(ALS) progression.

R&D Pipeline

http://corestem.com/en/

CORESTEM creates new hope for treatment of intractable diseases.

CEOKyung Suk Kim

Location24, Pangyo-ro 255 beong-gil, Bundang-gu, Seongnam-si, Gyeonggi-do, Korea

Specialty1. Stem Cell Therapy2. Cell based Therapy


Technology Transfer/LicensingYung Man LeeHead of Strategic & Business Development Team/DirectorT. +82-70-4706-9604E. [email protected]

etcSoo Hyun MoonStrategic & Business Development Team/ManagerT. +82-70-4706-9713E. [email protected]

CONTACT US

CORESTEM, Inc.

Neuronata-R®

CS10BR05

Neuronata-R® inj.

Neurological Disease

CS20AT04

CS20BR08

IIT (KR)

ALS: AmyotrophicLateral Sclerosis

MSA: Multiple SystemAtrophy

SLE: Systemic lupus erythematosus

CA: Cerebellar ataxia IIT

NMO: NeuromyelitisOptica

CS20BR08

Fibrosis

PD: Parkinson’s disease CS31PD10

CS30LU11

PRECLINICAL PHASE 1 PHASE 2 PHASE 3

R&D Pipeline

21


Pharmaceutical Com

pany

CrystalGenomics is a commercial stage biopharmaceutical company dedicated to the R&D and commercialization of novel pharmaceuticals to address significant unmet medical needs in the therapeutic area of infectious disease, oncology and inflammatory diseases. CrystalGenomics has a marketed product, Acelex (Polmacoxib), which has been approved by the MFDS and several export agreements has been signed with several countries. In addition to Acelex, CrystalGenomics is developing several first-in class/best-in class drug candidates.

Main Products

Products (Ingredient/Formulation) Use Exporting Countries

Acelex (Polmacoxib) 2mg Capsule Nonsteroidal anti-inflammatory drug for osteoarthritis

Turkey & MENA 19 countries, Brazil, Eurasian Economic Union (Russia, Belarus, Kazakhstan, Kyrgyzstan, Armenia)

Acelex (Polmacoxib) 2mg Tablet Nonsteroidal anti-inflammatory drug for osteoarthritis

R&D Pipeline

www.crystalgenomics.com/en

To become a global biopharma company

CEOJoong Myung Cho

Location5th F, Bldg A, Korea Bio Park, 700, Daewangpangyo-ro, Bundang-gu, Seongnam-si, Gyeonggi-do 13488, Republic of Korea

Specialty1. Inflammatory disease2. Oncology3. Infectious disease


Technology Transfer/Licensing/Overseas export/Overseas OfficeSteven KimBusiness Development/Executive Managing DirectorT. +82-31-628-2720E. [email protected]

etcHae Joo WiStrategy Planning Team/ManagerT. +82-31-628-2718E. [email protected]

CONTACT US

CrystalGenomics, Inc.

Pre- Clinical Phase 3 Phase 1 Phase 2

CG-549(1)

Ivaltinostat IV(2)

Ivaltinostat IV(2)

CG-806(1)

Camrelizumab(3)

CG-650

Infectious Disease

Oncology

MRSA, ABSSSI

Oncology MDS

Oncology AML

Oncology Solid Tumors

Pain/Inflammation Acute/Chronic Pain

Program Therapeutic Area Indication

CG-651 Pain/Inflammation Neuropathic Pain

Ivaltinostat + PD-1 Inhibitor Oncology HCC(1)

(1) First-in-class, (2) Best-in-class, (3) Korea only

CG-750 CAP(2) Fibrosis IPF

Ivaltinostat IV(2) Oncology Pancreatic Cancer (Maintenance Therapy: US)

CG-806(1) Oncology CLL/SLL, nHL

BLA in Korea

Pancreatic Cancer (1st Line Therapy: Korea)

Acelex (Polmacoxib) 2mg Tablet

Acelex (Polmacoxib) 2mg Capsule

22

Info

rmat

ion

of K

orea

n In

nova

tive

Ph

arm

aceu

tica

l Com

pany

Daehwa Pharmaceutical Co., Ltd., was established in 1984 with spirit of “Serving society and creating the better place for human being through the pharmaceutical business”. Its main goal is to improve Global health and people’s Quality of Life. Daehwa has specialized platform technologies such like DH-LASED(DaeHwa Lipid-bAsed Self-Emulsifying Drug delivery technology) and DH-TDDS(DaeHwa Transdermal Drug Delivery technology), etc. Then as the results, they were developed world firstly approved oral Paclitaxel call as Liporaxel Sol’n, and 1st generic of bronchodilator Resnalin Patch(Tulubuterol) and local action NSAIDs Loxona Cataplasma(Loxoprofen sodium). And as the diversity of business, Daehwa has acquired German aesthetic medical device company also established joint venture company in China, too. Also, with motto of “Dispense in Handy”, Daehwa is striving to grow into a global pharmaceutical company with the Vision 2030 project that “Think more, Act faster” to create a better tomorrow that mankind dreams of.

Main Products

Product Use Ingredient/Formulation Exporting Countries Remarks

Liporaxel Anti-cancer Paclitaxel/Oral Sol’n Asia Approved

Cephamethyl Anti-biotics Methyl cephalexin lysinate/Tab. & Cap. - Launched

Resnalin Bronchodilator Tulobuterol Asia Launched

Loxona External analgesics Loxoprofen sodium Asia Launched

Demacot Anti-infective Betamethasone dipropio-nate and others Asia & Africa Launched

R&D Pipeline

Platform Technology Indication Non-clinical Phase 1 Phase 2 Phase3 Launch DH-LASED Technology

Liporaxel®(DHP107): Oral paclitaxel formula Solid tumor (PK study)

Gastric cancer Breast cancer - USA / E EU / KR / CN

Liporaxel® Capsule Breast cancer

DHP23001: Oral HC-docetaxel formula Pancreatic cancer

DHP23002: Oral HC-paclitaxel formula Breast cancer

DHP23003: Oral irinotecan formula Colorectal cancer

DHP23007: Oral zanamivir formula Influenza

DHP33001: Oral GLP-1 agonist formula Diabetes & Obesity

DH-BIO/HERBAL Technology

DHP1401: DH-Herbal agent Dementia

DHP32005: DH-Wnt-targeted agent Osteoarthritis

DHP32007: DH-targeted agent Colon cancer

DHP32006A: DH-immune-oncology agent Breast cancer

DHP21001: ScFv AMD

Platform Technology Indication Optimization Safety & Manufacture Domestic Launch Global Launch DH-TDDS Technology

DHP26008: Tulobuterol patch Bronchial asthma

DHP26005: Rivastigmine patch Dementia

DHP27013: Loxoprofen sodium plaster Inflammation

www.dhpharm.co.kr

Be the No. 1 Pharmaceutical company with slogan of “Dispense in Handy/Think more, Act faster” for improving Quality of Life.

CEOByung-Tae No, Eun-Seok Kim

Location495 Hanu-ro, Hoengseong-eup, Hoengseong-gun, Gangwon-do, Republic of Korea

Specialty1. New anticancer combination drug2. Incrementally modified drug3. Transdermal drug4. First generic

Tel/Fax/E-mailT. +82-2-586-6451F. +82-2-587-0566BD. [email protected]. [email protected]

BD(Technology transfer / Licensing)Young-Sang Cho Business Development/HeadT. +82-2-6716-1072E. [email protected]

Overseas exportHan Wong Seo Overseas business team/DirectorT. +82-2-6716-1071E. [email protected]

etcHye Min KimDevelopment team/ManagerT. +82-2-6716-1068E. [email protected]

CONTACT US

Daehwa Pharmaceutical Co., Ltd.

23


Pharmaceutical Com

pany

www.daewonpharm.com/eng/main/index.jsp

Daewon Pharmaceutical's believe that customers is the most important core value of corporate management. Since Established in 1958 based on the founding philosophy of "partner for people to promise their healthy lives", we have effort to protect the healthy life of people as a company specialized in pure competent pharmaceutical company.Daewon Pharm is a pharmaceutical company that based on its advanced facility & Plant, investment and excellent R&D capabilities, we have developed the ' Pelubi Tab', a new drug for the Korean & Global market.

Main Products

Category Product Molecule

Analgesic

Pelubi CR Tab. Pelubiprofen

Pelubi Tab. Pelubiprofen

Nerexone SR Tab. Eperisone

Cardiovascular

Clow Tab. Rosuvastatin

Lipiwon Tab. Atorvastatin

Exombi Tab. Varsartan/amlodipine

TG Fenone Tab. Choline Fenofibrate

Twincombi Tab. Telmisartan/amlodipine

Tri-in-one Tab. Telmisartan/amlodipine/Rosuvastatin

Uptava Cap. Pitavastatin/Fenofibrate

GastrointestinalEswonamp Tab. Esomeprazole

Otillen F Tab. Artemisia herb isopropanol soft extract(20→1)

Respiratory

Codaewon Forte Syr. Dihydrocodeine/ammonium chloride/chlorpheniramine/dl-methylephedrine

Beposta Tab. Bepotastine

Beposta Tab. Bepotastine

Elsteine Tab. Erdosteine

Analgesic

Wontran ER Tab. Acetaminophen/Tramadol

Lyicaneuro ER Tab. Pregabalin

Freefol MCT Inj.1,2% Propofol

Others Renamezin Cap. Spherical adsorptive carbon

R&D Pipeline

Category Project Code Indication Stage

New chemical entity DW-4301 Cardiovascular Disease Phase I

DW-4902 uterine disease Phase I

GenericDW-2801 Gastrointestinal disease Phase I

DW-5903 Cardiovascular Disease Pre-Clinical

Incrementally modified drug

DW-1601 Respiratory Disease Phase III

DW-1807 Respiratory Disease Phase I

DW-1806 Metabolic Disorders Phase I

DW-1805 Metabolic Disorders Pre-Clinical

DW-8809 Gastrointestinal disease Pre-Clinical

DW-1804 Metabolic Disorders NDA submit

DW-1808 degenerative disease Pre-Clinical

DW-1809 degenerative disease Phase I

Be a partner who protects healthy life of Human beings based on a reliability and trust of customers.

CEOSeung Ryel Baek

Location386 cheonhodae-ro, Seongdong-gu, Seoul #04808, Korea

Specialty1. IMD (incrementally modified drug)2. NCE (New chemical entity)3. First Generic

Tel/Fax/E-mailT. +82-2-2204-7000 F. +82-2-3436-4878

Technology Transfer/LicensingMINPYO KIMBusiness Development/ManagerT. +82-2-2204-6960E. [email protected]

Overseas exportSTEVE KIMOverseas Business Dept./ManagerT. [email protected]

CONTACT US

Daewon Pharm. Co., Ltd.

24

Info

rmat

ion

of K

orea

n In

nova

tive

Ph

arm

aceu

tica

l Com

pany

www.daewoong.co.kr/en

A global healthcare group dedicated to improving quality of life

CEOJeon Seng Ho

LocationBongeunsa-ro 114-gil 12 Gangnam-gu Seoul 06170 Korea

Specialty1. new chemical entities for

intractable disease2. stem cell therapy for rare diseases

(cell & gene therapy)3. new formulation technology


Technology Transfer/Licensing/Overseas exportDoyoung KimGlobal Development Center/HeadT. +82-10-7474-4247E. Doyoung.kim@ daewoong.co.kr

Overseas OfficeCHO JOONG YOUNGlobal CorporationBusiness/Team ManagerT. +82-10-5736-1575E. [email protected]

CONTACT US

Daewoong Pharmaceutical Co., Ltd.

Since 1945, we have grown into Korea’s leading company in line with corporate philosophy of ‘developing quality medicine to safeguard the people’s health and contribute to a healthier society.’With $1.2B revenues, we have 8 manufacturing sites globally and branches in China, Japan, Indonesia, Thailand, Vietnam, Philippines, India and USA. We are the no.1 Korean player in Chinese GI market, and we acquired the no.2 Vietnamese company (Traphaco). We have the first Halal certified Indonesian bio facility and a POC center in India.

Main Products

Brands

Product name Description

Ursa® Liver diseases & dysfunction improvement

Bearse® Multilayer digestives

Biologics


Easyef® (EGF) Diabetic foot ulcer, Acute wounds

Novosis® (rh BMP-2) Dental sinus lift graft

Caretropin® (hGH) Growth hormone deficiency

Eposis® (EPO) Anemia in chronic kidney disease

Nabota® (Botulinum toxin) Anti-wrinkles

Formulation


Luphere ® Depot Peptide delivery system for prostate cancer

Olostar New combination drug for Hyperlipidemia/hyper-tension

R&D Pipeline

25


Pharmaceutical Com

pany

www.dongkoo.com/eng

To be a leader of total healthcare company which considers the customer’s satisfaction as the top priority and leads the health & medical industry

CEOCho Yong Joon

LocationB-14F, 114 Beobwon-ro, Sonpa-gu, Seoul, Korea

Specialty1. Incrementally Modified

Drug(Endocrine Disorder, Urologic Diseases)

2. First Generic3. ETC(Dermatologic Disorder)


Technology Transfer/LicensingIm Byung WookBD Team/General manager T. +82-2-2684-5421(236)E. [email protected]

Overseas exportKim Kyung hoOverseas Business Team/Assistant ManagerT. +82-2-2684-5421(318)E. [email protected]

Overseas OfficeLee Dae Liul Chinese Business DIvision/General ManagerT. +86 187-2171-7220E. [email protected]

etcKi No KwangManagement Planning Team/General managerT. +82-2-2684-5421(237)E. [email protected]

CONTACT US

DongKoo Bio & Pharma Co., Ltd.

DongKoo Bio&Pharma has been established in 1970 with the core business of production and selling ethical drugs. An industry leader specializing in Dermatology and Urology for many years, DongKoo Bio&Pharma in 2020 recorded #1 in Dermatology and #5 in Urology in terms of numbers of prescriptions issued. All employees of DongKoo Bio&Pharma strive to optimize the Company for the upcoming Quality of Life period by building a Total Business Model that covers a broad and complete business portfolio from developing cure for senile diseases and chronic diseases (such as diabetes, high blood pressure), strengthening the presence in ethical drugs market and CMO to trailblazing in new areas including, but not limited to, healthcare and cosmeceuticals. As a result, DongKoo Bio&Pharma constantly re-innovates itself as the Total Healthcare Leader who contributes to improving the well-being of mankind.

Main Products

PHARMACOLOGIC CATEGORY BRAND NAME GENERIC NAME INDICATIONS

Topical Corticosteroid

Dermotasone MLE Lotion/Cream Mometasone Furoate

inflammatory and pruritic manifes-tations of corticosteroid-responsive dermatoses

Bade Cream Prednicarbate eczema, dermatitis, psoriasis of corti-costeroid-responsive dermatoses

Antihistamine & Antialler-gic Allestin Tab. Epinastine bronchial asthma, allergic rhinitis, skin

rash

Urogenital agentsCernilton Tab. Cernitin T60

Cernitin GBXchronic prostatitis, benign prostatic hyperplasia

Uropa SR Tab. Tamsulosin benign prostatic hyperplasia

Cardiovascular agentsAvaltan A Plus Tab.

AtorvastatinAmlodipineValsartan

essential hypertension and dyslipid-emia

Atostan Tab. Atorvastatin dyslipidemia

Prolactin inhibitor Caverlactin Tab. Cabergoline hyperprolactinemia

Antiulcer Rabepri Tab. Rabeprazole stomach ulcer, duodenal ulcer, gastro-esophageal reflux

Antibacterial Newroxime Tab. Cefuroxime axetil otitis media, sinusitis, tonsillitis, pneumonia

R&D Pipeline

Category Project Code Indication Stage

Differentiated Generic Drugs

DKB1903 Diabetes NDA Submission

DKB2002 Diabetes BE Study

DKB2001 Diabetes Formulation Study

DKB1902 First line therapy for psoriasis NDA Submission

DKB2014 Second line therapy for psoriasis Formulation Study

DKB1904 Anti-allergic disease Phase Ⅰ

DKB1801 Acne NDA preparation

Incrementally Modified Drugs

DKB15003 Dyslipidemia IND Submission

DKB17001 Urinary diseases Phase Ⅰ, Ⅲ

DKB17002 Lumbago Phase Ⅰ, Ⅲ

DKB19001 Circulatory On Market

DKB19002 Diabetes Phase Ⅰ

DKB19003 Anti-allergic disease Formulation Study



DKB20003 Atopy Phase Ⅱ

26

Info

rmat

ion

of K

orea

n In

nova

tive

Ph

arm

aceu

tica

l Com

pany

CEOHeung-Ju, Oh

Location7, Teheran-ro 108-gil, Gangnam-gu, Seoul, Republic of Korea

Specialty1. Periodontal disease (Natural medicine), 2. Anticancer agent (First generic product), 3. Contrast agent


Technology Transfer/LicensingKyu Hwan KimStrategic Management/Senior ManagerT. +82-2-2191-9277E. [email protected]

Overseas exportAlice Jungyeon LeeBD Team/Overseas Business Dept.T. +82-2-2191-9896E. [email protected]

etcJaewon KimResearch Managemnet/Senior ManagerT. +82-31-888-6330E. [email protected]

CONTACT US

www.dkpharm.co.kr/en

Total healthcare group in Korea that delivers healthy value with sincere heart and contributes to customers’ life and society

Dongkook Pharmaceutical Co., Ltd.

Dongkook Pharmaceutical is a Korean pharmaceutical company founded in 1968 and listed on the KOSDAQ in 2007. OTC medicines for periodontal disease, wound, and women’s menopausal symptoms, etc, and ETC medicines such as the contrast agent and the anticancer drug, are well known not only in Korea but also in overseas markets. Currently, we export drug substances and products to more than 50 countries around the world, especially in advanced countries such as EU and Japan.

Main Products

Product Main Ingredients Use Exporting Countries

OTC

Peridol Plus Tablet Titrated extract of Zea Mays L,Magnolia extract Periodontal disease

Lipossol Ointment Titrated extract of centella Skin disease

Feramin Q Tablet Black cohosh extract,St. John's wort extract

Female menopausal symptoms

Pansidil Capsule Medicinal yeast Hair loss

ETC

Lorelin Depot Injection Leuprolide acetate Prostate cancer 9 countries(Mexico, Uruguay, Iran, etc.)

Pofol Injection Propofol anaesthesia 26 countries(Japan, Brazil, UAE, Thailand, etc.)

Teicon Injection Teicoplanin Infectious disease 3 countries(Japan, Mongol, Syria)

Hyaron Injection Sodium hyaluronate Osteoarthritis Vietnam, etc

OthersBellast Series Hyaluronic acid Temporal correction of

wrinkles Vietnam, etc

Centellian24 Centella Asiatica Extract Cosmetic

R&D Pipeline

27


Pharmaceutical Com

pany

www.dong-wha.co.kr/english

Human & Happiness

CEOJunha Yoo

Location6~8F, FastFive Tower, 24, Namdaemun-ro 9-gil, Jung-gu, Seoul, KOREA

Specialty1. COVID-19 NCE2. Astma/COVID-19 Natural Drug3. Diabetes IMD


Technology Transfer/LicensingMase LeeResearch Institue/Senior Managing DirectorT. +82-31-270-0601E. [email protected]

Overseas exportWena ChoGlobal Business Team/ManagerT. +82-2-2021-9345E. [email protected]

CONTACT US

DONGWHA PHARM

Established as the first Korean pharmaceutical company in 1897, Dongwha has always remained committed to bringing happiness to customers and employees with its management focusing on happiness of people. Whal Myung Su, Korea’s first western-style medicine, by integrating the advantages of Western medicine into the royal court’s secret recipe in 1897. The key R&D outcomes include successful development of "Zabolante" in 2015, as a next-generation antibacterial agent, and currently distributing in Korea.

Main Products

Category Product Ingredient Use

Antibacterial agent Zabolante Zabofloxacin AE COPD

Digestive System Whal Myung Su Gambir, Ginger etc. Anorexia, Indigestion, etc.

Cold Remedy Pancold Acetaminophen etc. Relief of common cold symptoms

Gum treatment toothpaste Each Paste Myrrh, Rhatany, Chamomile gingivitis and alveolar pyorrhea

R&D Pipeline

Category Project Indication Discovery Preclinical Phase I Phase II Phase III

NCE

DW2008

Antiviral drugDW1027

DW1026

DW1022Autoimmune

DiseaseDW1024

DW1023 Oncology

DW1025 Asthma

IMD

DW6012

DiabetesDW6013

DW6014

28

Info

rmat

ion

of K

orea

n In

nova

tive

Ph

arm

aceu

tica

l Com

pany

GC Pharma (Former Green Cross Corp.)www.globalgreencross.com/eng

A Global Leader in Healthcare Industry

GC Pharma has been a leading biotech company for developing innovative biotherapies including vaccines, plasma-derivatives, recombinant proteins and therapeutic antibodies.GC Pharma developed the world's first vaccine against epidemic hemorrhagic fever “Hantavax” and the world's second vaccine for varicella zoster virus vaccine “Suduvax”.GC Pharma is also pursuing opportunities in rare diseases by developing therapies such as Hunterase (world’s second ERT for Hunter syndrome) and GreengeneF (3rd generation of hemophilia A treatment. Also, GC Pharma is). GC Pharma is developing a COVID-19 antibody treatment.

Main Products

Product Name Indication Active Ingredient Category

I.V.-Globulin SN inj. 5% I.V.-Globulin SN inj. 10%

A-/HypogammaglobulinemiaCombined therapy with antibiotics for severe bacterial or viral infections Idiopathic thrombocytopenic purpuraGuillain-Barre syndrome Kawasaki syndrome

Human Intravenous Immuno-globulin Plasma Derivatives

Albumin inj.-GCCHypoalbuminemia and shock in acute hemorrhage from loss of albumin (burns, nephrotic syndrome, etc.) and low synthesis of albumin (hepatic cirrhosis, etc.)

Human Albumin Solution Plasma Derivatives

Green-VIII inj Treatment of hemophilia A with supplies of blood coagulation factor VIII

Human Blood Coagulation Factor VIII Plasma Derivatives

GreenGene F inj. Prevention and control of bleeding episodes and preoperative management in hemophilia A

Recombinant Coagulation Factor VIII (Beroctocog ∝) Recombinant

I.V.-Hepabig inj. Prevention of recurrence of hepatitis B in patients with liver transplants

Human Hepatitis B Immuno-globulin Plasma Derivatives

Sero-Tet inj. (Hyper-Tet inj.) Prophylaxis of tetanus and the reduction of tetanus symptoms

Human Tetanus Immunoglob-ulin Plasma Derivatives

GCFLU Quadrivalent Pre-filled syringe inj. Prophylaxis against influenza Split Virion Inactivated Influ-

enza Vaccine Vaccines

BARYCELA Inj. Prophylaxis against varicella Live Attenuated Varicella Vaccine Vaccines

HunterasePatients with Hunter syndrome (MPS II) which is caused by a deficiency of the lysosomal disease, Iduronate 2-sulfatase (IDS)

Idursulfase beta Recombinant

Neulapeg Pre-filled syringeDecrease the duration of severe neutropenia for patients receiving cytotoxic chemotherapy for solid tumor and malignant lymphoma

PEG-GCSF Recombinant

R&D Pipeline

CEOEun-chul Huh

Location107, Ihyeon-ro 30beon–gil, Giheung-gu, Yongin-si, Gyeonggi-do 16924, Korea

Specialty1. Plasma derivatives2. Vaccines3. Recombinant Products

Tel/Fax/E-mailT. +82-31-260-9300F. +82-31-260-9412

Technology Transfer/LicensingYoung Seoub ParkBD/General ManagerT. +82-31-260-9417E. [email protected]

Overseas exportByung Lim LeeGlobal biz./General ManagerT. +82-31-260-9493E. [email protected]

CONTACT US

혁신형제약기업홍보책자 영문

기준일자

Hepatitis B treatment

29


Pharmaceutical Com

pany

To Save the Lives of Patients and Improve Patients’ Quality of Life

CEOYoung Chul Sung, Jung Won Woo

Location700 Daewangpangyo-ro, Korea Bio ParkBldg. B, Bundang-gu, Seongnam-si,Gyeonggi-do 13488, Republic of Korea

SpecialtyCancer Immunotherapeutics, Therapeutic and Preventive DNA Vaccines, Next Generation Long-acting Biologics.


[email protected]

Technology Transfer/LicensingPio (Jae Beom) KimBusiness Development/DirectorT. +82-31-628-3401E. [email protected]

CONTACT US

Genexine, Inc. www.genexine.com

Genexine (KOSDAQ, 095700) is a clinical stage biotechnology company focused on the development and commercialization of innovative immunotherapeutics and next generation novel long-acting biologics. Our goal is to bring to patients medicines that will transform their lives. hyFc platform and DNA therapeutic vaccine platform are our own core proprietary technologies, which are designed to drive the discovery of a wide range of differentiated therapeutics.

R&D PipelineGX-I7 (Long-acting IL-7)

Areas Indication Regimen Non-clinical Phase 1 Phase 2 Site

Healthy Volunteers

SAD KR

Immuno-Oncology

Solid tumor

Mono KR

Mono CN

Glioblastoma

Mono KR

TMZ Combo CN

AVASTIN® Combo KR

Triple Negative Breast Cancer

KEYTRUDA® Combo KR

Infectious Disease

COVID-19 Mono KR/ID

Completed

Completed

Ongoing Ph 1

Completed

Ongoing Ph2

Ongoing Ph 1b/2

Ongoing Ph 1b & Ph 2

Ongoing Ph2

GX-I7 (Long-acting IL-7)

GX-188 (HPV DNA Therapeutic Vaccine)

Areas Indication Regimen Non-clinical Phase 1 Phase 2 Site

Immuno-Oncology

Cervical Cancer KEYTRUDA® Combo KR Ongoing Ph 1b/2

GX-188 (HPV DNA Therapeutic Vaccine)

GX-H9 (Long-acting hGH)

Areas Indication Regimen Non-clinical Phase 1 Phase 2 Phase 3 Site

Endocrine disease

AGHD Mono KR/EU

PGHD Mono CN

Completed

GX-G3 (Long-acting G-CSF)


Hematologic diseases

Neutropenia Mono KR/EU Completed

GX-E4 (Long-acting EPO)



CKD-induced Anemia

Mono KR/ASEAN Ongoing Ph 3

*AGHD; Adult Growth hormone Deficiency, PGHD; Pediatric Growth hormone Deficiency

*CKD; Chronic kidney disease

Ongoing Ph 3




Endocrine disease

AGHD Mono KR/EU

PGHD Mono CN

Completed








CKD-induced Anemia




Ongoing Ph 3





Endocrine disease

AGHD Mono KR/EU

PGHD Mono CN

Completed








CKD-induced Anemia




Ongoing Ph 3

GX-G6 (Long-acting GLP-1)


Metabolic disease

Type 2 Diabetes

Mono EU Completed



Metabolic disease

Short Bowel Syndrome

Mono EU Phase 1 IND

Approved

GX-P1 (Long-acting PD-L1)


Autoimmune Autoimmune Transplantation Mono KR

Phase 2 IND Approved

GX-19N (COVID-19 preventive vaccine)


Preventive Vaccine COVID-19 Mono KR Ongoing Ph 1/2a

Completed




Metabolic disease

Type 2 Diabetes

Mono EU Completed



Metabolic disease


Mono EU Phase 1 IND

Approved








Completed




Metabolic disease

Type 2 Diabetes

Mono EU Completed



Metabolic disease


Mono EU Phase 1 IND

Approved








Completed




Metabolic disease

Type 2 Diabetes

Mono EU Completed



Metabolic disease


Mono EU Phase 1 IND

Approved








Completed


30

Info

rmat

ion

of K

orea

n In

nova

tive

Ph

arm

aceu

tica

l Com

pany

CEOMiyeon Kim

Location14F, MajestaCity Tower 1, 12, Seocho-daero 38-gil, Secho-gu, Seoul, South Korea

Specialty1) First Generic and incrementally

modified drug2) PreMix Injection3) Topical (ex. Nail Lacquer)


Technology Transfer/LicensingAekyoung LeeDevelopment Group/Head of Development GroupT. +82-2-2059-2710E. [email protected]

Overseas exportSuna RyuOverseas Group/Team LeaderT. +82-2-2059-2800E. [email protected]

CONTACT US

www.genuonesciences.com/en/main.html#

Building Trust Through Integrity

GENUONE Sciences (the integrated entity from the acquisition of Kolmar Korea’s Pharmaceutical Division and Kolmar Pharma in December, 2020) is South Korea’s top CMO pharmaceutical company, specializing in the full range of services from formulation development to manufacturing and clinical development of small molecule. Since 2002, provided complete services from product development to finished dose formulations including regulatory services. About 80% of K-pharmaceutical companies (Hanmi, Yuhan, LG, etc.) have business relationship as our customers. We are exporting 250 products to 20 countries through cooperation with overseas partners, and also have global CMO capabilities such as supplying hepatitis B treatment to the Hong Kong government. (Major Exporting Countries: Hong Kong, Japan, Vietnam, Russia, Peru.)

Main ProductsDosage

Form Description

Oral Solid Tablets, Capsules, Powder

Sterile Injection(Ample, Vial, Bag), Eye-drops, Lyophilized injectables

Oral Solu-tions Syrup, Suspension

Topical Oinment. Cream, Lotion, Solution, Nail Lacquer

Quasi Drup Toothpaste, Gargle, Sanitizer

Lid-cap Liquid filling in Hard Capsules (GENUONE’s innovative Tech)

R&D Pipeline

Classification R&D IND NDA E/O

Cardiovascular system

2 cases 2cases

ETC

ETC

ETC

ETC

Endocrine system

6 cases 1 case

ETC

ETC

ETC

ETC

ETC

ETC

ETC

Musculoskeletal system

2 cases

ETC

ETC

Digestive system1 case

ETC

GENUONE Sciences Inc.

Indication Product Name API

Circulatory / Cardiovascular

Hiforge Tab Valsartan, AmlodipineTelopin Tab Telmisartan, AmlodipineLipar Tab Atorvastain

Endocrine System

K-Tosmet Tab Pioglitazone, MetforminFebuxt Tab Febuxostat

Gastro-Intesti-nal

Nexpesol Tab EsomeprazoleLafuton Tab Lafutidine

NSAIDSPainless Tab Acetaminophen, Tramadol HCI

Celecoxib Cap Celecoxib

RespiratoryPelium Syrup, Tab Pelagonium SidoidesEldobron Tab/Cap Erdosteine

DermatologicalsCiclopirox Nail Lacquer CiclopiroxProsol Oinment, Lotion Clobetasol Propionate

InfusionPara-K Acetaminophen

Penta-amin, Suppramin Amino acidLid-cap(Liquid

Hardcap) Colin-K Lidcap Choline alfoscerate

31


Pharmaceutical Com

pany

Handok, a leading innovation-driven pharmaceutical/healthcare company in Korea, develops, manufactures and distributes healthcare solutions to improve the health and quality of human life. Handok has a core business focus in diabetes, cardiovascular, muscular skeletal, psychoneurotic disease, human vaccines, medical devices, diagnostics and consumer health. Handok, founded in 1954, grew as a joint venture with Hoechst/Aventis/Sanofi from 1964 to 2012. Handok has also established strategic collaborations in several areas with multiple multinational pharmaceutical companies. For more information, please visit www.handok.co.kr.

Main Products

Category Products Description

ETCAmaryl Tab, Amaryl M Tab, Amaryl Mex SR Tab

Leader in Diabetes MarketTenelia Tab, Tenelia M SR Tab.

Soliris Inj. Specialized in Orphan Drugs and Rare Diseases

OTCKetotop Plaster No 1. Topical Pain Relief Product Festal Plus Tab. No 1. Digestive Product

Medical Devices & Diagnostics Brozen Blood Glucose Monitors

Healthcare ProductsNatureSet Food Supplements

Ready Q Hangover remedy(High-Absorption Curcumin)

R&D Pipeline

www.handok.co.kr/eng

“The Health Innovator” as Korea’s leading global total healthcare company.

CEOYoung Jin Kim, Jin Ki Baik

Location132, Teheran-ro, Gangnam-gu, Seoul, 06235, Korea

Specialty1. Anti-diabetics New Chemical

Entities2. Anti-diabetics Diabetes

Incrementally Modified Drugs3. Anti-arthritis Plaster


Technology Transfer/Licensing Overseas exportSoHyun KwonCorporate&Business Development/Senior Vice PresidentT. +82-2-527-5316E. [email protected]

etcHyoJoo ChaPlanning&Coordination Office/Team LeaderT. +82-2-527-5157E. [email protected]

CONTACT US

HANDOK, Inc.

Therapeutic Area Project Category Indication Resear

ch Pre-

Clinical P1 P2 P3 Remarks

Orphan HL2356 (GX-H9) Bio-better

Growth Hormone Deficiency in

Adults


Pediatrics

Oncology HL5101 NCE Cancer

Genexine partnered

CMG Pharm. partnered

Therapeutic Area Project Category Indication Development Clinical Regulatory

Approval Remarks

CV DENEX Medical Devices

Refractory Hypertension

CV/ Infection RST Kit Diagnostics CV/Infection

• CE mark (2016)

NB POSTECH partnered

Handok Kalos Medical partnered

Therapeutic Area Project Category Indication Resear

ch Pre-

Clinical P1 P2 P3 Remarks

Orphan HL2356 (GX-H9) Bio-better


Adults


Pediatrics

Oncology HL5101 NCE Cancer

Genexine partnered

CMG Pharm. partnered

Therapeutic Area Project Category Indication Development Clinical Regulatory

Approval Remarks

CV DENEX Medical Devices

Refractory Hypertension

CV/ Infection RST Kit Diagnostics CV/Infection

• CE mark (2016)

NB POSTECH partnered

Handok Kalos Medical partnered

Therapeutic Area Project Category Indication Resea

rch

Pre-Clinic

al P1 P2 P3 Remarks

Oncology

ABL001 VEGF/DLL4

Solid cancer

ABL103 4-1BB/B7H4

ABL501 PD-L1/LAG3

ABL503 PD-L1/4-1BB

ABL506 PD-L1/B7-H3

CNS ABL301 SNCA x IGF1R Parkinson’s

Disease

Orphan

RZ358 Bio

Intravenous monoclonal antibody for Congenital

Hyperinsulinism

RZ402 Bio Oral Plasma

Kallikrein Inhibitor for Diabetic

Macular Edema

Derma SCM-AD Stem Cell Therapy

Atopic Dermatitis

REZOLUTE partnered

ABL Bio partnered

SCM Lifescience partnered

Open Innovation Project

32

Info

rmat

ion

of K

orea

n In

nova

tive

Ph

arm

aceu

tica

l Com

pany

With the corporate mission of protecting the precious human life from various forms of diseases, HANLIM has consistently endeavored to improve the health standards of people, and we have grown to become one of the leading companies in Korea.In 1993, the future-oriented GMP factory was completed together with the founding of the central research center. As a part of the long-term investment scheme of the company, we continue to make a great investment in accumulating advanced technologies and reorganizing manufacturing facilities lately to enhance the health of mankind as a leading pharmaceutical company.

Main Products

Product Name Active Ingredient(s) Category RemarkT-Sporin

Eye Drops Cyclosporin 0.5mg Ophthalmic IMD Product

Nasaflex Nasal Spray

Mometasone furoate 0.5mg,Azelastine HCl 1.4 mg Allergy&ENT IMD Product

Risenex Plus Tab. Sodium Risedronate 35mg,Cholecalciferol 5,600IU Endocrine IMD Product

Dages Cap. Pepsin 25mg, Papain 50mg, Diastase 15mg, Cellulase 15mg, Pancreatin 50mg, Pancrelipase 13mg, UDCA 25mg Digestive

R&D Pipeline

Mesenchymal stem cells

Prodocut Indication Pre-clinicalClinical phase

1 2 3

HL401 Lupus Nephritis

NCE (New Chemical Entity) Discovery


NDA1 2 3

HL301 Acute Bronchitis

HL301A Radiation Pneumonia

HL301B Chronic Bronchitis

HL217 AMD

HL237 Rheumatoid Arthritis

HL237A Liver Transplantation

HL237B Sjogren’s Syndrome

IMD (Incrementally Modified Drug)


NDA1 2 3

Lodien-T Tab. Hypertension

HL188 Hyperlipidemia+ Hyper-tension

Lumino-mark Inj. Breast Lesion Surgery Marker

Jakfas XR Tab. Rheumatoid Arthritis

www.hanlim.com/eng

R&D, Manufacturing of API/BPIs and Pharmaceutical Product

CEOJae Yoon Kim, Jung Jin Kim

Location42, Seocho-Daero 52 Gil, Seocho-Gu, Seoul 06634 Republic of Korea

SpecialtyR&D, Manufacturing of API/BPIs and Pharmaceutical Product


Technology Transfer/LicensingMi Jin ODelveopment Dept./Director T. +82-2-3489-6166 E. [email protected]

Overseas exportJeonghwa Jenny YangGlobal Business Dept./DirectorT. +82-2-3489-6214 E. [email protected]

CONTACT US

HANLIM PHARM. CO., LTD.

33


Pharmaceutical Com

pany

Hanmi Pharmaceutical Co., Ltd. is a global pharmaceutical focused on the development and commercialization of new pharmaceutical products. The Company invested nearly 21% of its sales on R&D in 2020. Hanmi Pharmaceutical Co., Ltd. plans to create a global R&D achievement based on innovations of inflammation–fibrosis treatment, Triple-acting drug for NASH (non-alcoholic steatohepatitis) treatment as well as various other innovations in metabolic disease, oncology and rare disease fields. Hanmi Pharm is continuing its endless challenges by raising synergy of various R&Ds such as AI drug development and immune anticancer development through the “Open Innovation” strategy that opens the door to excellent externals. R&D capabilities of Hanmi Pharmaceutical Co., Ltd. and the strong trust among multiple partners remain solid.

Main ProductsCategory Product Use Ingredient Exporting countries

Cardiovascular disease

Amosartan Hypertension Amlodipine 21 countries in APAC, LAT-AM, CIS, AFRICA continents

Amosartan Plus Hypertension Amloidpine + Losartan + Chlorthalidone LATAMAmosartan Q Hypertension, dyslipidemia Amloidpine + Losartan + Rosuvastatin CIS, LATAM

Amosartan XQ Hypertension, dyslipidemia Amloidpine + Losartan + Ezetimibe + Rosuvastatin Do not export

Rosuzet Dyslipidemia Ezetimibe + Rosuvastatin CIS, LATAM, SEAAmodipin Hypertension Amlodipine camsylate Do not exportRovelito Hypertension, dyslipidemia Irbesartan + Atorvastatin Do not export

Carnitil Alzheimer’s disease, dementia Acetyl-L-carnitine hydrochloride Do not export

Pidogul Antiplatelet Clopidogrel napadisilate APACGastrointestinal

disease Esomezol GERD, Gastric ulcer Esomeprazole strontium Do not export

Urology Palpal Erectile dysfunction Sildenafil JAPANGugu Erectile dysfunction Tadalafil JAPAN

HANMI TAMS BPH Tamsulosin hydrochloride Do not exportNeurology Naxozol Anti-inflammatory Naproxen + Esomeprazole Do not export

Ophthalmology, etc

Hyalumini eye drop

Artificial tear, Sjögren's syndrome Sodium hyaluronate Do not export

Rabone D Osteoporosis Raloxifene + cholecalciferol Do not export

R&D Pipeline

www.hanmipharm.com

R&D Driven Pioneer for Innovation in Life Sciences

CEOJong-Soo Woo, Se Chang Kwon

Location14, Wiryeseong-daero, Songpa-gu, Seoul, 05545, Korea

SpecialtyR&D based pharmaceutical products

Tel/Fax/E-mailT. +82-2-410-9114

Technology transfer/Licensing-inInkie ChungGlobal BDT. +82-2-410-0408E. [email protected]

Overseas exportSteven ChoFinished products/APIs/CMO business/Team LeaderT. +82-2-410-0462E. [email protected]

CONTACT US

Hanmi Pharmaceutical Co., Ltd.

34

Info

rmat

ion

of K

orea

n In

nova

tive

Ph

arm

aceu

tica

l Com

pany

Helixmith has expanded its products and pipelines with biologics and phytotherapeutics.Helixmith’s lead gene therapy product in the biologics business is Engensis (VM202), currently in phase III clinical study targeting diabetic peripheral neuropathy (DPN) in the US. Engensis is a plasmid DNA designed to simultaneously express two isoforms of hepatocyte growth factor (HGF), HGF728 and HGF723. In addition to DPN, Engensis is being studied for the treatment of diabetic foot ulcers (DFU), amyotrophic lateral sclerosis (ALS), and Charcot-Marie-Tooth disease (CMT). Helixmith has the experience and capabilities necessary to advance a product through the entire drug development process. The company is focused on developing innovative products to address unmet needs in both chronic and rare diseases . Helixmith is also developing phytotherapeutics with excellent efficacy and low side effects, utilizing experience and knowledge in research and development accumulated over the past 20 years. The company has unique experience in areas including drugs, health functional food and cosmetic products using botanical sources. Helixmith possesses the organization and abilities that exceeds most leading global biotech companies. The company has experience in basic science, candidate screening, preclinical, analytical processing, production, quality control, regulatory and clinical development. Helixmith will continue to strengthen our pipelines with new technologies and knowledge to maintain a high growth and create a high revenue business.

Main Products

Diabetic peripheral neuropathy(DPN) Amyotrophic lateral sclerosis (ALS) Diabetic foot ulcers(DFU) Claudication Charcot Marie Tooth disease(CMT) Coronary artery disease(CAD)

VM507

Chronic Kidney

Disease

(VM507)

PG201

HX204

Osteoarthritis

(PG201)

Inflammatory Bowel

Disease

(HX204)

Improvement of immune

hypersensitivity (PG102)

Improvement

of Woking memory

(HX106)

Engensis

(VM202)

Phytotherapeutics Gene Therapy Products

Plasmid DNA Antibody treatment Drugs Nutraceuticals

PG102 HX106

R&D PipelineIndication

Phase 1 Phase 2 Phase 3

Status of clinical trials

Engensis (VM202)

Plasmid

DNA

VM507 Antibody treatment

Pre-clinical

Diabetic peripheral neuropathy (DPN)

Diabetic foot ulcers (DFU)

Amyotrophic lateral sclerosis (ALS)

Charcot Marie Tooth disease (CMT)

Chronic kidney disease

Coronary artery disease (CAD)

Claudication

Gene

Therapy

Products

Phytotherapeutics

Drugs

Nutraceuticals

PG201

HX204

Osteoarthritis

Inflammatory bowel disease

LAYLA Tab.

BLA

PG102

HX106

HX109

HX110

HX112

Hypersensitivity improvement

Memory improvement

Indication & Function Development Status

Basic research Pre-clinical Clinical study Market

ALLEX

MNEMOSYNE

Prostate health

Respiratory health

Climacteric women’s health

www.helixmith.com/eng

The frontrunner in gene therapy

CEOSunyoung Kim, Seungshin Yu

Location21, Magokjungang 8-ro 7-gil, Gangseo-gu, Seoul 07794, Korea

SpecialtyPlasmid DNA-based gene therapy


Technology Transfer/LicensingSunkyung YangBusiness Development T. +82-2-2102-7238E. [email protected]

CONTACT US

Helixmith

35


Pharmaceutical Com

pany

CEOSeok Hee Kang

LocationPine Avenue Tower A, 100, Euljiro, Jung-gu, Seoul, 04551, Korea

SpecialtyETC (CVs, Antibiotics, IV Solution, Oncology, Endocrinology,Nephrology&Urology, Gastro Intestinal, Musculoskeletal, Respiratory, Others) & Health functional products


Technology Transfer/LicensingHyunjung Kim Innovation Team/ManagerT. +82-2-6477-0183E. [email protected]

Overseas exportJinho MaengGlobal Business/ManagerT. +82-2-6477-0190E. [email protected]

Overseas OfficeSungbin ChoK-CAB BD/ManagerT. +81-80-1249-0427E. [email protected]

Overseas OfficeMinki KuVietnam branch office/ManagerT. +82-70-4990-2712E. [email protected]

CONTACT US

www.inno-n.com/engHK inno. N

Global Top Tier Biohealth Company

inno.N has technology-focused business competitiveness in the fields of ETC Drugs, APIs, and Health & Beauty Care. In 2019, inno.N launched the new medicine for gastroesophageal reflux disease, "K-CAB Tab.," was released as the 30th new drug in Korea. Furthermore, inno.N unrivaled in the basic IV fluids and anti-hangover drink markets. It has more than 20 new drug and biopharmaceutical pipelines centered on digestion, oncology, liver, Auto immune, and infection, and recently established a future growth engine by entering the cell gene therapy business. With the 'Heal the World For Better Life' mission, inno.N will develop innovative new drugs and become a global pharmaceutical company that customers can trust.

Main ProductsProduct Indication & Use Exporting Countries

K-CAB Tab. (Tegoprazan) Gastroesophageal reflux disease (GERD) China, Vietnam, Latin America 24 countries including Mexico

Epokine Inj.(rh-EPO) Anemia of hemodialysis patients with end-stage renal disease Asia, Latin America and Africa

Vancorin Inj. (Vancomycin) Serious, life-threatening infections by gram-posi-tive bacteria Asia

Tapocin Inj. (Teicoplanin) Serious infections by gram-positive bacteria Aisa

Moveloxin I.V. solution bag (Moxifloxacin)Acute bacterial sinusitis, acute bacterial exacer-bation of chronic bronchitis, community acquired pneumonia and so on

Asia

Cinezolid I.V. solution bag (Linezolid) Vancomycin-resistant Enterococcus faecium infections -

Citopcin I.V. Solution bag (Ciprofloxacin) Infections caused by microorganism AsiaLevotopcin I.V. Solution bag (Levofloxacin) Infections caused by microorganism -Calmtop Inj. (Irinotecan) Colorectal cancer -

Pemta Inj. (Pemetrexed) Pleural mesothelioma and non-small cell lung cancer -

OmapOne Lipid Inj. bag (Fish/MCT/Soybean/Olive oiil)

Supplying energy, essential fatty acids and omega-3 fatty acids to patients. -

OmapOne Peripheral Inj. bag (Lipid, Amino acid, Glucose)

Supplying Lipid, Amino acid and Glucose to patients Aisa

Atomet XR Tab. (Atorvastatin/Metformin) Type2 Diabetes/Hyperlipidemia -Exone Tab (Valsartan/Amlodipine) Hypertension -Machkhan Tab. (Candesartan/Amlodipine) Hypertension -CONDITION (Hyaluronic acid) Anti-hangover drink China, Japan

HongSamJin Gold (Red Ginseng drink) Outstanding energy drink produced with 6-yeared red ginseng China

R&D Pipeline

Pipeline Target Indication DS PCClinical Trial

NDA MKT Partnering availabilityPI PII PIII

NCE

IN-A002 Autoimmune disease

Global

IN-A011 NutritionA2AR inhibitor CancerFER/T inhibitor CancerDCLK1 inhibitor Cancer

IN-A013 Cancer

IMD

IN-C008 Hypertension/yperlipidemiaIN-C009 Type 2 DiabetesIN-C010 Type 2 DiabetesIN-C011 Type 2 DiabetesIN-C001 Gastroesophageal reflux disease

Biologicals

IN-B001 Hand, Foot & Mouth DiseaseIN-B002 SmallpoxIN-B003 PneumoniaIN-B009 Covid-19TANKIO Cancer

DS: Discovery, PC: Preclinical Studies, MKT: Market, IMD: Incrementally Modified Drug

36

Info

rmat

ion

of K

orea

n In

nova

tive

Ph

arm

aceu

tica

l Com

pany

www.hyundaipharm.co.kr/english

People-centered R&D and Future Innovation

CEOSang-Joon, Lee

LocationHyundai Pharm Bldg, Bongeunsa Street 135, Gangnam-Gu, Seoul

Specialty1. NCE - Diabetes2. IMD – Fixed dose combination of

Alzheimer’s disease3. IMD – Fixed dose combination of

Respiratory disease


Technology Transfer/Licensing Overseas exportShin-Sook, RyouVP, Head of Global Business, RA & MAT. +82-2-2600-3803E. [email protected]

CONTACT US

HYUNDAI Pharm.

HYUNDAI Pharm. was founded in 1965 as a pharmaceutical company with the corporate philosophy of "Contributing to the improvement of the health of mankind” based on the philosophy of the CEO who aims at the esteem of human respect and transparent corporate spirit. As a global R&D company, we aim to fulfill our responsibilities for improving public health by focusing on developing new drugs and incrementally modified drugs through continuous investment.

Main Products

Product name Active ingredients Indications

Minoxyl - 3%, 5% Solution

- 3%, 5% GelMinoxidil Androgenetic alopecia

Minoxyl complex Solution 5% Minoxidil, Vitamin V6 / E, L-menthol Androgenetic alopecia

Tenormin Tab. Atenolol Hypertension, Angina Pectoris

Uremin Tab. Desmopressin acetate Nocturnal enuresis

Mirtapin Tab. Mirtazapine Major depressive disorder

Mirap Tab. / ER Tab. Pramipexole HCl Parkinson's disease

Hipezil Tab. Donepezil HCl Alzheimer's disease

Dimantin Tab. Memantine HCl Alzheimer's disease

Tamirin SR Tab. Galantamine HCl Alzheimer's disease

Pemirosal Tab. / Dry Syrup Pemirolast potassium Bronchial Asthma, Allergic Rhinitis

Surfolase Cap. / CR Tab. Acebrophylline Acute & chronic Bronchitis

Levotuss Tab. / Syrup Levodropropizine Acute & chronic Bronchitis

Clinium Vaginal Tab. Dequalinium Chloride Bacterial & Candida Vaginitis

R&D Pipeline

CODE PROJECT INDICATION Disco-very

Pre-clinical Phase I Phase II Phase III NDA

NCE HDNO-1605[HOB-047]

HD-6277Novel antidiabetics

Type-2 Diabetes

IMD

BPDO-1603[BPS-034]

New fixed-dose combina-tion

Senile disease

HDDO-1728 New dosage form Senile disease

HDDO-1756 New fixed-dose combina-tion

Endocrine disease

HDDO-1801 New fixed-dose combina-tion

Respiratory disease

37


Pharmaceutical Com

pany

www.ildong.com/eng

An elite organization contributing to the health and happiness of humankind

CEOPaul Woong - sup Yun

Location2, Baumoe-ro 27-gil, Seocho-gu, Seoul, Korea

Specialty1. Ethical drug/Over-the-counter

drug(Vitamins, Probiotics)2. Antibiotics3. Anticancer drug

Tel/Fax/E-mailT. +82-2-526-3114F. +82-2-526-3030

Technology Transfer/LicensingDong Young ParkBusiness Development Team/ManagerT. +82-2-526-3383E. [email protected]

Overseas exportNathan AhnOverseas Business Team/Manager T. +82-2-526-3500E. [email protected]

CONTACT US

Ildong Pharmaceutical Co., Ltd.

Since Ildong Pharmaceutical Group was founded in 1941 under the philosophy of ‘pharmaceuticals are rooted in humans’, We have created and shared significant value for health and prosperity throughout many years and will continue this endeavor. Ildong has become one of the leading pharmaceuticals in South Korea with powerful brand lineups including Aronamin, Biovita, and other major OTC products. We developed robust product pipelines for ethical drugs using our advanced technologies and diverse strategic partnerships.

Main Products

R&D Pipeline

2

Development Pipeline

Preclinical Phase 1/2

GPR40: G-Protein-coupled Receptor 40, NASH: Non-Alcoholic SteatoHepatitis, FXR: Farnesoid X Receptor, A2A: ATX: Autotaxin, CFTR: Cystic Fibrosis Transmembrane Conductance Regulator, NO/PDE: Nitric Oxide/Phosphodiesterase E VEGF-A/NRP1: Vascular Endothelial Growth Factor-A/Neuropilin-1, GLP-1R: Glucagon-Like Peptide-1 Receptor

Oncology

Liver disease

CNS disease

Eye Disease

Metabolic disease

ID11014 T2DM GPR40

ID11052 T2DM

GLP-1R

ID13010 wAMD

VEGF-A /NRP1

ID11901 Glaucoma NO/PDE

ID11041 Dry eye CFTR

ID11904 Parkinson A2A/A1

ID11916 Solid tumor

N.G. Antiandrogen

ID11903 NASH FXR

ID11905 NASH ATX

IDB0076 Solid tumor VEGF-A/

NRP1

IDX1197 Solid tumor

A PARP-i licensed out to an Ildong group NRDO, idience in

August 2019

ID11902 Solid tumor

A2A

COVID19 ID-COVID-02

Anti-Virus Undisclosed

ID-COVID-01 ARDS

Undisclosed

Myni GQlab Telostop, Twotops

Meditouch Aronamin 비오비타 Besivo

38

Info

rmat

ion

of K

orea

n In

nova

tive

Ph

arm

aceu

tica

l Com

pany

www.abxis.com/eng/index.do

Biopharmaceutical Company Developing Innovative Treatment of Cancer

CEOSeok Joo Lee

LocationGlobal R&D Center Building C 5th Fl, 22 Daewangpangyo-ro, 712 Beongil, Bundang-gu, Seongnam-si, Gyoenggi-do 13488

Specialty1. Novel biological cancer drugs2. Biosimilars in rare diseases


Technology Transfer/LicensingJunho LimStrategic Planning/Deputy General ManagerT. +82-31-696-4671E. [email protected]

Overseas exportHenry SungPharmaceutical Business/ManagerT. +82-31-696-4717E. [email protected]

Overseas exportDaniel YangPharmaceutical Business/ManagerT. +82-31-696-4644E. [email protected]

CONTACT US

ISU ABXIS Co., Ltd.

ISU ABXIS is a biopharmaceutical company founded in 2001 with a desire of being an axis of therapeutic antibody as its names stands for ABXIS = AntiBody + aXIS. Beginning with the successful development and market launch of the Korean first therapeutic antibody Clotinab® in 2007, ISU ABXIS has established its own biotherapeutics development technologies and led Korean biopharmaceutical industry. ISU ABXIS will be dedicated to improving the lives of patients with cancers and incurable diseases.

Main Products

Therapeutic Area Product Generic Name Major Market

Rare DiseaseAbcertin® Imiglucerase Korea, Iran

Fabagal® Agalsidase beta Korea

Cardiovascular Clotinab® Abciximab Korea, Turkey

R&D Pipeline

Category Project INN IndicationDevelopment Status

Discovery Non-clinical Phase 1 Phase 2 Phase 3

Oncology

ISU104 Barecetamab

Head and Neck Cancer

Colorectal Cancer

Breast Cancer

ISU104ADC - Solid Tumor

ABX1701 - Solid Tumor

ABX2001 - Solid Tumor

Rare Incur-able

Disease

ISU304 Dalcinonacog alfa Hemophilia B

ISU305(Soliris®

Biosimilar)Eculizumab Paroxysmal Nocturnal

Hemoglobinuria

Abcertin®

(Cerezyme® Biosimilar)

Imiglucerase Gaucher’s Disease

Novel Target A - Alzheimer’s Disease

Abcertin® Clotinab®Fabagal®

39


Pharmaceutical Com

pany

Janssen Korea, the Korean branch of the pharmaceutical division of Johnson & Johnson, started as a joint company with Yuhan Corporation in 1983. For the last 30 years, it has been committed to provide useful medicines for the treatment of diverse diseases. We focus on areas of medicine where we can make the biggest difference: Cardiovascular & Metabolism, Immunology, Infectious Diseases & Vaccines, Neuroscience, Oncology, and Pulmonary Hypertension.

Main Products

Theraputic Area Product Ingredient Indication

Neuroscience

Invega Sustenna Paliperidone palmitate Schizophrenia

Invega Trinza Paliperidone palmitate Schizophrenia

SPRAVATO Esketamine TRD(Treatment Resistant Depression), MDSI(Major Depressive Disorder who have acute Suicidal Ideation or behavior)

Oncology

Velcade Bortezomib Multiple Myeloma, Mantle Cell Lymphoma

Darzalex Daratumumab Multiple Myeloma

Imbruvica Ibrutinib Mantle Cell Lymphoma, Chronic Lymphocytic Leukemia

Zytiga Abiraterone acetate Meta Castration-Resistant Prostate Cancer

Infectious Diease Sirturo Bedaquiline Multi-Drug Resistant Tuberculosis

Pulmonary Hypertension Opsumit Macitentan Pulmonary Hypertension

PainUltracet Tramadol Moderate to severe Pain

Nucynta Tapentadol Severe Pain

Immunology

Simponi Golimumab Rheumatoid Arthritis, Ankylosing Spondylitis, Psoriatic Arthritis

Remicade Infliximab Rheumatoid Arthritis, Ankylosing Spondylitis, Crohn’s Disease, Ulcerative Colitis

Stelara Ustekinumab Psoriasis, Psoriatic Arthritis, Crohn’s Disease, Ulcerative Colitis

Tremfya Guselkumab Psoriasis

R&D Pipeline

TA Project/Product Indication Phase 2 Phase 3

Immunology

TREMFYA® Crohn's Disease, Pediatric Psoriasis, Ulcerative Colitis ∨

SIMPONI® Pediatric Ulcerative Colitis ∨

nipocalimab Warm Autoimmune Hemolytic Anemia ∨

Oncology

BALVERSATM Urothelial cancer, Tumor Agnostic, Non-muscle Invasive Bladder Cancer (NMIBC) ∨ ∨

ERLEADA® Prostate cancer ∨

niraparib L3 Prostate cancer metastatic castration-resistant ∨

Lazertinib / amivantamab Non Small Cell Lung Cancer ∨

ciltacabtagene Autoleu-cel (BCMA CAR-T) Relapsed refractory multiple myeloma ∨ ∨

teclistamab Relapsed refractory multiple myeloma ∨

Neuroscience seltorexant Adjunctive treatment for major depressive disorder with insomnia symptoms ∨

Infectious Disease

VAC31518 Janssen COVID-19 Vaccine ∨

VAC52150 Monovalent Ebola Virus Vaccine ∨

VAC89220 HIV Prevention Vaccine ∨

Pulmonary Hyper-tension

OPSUMIT®Fontan-palliated in adolescent (>12 years old) and adult patients, Pediatric pulmonary arterial hypertension, Chronic thromboem-

bolic pulmonary hypertension ∨

UPTRAVI® Chronic thromboembolic pulmonary hypertension, Pediatric pulmonary arterial hypertension ∨

www.janssen.com

Innovative and Responsible

CEOCherry Huang

Location25F LS-Yongsan Tower, 92 Hangangdaero, Yongsan-gu, Seoul, Korea

Specialty· Invega Sustenna/Invega Trinza: Schizophrenia

· SPRAVATO®/Depression · Sirturo: Multi-drug-resistant tuberculosis(MDR-TB)

· Velcade/Darzalex: Multiple Myeloma

· Imbruvica: Mantle Cell Lymphoma· Zytiga: Prostate Cancer· Ultracet: Moderate to severe Pain· Nucynta: Severe Chronic Pain· Simponi: Rheumatoid Arthritis, Ankylosing Spondylitis

· Remicade: Rheumatoid Arthritis, Ankylosing Spondylitis, Crohn’s Disease, Ulcerative Colitis

· Stelara: Psoriasis, Psoriatic Arthritis, Crohn’s Disease, Ulcerative Colitis

· Tremfya: Psoriasis


Technology Transfer/LicensingLee, JoonYupMESO/Business Intelligence & Innovation Sr. ManagerT. +82-10-8928-5651E. [email protected]

CONTACT US

Janssen Korea Ltd.

40

Info

rmat

ion

of K

orea

n In

nova

tive

Ph

arm

aceu

tica

l Com

pany

CEOSHIN YOUNG SUBLEE SEUNG RYLL

Location2477, Nambusunhwan-ro, Seocho-gu, Seoul, 06725, Korea

SpecialtyI.V-solutions, antibiotic, cardiovascular, urology, gastrointestinal, nephrology and anticancer

Tel/Fax/E-mailT. +82-2-840-6777F. +82-2-831-8351

Technology Transfer/LicensingJiseon LimLicensing/ManagerT. +82-2-840-6883E. [email protected]

Overseas exportJungoo LeeGlobal Sales/DirectorT. +82-2-840-6718E. [email protected]

etcGyungmo YeunCorp. Planning Office/AssociateT. +82-2-840-6836E. [email protected]

CONTACT US

www.jw-pharma.co.krJW Pharmaceutical

We are a healthcare leader & pioneer making what is impossible today, possible tomorrow with the innovative technology.

JW group Provides pharmaceuticals vital for maintaining the lives of patients such as anticancer drugs and antibiotics, and has developed into a leading pharmaceutical company and global manufacturer of I.V. Solutions.For 75 Years ever since its foundation in 1945, JW group focuses on healthcare, ETC, OTC, diagnostics and medical equipment. Based on new technologies and services for healthy lives of human beings, JW group has built up strong sales network across the country and superior pipelines in I.V. solutions, antibiotics, oncology, cardiology, rheumatology and gout.

Main Products

1. Finished Product

- Carbapenem Antibiotics- Amino Acid Solutions- General I.V Solutions & Other Sterile Solutions- Antimicrobial & Antifungal Agents- Gastrointestinal Agents- Topical- Multivitamins- Agents for Antibiotics- Miscellaneous

2. API (Active Pharmaceutical Ingredient)

- Carbapenem Antibiotics: Imipenem/Cilastatin- Anti-fungals: Ketoconazole, Itraconazole, Fluconazole- Chiral Products for Custom Synthesis & Specialty Amino Acid- Miscellaneous

R&D PipelineR&D Pipeline Preclinical Phase 1 Phase 2 Phase 3 Registration

Oncology

Project A1 WNT inhibitor

JW2286 STAT3 inhibitor

CWP291 WNT inhibitor

Project B1 Project B2 CreaVax-BC GBM*

CreaVax-HCC HCC*

CreaVax-RCC RCC*

Project B3 Project B4

Immune diseases

Project A2 WNT inhibitor Project B5

Cardiovascular and

Metabolic diseases

LIVALO

LIVALO E LIVALO V

J-DART

Regenerative medicine

CWL080061 WNT activator

Project A3 WNT activator

Orphan Project A4 WNT activator

HEMLIBRA Hemophilia

Eye diseases

Project A5 H4R antagonist

JWP1601 H4R antagonist

URC102 Anti-gout

*GBM : glioblastoma multiforme *HCC : Hepatocellular carcinoma *RCC : Renal Cell Carcinoma

41


Pharmaceutical Com

pany

www.otsuka.co.kr/introduction_en

Korea Otsuka Pharmaceutical Co., Ltd.

CEOMoon, Sung-ho

Location226, Yeoksam-ro, Gangnam-gu, Seoul, Republic of Korea

Specialty1. Chemical drug of CNS category2. Chemical drug of Oncology

category3. Orphan drugs & First in class

products

Tel/Fax/E-mailT. +82-2-3287-9000F. +82-2-3287-9069 E. [email protected]

Technology Transfer/LicensingLee sang wook Market Access Team/Team LeaderT. +82-2-3287-9150E. [email protected]

Overseas exportHeo won nyoungResource Management Team/Team LeaderT. +82-2-3287-9060E. [email protected]

CONTACT US

Korea Otsuka Pharmaceutical Co., Ltd.

Korea Otsuka Pharmaceutical supplies excellent and innovative pharmaceutical and healthcare products. At a multinational pharmaceutical company equipped with large-scale production facilities in Korea, we contribute to the growth of national economy through domestic production as well as export. With understanding of customers, markets and social responsibilities, we are fulfilling our role and mission to become a company contributing to the healthy life of Koreans.

Main Products

Category Product Generic name Export

CNS

Abilify Tab.

Aripiprazole EU,Hongkong,Thailand, Indonesia,Philippine,TaiwanAbilify OD Tab.

Abilify Maintena Inj.

Abilify Oral Solution

Rexulti Tab. Brexipiprazole Indonesia

Renal/CV

Pletaal Tab.Cilostazol Japan,China,Indonesia,Taiwan,Philippine,Thailand,Malaysia,

Myanmar,Pakistan,Vietnam,HongkongPletaal SR Cap.

Samsca Tab. Tolvaptan Thailand,Phillippine,Indonesia,Vietnam,Myanmar

GIMucosta Tab.

Rebamipide Japan,China,Indonesia,Philippine,Cambodia,Macau,Malaysia, Myanmar,Pakistan,Thailand,VietnamMucosta SR Tab.

OncologyBusulfex Inj. Busulfan

Iclusig Tab. Ponatinib

Pulmonary Deltyba Tab. Delamanid

R&D Pipeline

TA Product IndicationDevelopment

Discovery Preclinical Phase1 Phase2 Phase3 Launch

OrphanDeltyba Tab Multi-drug resistant

tuberculosis

Iclusig Tab CML, Ph+ ALL

New drug

OPB-111077 DLBCL

ASTX-727 AML, MDS

OPA-15406 Atopic dermatitis

SGI-110-04,06,07,12 AML, MDS

TEV-48125 Migraine

Rexulti Schizophrenia, Pediatric

Abilify Maintena Inj Schizophrenia, etc.

Samsca Tab Hyponatremia, ADPKD

Incrementally Modified

Drug

Pletaal SR Cap Cerebral infarction, etc.

Abilify OD Tab Schizophrenia, etc.

Mucosta SR Tab Gastritis

Medical Device Paradise Resistant hyperten-

sion

42

Info

rmat

ion

of K

orea

n In

nova

tive

Ph

arm

aceu

tica

l Com

pany

kup.co.kr/main.do?lang=en_us

For the Best Global Pharmaceutical Company

CEODUK YOUNG KANG

LocationSeoul, Gangnam-gu, Nonhyeon-ro 121 street 22

SpecialtyIncrementally Modified Drugs for1. Antithrombotic 2. Gastrointestinal 3. Bronchitis disease


Technology Transfer/LicensingWon-Wook LeeBD Licensing/Senior ManagerT. +82-2-558-8612E. [email protected]

Overseas exportHans ChoOverseas Business/General ManagerT. +82-2-543-4079E. [email protected]

Overseas OfficeJae Hyeok ChoiOverseas Marketing/Assistant ManagerT. +82-2-512-9982E. [email protected]

etcJUNGWOOK LEEPublic Relations/ManagerT. +82-2-512-9981E. [email protected]

CONTACT US

KOREA UNITED PHARM. INC.

Established in 1987, Korea United Pharm. Inc. has continued to develop various products through prestigious R&D investment. It was named one of Asia's 200 most promising companies by the US economy magazine Forbes in recognition of its growth potential. it has established several overseas branches and corporations to make inroads into the global market. Also, it is striving to do the best to fulfill social responsibilities through various social contribution activities.

Main Products

Product Active ingredient Indication

Clanza CR Tab Aceclofenac anti-inflammatory

Clavixin Duo Cap. Clopidogrel + Aspirin antithrombatic

Cilostan CR Tab. Cilostazol antithrombatic

Gastiin CR Tab. Mosapride functional dyspepsia

Levotics CR Tab. Levodropropizine bronchitis

Unigril CR Tab. Sarpogrelate HCl antithrombatic

Fenorics EH Tab. Fenofibric acid Dyslipidemia

Kalomin S Tab. Pelargonium sidoides bronchitis

Glicetil Syrup Choline alfoscerate brain functioning

Omethyl QTlet Soft Cap. Omega-3-acids ethyl esters 90 2g Dyslipidemia

Romin Comp Syrup Lomincomp 9ml/pkg syrup (pelargonium sidoides/coptidis rhizome extract) Bronchitis

ATMEG Combigel softcap. Atorvastatin + Omega-3-acids ethylesters Dyslipidemia

R&D Pipeline

43


Pharmaceutical Com

pany

CEOHak Cheol Shin

LocationLG Twin Towers, 128, Yeoui-daero, Yeongdeungpo-gu, Seoul, South Korea

SpecialtySmall molecules/biologics-based new medicine in oncology and immunology, Small molecules/biologics-based new medicine for diabetes and metabolic disease, Vaccine

Tel/Fax/E-mailT. +82-2-3773-1114F. +82-2-3773-7813

Technology Transfer/LicensingJong Heon WonBusiness Development Team/ManagerT. +82-2-6987-4072E. [email protected]

CONTACT US

Since its foundation in 1947, LG Chem has served as Korea’s representative chemical company, contributing to the development of the national economy and the enhancement of the quality of life through continuous technological development, new product introduction, and quality innovation based on its stable growth.We have established the production, sales, and R&D networks at home and abroad, expanding our business into the global market, aiming to become a world-class company that provides innovative materials and solutions by sharpening our competitive edge in high-value added core businesses while expanding new business opportunites in IT & Electronic Materials and Energy Solutions.In addition, we have recently merged LG Life Sciences, a former subsidiary of LG Chem in order to strengthen and expand its business in Life Science area.In the business area which LG Chem has focused on nurturing as a new growth engine of the future, LG Chem became the first in Korea to develop gamma interferon by applying genetic engineering technologies in 1989 and the first to receive approval for a new drug from U.S Food and Drug Administration (FDA) with its development of “Factive”(quinolone antibiotic) in 2003. LG Chem will continue to secure competitiveness in the global market through aggressive investment and enhancement of its R&D capabilites based on its technological prowess that has succeeded in commercializing the drugs.

Main Products

Product Description

Zemiglo/ Zemimet The optimized DPP-4 inhibitor having potent efficacy, reliable safety and better compliance benefits/Once daily DPP-IV inhibitor and Metformin SR combination product

Eucept The first biosimilar of Etanercept ever developed by LG Chem

Eutropin The right choice for managing short stature recombinant human growth hormone with proven efficacy and safety since 1993

Eupenta Combined Diphtheria, Tetanus, whole cell Pertussis, Hepatitis B and Haemophilus influenza typeB.Eupen-ta can prevent five different childhood disease with a single injection

Eupolio the first Sabin-Inactivated Polio Vaccine pre-qualified by the WHO

YVOIRE Cross-linked sodium hyaluronate made by microbial fermentation for tissue augmentation and wrinkle correction

R&D Pipeline

Field Projects Indication Discovery PreclinicalClinical Trial

Phase I Phase II Phase III

Vaccine LR19114 DTP/HepB/Hib/IPV prevention ●

Biologics

LR19055 Autoimmune disease ●

LR19127 HNSCC ●

LR19125 NSCLC ●

LR19156 (Undisclosed) Obesity ●

LR19023 Cancer ●

LR19129 Cancer ●

Chemicals

LR19052 Diabetes ●

LR19019 Ulcerative colitis ●

LR19074 Gout ●

LR19021 Obesity ●

LR19123 Diabetes ●

LR19018 (Undisclosed) NASH ●

LR19024 (Undisclosed) OA ●

LR20009 (Undisclosed) Cancer ●

www.lgchem.com

We connect science fo life for a better future

LG Chem, Ltd.

44

Info

rmat

ion

of K

orea

n In

nova

tive

Ph

arm

aceu

tica

l Com

pany

www.medytox.com/?site_id=en

Leap forward to become one of the world’s top bio-pharmaceutical companies

CEOJung Hyun Ho

Location78, Gangni 1-gil, Ochang-eup, Cheongwon-gu, Cheongju-si, Chungcheongbuk-do, Republic of Korea

SpecialtyBotulinum toxin products, Medical aesthetics, Bio-pharmaceuticals

Tel/Fax/E-mailT. +82-43-217-1555F. +82-2-3476-8372

Technology Transfer/LicensingYoon SukwonBusiness Development Team/DirectorT. +82-2-6901-5825E. [email protected]

Overseas exportOh YongkiInternational Business Team/DirectorT. +82-2-6901-5463E. [email protected]

Overseas OfficePark YoungsangNortheast Asia Biz Team/DirectorT. +82-2-6901-5875E. [email protected]

CONTACT US

Medytox, Inc.

Medytox is a biopharmaceutical company that changes the future with ceaseless R&D.

As the first company in Korea to develop a botulinum toxin type A product, Medytox feels a sense of pride and responsibility for the Korean biopharmaceutical industry. Therefore Medytox is leading the efforts to improve the transparency and the competitiveness by pushing for implementation of more objective and scientific guidelines.Medytox has been working towards the vision of growing as a global biotechnology company. Linked to this, Medytox strives to tackle the advanced markets such as USA, EU and to directly penetrate and expand into the emerging markets. In addition, Medytox will continue to develop and commercialize new products by increasing investment in R&D to create meaningful results.

Main Products

Products Content Characteristic

Neuronox® Clostridium botulinum toxin type A (Hall group)

Neuronox® is the first botulinum toxin type A product developed in Korea. Neu-ronox(R) ranked No.1 market share in major countires including Korea, and has also been registered in 34 countries such as Brazil, Saudi Arabia, etc.

Innotox® Clostridium botulinum toxin type A (Hall group)

INNOTOX® is the world’s first liquid formulation of botulinum toxin type A product which has been developed by totally excluding animal derived ingredi-ents and human serum albumin (HSA) in order to enhance product safety.

Coretox® Clostridium botulinum toxin type A (150kDa) (Hall group)

Coretox® is an advanced new botulinum toxin type A product that also ex-cludes animal derivatives and HSA. Especially, Coretox® successfully excludes non-toxin proteins from its ingredients to prevent the immune system from de-veloping antibodies that would eventually wear down the effects of botulinum toxin.

R&D Pipeline

Division Code Indication Stage

Biodrug

Neuronox®Benign Masseteric Hypertrophy, Overactive Bladder, Migraine, Gla-bellar Line(US, EU, China, Taiwan, Russia), Lateral Canthal Line(US, EU), Blepharospasm(China)

Approved+ clinical

Innotox® Aesthetic and Treatment (US, EU) Approved+ Clinical

Coretox® Upperlimb Spasticity Approved + Clinical

MT912 Macular degeneration Preclinical

MT107 Anticancer drugs Preclinical

MT981 Solid Cancer Preclinical

MT971 Inflammatory bowel disease Preclinical

MT116 Solid Cancer Preclinical

Synthetic DrugsMT921 Fat Reduction Clinical

MT106 Lymphoma Preclinical

45


Pharmaceutical Com

pany

OliX Pharmaceuticals (KOSDAQ, 226950) is an RNAi-based pharmaceutical company developing innovative therapeutics against a variety of disorders. Based on its proprietary cp-asiRNA technology that minimizes adverse effects and maximizes intracellular delivery, OliX is focused to address significant unmet medical needs in dermal, ophthalmic, and liver areas. Over the past years, the excellence of its technology has been globally recognized through notable license and collaboration agreements. Since the 2018 KOSDAQ listing, OliX is actively expanding its business by establishing subsidiaries and labs in the US.

Main Products

Indication Area Program Indication Remarks

SkinOLX101A Hypertrophic Scar Hugel (Asia)

OLX104C Androgenic Alopecia

Eye

OLX301A Dry & Wet AMD Théa (Worldwide Excl. Asia-Pacific)

OLX301D Subretinal Fibrosis Théa (Worldwide Excl. Asia-Pacific)

OLX301E Wet AMD

OLX304A Retinitis Pigmentosa

Liver

OLX701 Liver Fibrosis

OLX702 Liver Disease (NASH, Diabetes etc.)

OLX703 HBV

LungOLX201A Idiopathic Pulmonary Fibrosis

OLX204A COVID-19

CNS OLX401A Neuropathic Pain

Oncology OLX801A Cancer Immunotherapy

R&D Pipeline

Program Indication R&D AnimalPOC Pre clinical Clinical

OLX101A Hypertrophic Scar

OLX104C Androgenic Alopecia

OLX301A Dry & Wet AMD

OLX301D Subretinal Fibrosis

OLX301E Wet AMD

OLX304A Retinitis Pigmentosa

OLX701 Liver Fibrosis

OLX702 Liver Disease (NASH, Diabetes etc.)

OLX703 HBV

OLX201A Idiopathic Pulmonary Fibrosis

OLX204A COVID-19

OLX401A Neuropathic Pain

OLX801A Cancer Immunotherapy

www.olixpharma.com/eng

CEODong Ki Lee

LocationAce Gwanggyo Tower1, Suite 1014, 17, Daehak 4-ro, Yeongtong-gu, Suwon-si, Gyeonggi-do, 16226, Republic of Korea

Specialty1. RNAi based therapeutics 2. Nucleic acid therapeutics 3. New drug development


Technology Transfer/Licensing/Overseas exportSun Woo HongBusiness development team/Vice PresidentT. +82-31-779-8407E. [email protected]

Overseas OfficeJason choiDirectorE. [email protected]

CONTACT US

Become one of the world’s top three nucleic acid companiesBecome a world-class advanced research center for biomedical technology

OliX Pharmaceuticals, Inc.

(Korea) Currently in Phase2 (US) Currently in Phase2

46

Info

rmat

ion

of K

orea

n In

nova

tive

Ph

arm

aceu

tica

l Com

pany

www.pharmaresearch.co.kr/eng

PharmaResearch Co., LTd has been researching and developing healthcare products for anti-aging and improving Quality of Life. In 2007, PharmaResearchProducts stood up as a leading regenerative medicine company by developing endogenous repair stimulator PDRN®

Moreover, PharmaResearch Co., LTd diversified the product pipelines for regenerative medicine from on license-in, co-developments to strategic investments. PharmaResearch Products is promoting market expansion in both domestic and global.

Main Products

Category Product name Use

DrugRe-an eye drop Cornea and conjunctiva regenerative eye drop

Rejuvenex Injcetion Wound healing and tissue regenerative injection

Medical DeviceRejuran New Regenerative Filler (Healer) for Satisfying both skin regeneration and

filler effect

Conjuran Intra-articular injection for Cartilage regenerative osteoarthritis treatment

R&D Pipeline

Projects 2019 2020 2021 2022

Tendinopathy IND Clinical Study(Phase 3) Approval

Atopy medicines IND Clinical Study Approval

Dry eye syndromes Pre-review Approval

PXL01(Global) IND Clinical study(Phase 3) Approval in Europe

PXL01(Domestic) IND Clinical study Approval

LL-37 Clinical study(Phase 2) Licessing out

PDRN New Formulation Non-ClinicalStudy IND Clinical Study Clinical Study

(Phase 3)

Zadaxin New Formulation Non-ClinicalStudy IND Clinical Study

(Phase 1)Clinical Study

(Phase 2)

REGENERATIVE SCIENCE FOR A BETTER & LONGER LIFE

CEOKi-Seock Kang, Thin-Kyu Kim

Location77-19, Gwahakdanji-ro, Gangneung-si, Gangwon-do, Korea

Specialty1. Regenerative and immuno-

stimulative medicine2. Advanced medicine to improve

QOL(Quality of life)

Tel/Fax/E-mailT. +82-31-8039-1500F. +82-31-8039-1501

PharmaResearch Co., Ltd.

Re-an eye drop Rejuvenex Injcetion Rejuran Conjuran

47


Pharmaceutical Com

pany

Pharmicell Co., Ltd. is a biopharmaceutical company that developed the world's first stem cell therapy (Hearticellgram-AMI) in 2011. The company's business area divided into two sectors(bio and biochemical) as below in detail.First, in the bio business sector, stem cell therapy R&D and sales business for curing obstinate disease and improving human health and stem cell storage business preparing for the outbreak of the disease. We are focusing on bio-based construction business and cosmetic business based on stem cells.Second, the biochemical division develops and produces Raw Material Pharmaceutical Intermediates (Nucleoside and mPEGs) needed for the development of new pharmaceuticals by global pharmaceutical companies. Furthermore, we also provide Low Dielectric Constant Resin required for cutting edge network equipment such as 5G network boards, base station antennas, and mobile devices. Now, we are diversifying our business by producing Reactive and Additive Flame Retardants used in Printed Circuit Board (PCB) such as mobile and home appliances.Pharmicell Co., Ltd. will do its best to grow into a respected company for curing obstinate disease and improving human health.

Main Products

Product(Ingredient/Formulation) Use Exporting

Countries Remarks

Hearticellgram-AMI(Autologous Bone Marrow-Derived Mesenchymal Stem Cell) Acute Myocardial Infarction - Launched

Cellgram-LC(Autologous Bone Marrow-Derived Mesenchymal Stem Cell) Alcoholic Liver cirrhosis -

Developing(Clinical Trial, Phase II

completed)

Cellgram-ED(Autologous Bone Marrow-Derived Mesenchymal Stem Cell) Erectile Dysfunction -

Developing(Clinical Trial, Phase I

completed)

Cellgram-DC-PC( Autologous Dendritc Cell pulsed with prostate cancer antigen)

AnticancerImmuncell Thera-peutic Vaccine for Prostate

Cancer. - Developing

(Clinical Trails)

Cellgram-DC-OC( Autologous Dendritc Cell pulsed with ovarian cancer antigen)

AnticancerImmuncell Thera-peutic Vaccine for Ovarian

Cancer. - Developing

(Clinical Trails)

R&D Pipeline

Cellgram®-AMI

Acute Myocardial Infarction

®-LC

Liver Cirrhosis (KR)

Liver Cirrhosis (US)

Erectile Dysfunction

Chronic kidney disease

Cancer Cellgram-DC

Prostate Cancer

Ovarian Cancer

It is the world first stem cell drug approved by MFDS (The Ministry of Foods and Drug Safety of Korea) in July 2011.

Phase III clinical trial

Phase 1 clinical trial



R&D Pipeline (출판용)

Phase 1 clinical trial (planned)

www.pharmicell.com/eng

Respected Company for curing obstinate disease and improving human health.

CEOKim, Hyun Soo

Location7th floor, Ssangbong Building, 874 Unju-ro, Gangnam-gu, Seoul-si

Specialty1. Stem Cell Therapeutics2. Next Generation Dendritic Cell

Therapeutic Vaccines3. Raw Material Pharmaceutical

Intermediates


Technology Transfer/Licensing/Overseas export/Overseas Office/etc DongHuk JangPlanning & Coordination Dept./ManagerT. +82-10-4056-5753E. [email protected]

CONTACT US

Pharmicell Co., Ltd.

48

Info

rmat

ion

of K

orea

n In

nova

tive

Ph

arm

aceu

tica

l Com

pany

www.samyangbiopharm.com/eng

Value Generating Pharma Company

CEOTae-Ung Eom

Location295, Pangyo-ro, Bundang-gu, Seongnam-si, Gyeonggi-do, Republic of Korea

Specialty1. Drug delivery system of anti-cancer

drugs based on small molecules, virus and nucleic acid

2. New biologic anticancer drugs and Rare disease drugs

3. Cytotoxic anticancer drugs4. Small molecule anticancer drugs


Technology Transfer/LicensingChoi HyangR&D Planning/ManagerT. +82-2-2157-9814E. [email protected]

Overseas exportSeo Yoon CheongOverseas Business Team/Assistant ManagerT. +82-2-2157-9867E. [email protected]

Overseas OfficeSeyoon KimBD/Senior ManagerT. +1-617-812-6969E. [email protected]

AdministrationJin Woo KimBiopharm. Planning TeamT. +82-2-2157-9808E. [email protected]

CONTACT US

Samyang Holdings Corporation (Biopharmaceuticals Business)

Samyang Holdings Corporation(Biopharmaceuticals Business) is specialized in development of small-molecule drugs, new biologic drugs and virus vaccines, and commercialization of DDS-based modified drugs and first generics for cancer treatment. Samyang is exporting its oncology products and expanding its product portfolio. Samyang’s cytotoxic facility obtained GMP certifications from KR, EU, and JP. The new facility is expected to achieve full cGMP operation. Samyang Biopharm USA Inc. in Cambridge concentrates on global new drug development in immune-oncology and rare diseases.

Main ProductsFDF Product Formulation Strength Specifications

Polymeric Micelle

Genexol® PM Lyophilized Injection 30mg, 100mg/vial In-houseNanoxel® M Lyophilized Injection 20mg, 80mg/vial In-house

Generics for Solid Tumors

Paclitaxel Liquid Injection 30mg, 100mg, 150mg, 300mg/vial USP, EPDocetaxel Liquid Injection 20mg, 80mg, 140mg, 160mg/vial EPOxaliplatin Liquid Injection 50mg, 100mg, 200mg/vial EP, JP

Gemcitabine Liquid Injection 200mg, 1g/vial USP

PemetrexedLiquid Injection 1g/vial In-houseLiquid Injection 100mg, 500mg/vial In-house

Lyophilized Injection 100mg, 500mg/vial In-houseEverolimus Oral Tablet 2.5mg, 5mg, 10mg/tab In-house

Generics for Blood Cancers

Azacitidine Lyophilized Injection 100mg, 150mg/vial In-houseDecitabine Liquid Injection 40mg, 50mg/vial In-houseBortezomib Lyophilized Injection 2.5mg, 3.5mg/vial In-house

Bendamustine Liquid Injection 25mg, 100mg/vial USPLenalidomide Oral Tablet 2.5mg, 5mg, 10mg, 15mg, 20mg, 25 mg/tab KP

Generis for Supportive Care

Palonosetron Liquid Injection 0.075mg, 0.25mg, 0.4mg/vial KPZoledronic Acid Liquid Injection 4mg/vial KP

Transdermal Drug Delivery System

Diclofenac Plaster 120mg BP

NicotinePatch 14mg, 28mg, 42mg EPGum 2mg USP

Fentanyl Patch 12㎍, 25㎍, 50㎍, 100㎍/h EPRivastigmine Patch 6mg(4.6mg/24hr), 12mg(9.5mg/24hr) EPTulobuterol Patch 0.5mg, 1mg, 2mg In-house

Nitroglycerin Patch 22.4mg(0.2mg/hr) USP

API Product Package DMF

Cytotoxic APIs

Paclitaxel Up to 500 g US DMF, CEP, KDMFDocetaxel Up to 500 g US DMF, CEP, KDMF

Pemetrexed Up to 500 g KDMFBortezomib Up to 500 g KDMFCabazitaxel Up to 500 g -

R&D Pipeline

Technology Research Clinical Registration

PM

Paclitaxel

Docetaxel

SYP-1261

PNPSYP-0709

SYP-0709S

SEMP SYO-1906

FDT Ramosetron

CSDS Prednisolone

SENS

SYP-1758

SYP-1765

SYP-1914

Metabolic Anticancer SYO-2001

49


Pharmaceutical Com

pany

www.shinpoong.co.kr/en/main/main.php

We never compromise on quality of drugs to create a healthy and desease - free society

CEOJei Man, Ryu

Location161, Yeoksam-ro, Gangnam-gu, Seoul, 06246, Republic of Korea

Specialty1. Synthesis of antibiotic raw

materials and dedicated production line

2. New drug and first generic drug in finished products

3. API


Technology Transfer/LicensingTae Hoon KimBD/Senior ManagerT. +82-2-2189-3483E. [email protected]

Overseas exportJohn H, WonGlobal Marketing & BD Team/Chief ManagerT. +82-2-2189-3511E. [email protected]

Overseas OfficeSung Je, Chu Global Branch Mgt. Team/Chief ManagerT. +82-2-2189-3510 E. [email protected]

CONTACT US

SHIN POONG PHARM. CO., LTD.

Shin Poong Pharm. Co., Ltd. is a R&D oriented pharmaceutical company with global presence in over 50 countries, and specializes in one-stop manufacturing from API to FPP from quality generics to NCE development. Under the management philosophy of “for the health of the People”, an EMA-approved new anti-malarial is well-exemplified, Pyramax®. Shin Poong Pharm.Co.,Ltd. is sustaining its efforts to fulfill the corporate goals of developing cutting-edge technologies for public health of our people.

Main Products

Classification Name Active Ingredient Indication

NCEPyramax® Tablets Pyronaridine tetraphosphate

& Artesunate Malaria

Pyramax® Granules Pyronaridine tetraphosphate& Artesunate

Malaria(Pediatric formulation)

IMD/FDCCandeAmlo® Tablets Amlodipine & Candesartan Hypertension

EzeRosu® Tablets Rosuvastatin & Ezetimibe Hyperlipidemia

Generic Hyalforte® Injection Sodium hyaluronate Osteoarthritis

※ NCE (New Chemical Entity), FDC (Fixed Dose Combination), IMD (Incrementally Modified Drug)

R&D Pipeline

Classification Products Indication Stage

NCE

SP-8203 Acute ischemic stroke Phase 2b (Korea) On-going

SP-8008 Anti-platelet Phase 1(Europe) On-going

SP-8356 Cerebro-cardiovascular diseases Phase 1(Europe) On-going

SP-8416 Heart failure Lead compound (Korea) On-going

SP5M001 Osteoarthritis(Long-lasting) Phase 3 IND (Korea) Completed

SP5M002 Osteoarthritis(Rapid pain relief) Phase 1/2 IND (Korea) On-going

SP1M002 Osteoarthritis(Anti-inflammatory) Non-clinical (Korea) On-going

IMD SPC1001 Hypertension Phase 2 IND (Korea) On-going

Drugrepositioning

Pyramax® tablets COVID-19 Phase 2 (Korea, South Africa)

Phase 2/3 (The Philippines) On-going

50

Info

rmat

ion

of K

orea

n In

nova

tive

Ph

arm

aceu

tica

l Com

pany

https://www.skchemicals.com

Beginning with "Sunpla“, the nation's first self-developed drug that opened a new chapter in Korea’s synthetic drug business, SK Chemical has since continued to launch new drugs such as "Mvix"(for erectile dysfunction) and "Joins"(the nation's first natural medicine), establishing a sizable product portfolio. In addition, SK Chemical has marketed a variety of drugs including "Trast"(the world's first patch for arthritis), "Ginexin"(No.1 market share drug for improving blood circulation), and ”Rinexin“(platelet aggregation inhibitor).

Main Products

R&D Pipeline

Indication Product Product type

Arthritis Joins Natural Medicine

Erectile Dysfunction MVIX Chemical Drug

Blood circulation Ginexin Natural Medicine

blood aggregation inhibitor Rinexin Natural Medicine

Anti inflammatory analgesic Trast Patch Chemical Drug

R&D Pipeline

TA Project indication Discovery Preclinical Phase Ⅰ Phase Ⅱ Phase Ⅲ launch

CNS SID710 dementia FDA approval

CNS SID1606 Parkinson Disease

CV SID1901 hypertension

CV SID1902 hypertension

CV SID142 Peripheral ArteryDisease

Rheumatology

SID1806RA

(Rheumatoid Arthri-tis)

SKR201

SKR202

Metabolic disease

SKR203

NASH(Non-

alcoholic Steatohep-atitis)

SKR204

NCE201

NCE202

NCE204

CNS SKP161 Parkinson Disease

Neurology SKP191 insomnia

Rheumatology SKP201 RA MFDSapproval

CV SKP203 hyperlipidemia MFDSapproval

CNS SKP204 amyotrophic lateral scerlosis

MSDS approval(on-going)

Global leading Solution Provider in ECO-friendly material and Total Healthcare

CEOKwanghyun Jeon

Location310, Pangyo-ro, Bundang-gu, Seongnam-si, Gyeonggi-do, Korea

Specialty1. Arthritis drug (the nation’s first

natural medicine)2. Blood circulation improvement drug

(natural medicine)3. Patch formulation arthritis drug

(Incrementally modified drug)


Technology Transfer/Licensing/Overseas exportJeonghyun Moon Licensing & Development Team/Team leaderT. +82-2-2008-2551E. [email protected]

CONTACT US

SK chemicals Co., Ltd.

51


Pharmaceutical Com

pany

www.stpharm.co.kr

cGMP compliant ST Pharm is providing top manufacturing services to satisfy our customers’ high expectations to use our products in pharmaceutical industry.As a member of Dong-A Socio Holdings, ST Pharm is proactively investing our manufacturing equipments to provide cutting edge services which are comprehensive and matching to the fast phased global market.ST Pharm will continually challenge ourselves to prosper as not only a leading pharmaceutica l company but also a global chemical company.

Main Products

Category Products Customer Indication/Stage

New Drug APIs

HCV drug Originator (Global) HCV/Marketed

Diabetes drug Originator (Global) Diabetes/Marketed

Antibiotics drug Originator (Global) Antibiotics/Marketed

Gastric Cancer Originator (Global) Gastric Cancer / Phase 3

Mitochondrial DNA Depletion Syndrome Originator (Global) MDDs/Phase 3

PharmaceuticalIntermediates

Chiral epoxide Originator (Global) HIV/Marketed

Chloro-(L)-sugar Originator (Global) HBV/Marketed

Nucleoside monomers US/EP/JP Various RNA therapeutics/Clinical

APIs

Atorvastatin Domestic/JP Hyperlipidemia/Marketed

Clopidogrel Domestic Anticoagulant/Marketed

d-Cycloserine Domestic/JP/WHO/ROW Tuberculosis/Marketed

Terizidone S.Africa/Germany/CIS Tuberculosis/Marketed

Gadobutrol Domestic/EU/CIS MRI contract/Marketed

R&D Pipeline

Category Project (Indications) Stage (on going)

New Drug

STP1002 (cancer) Phase I

STP0404 (HIV ALLINI) Phase I

STP3725 (Anticoagulants) Preclinical

NASH Discovery

IBD Discovery

Influenza Discovery

VISION - To Be a Global Healthcare Player by Establishing DistinctiveCompetencies in Each Business Area

CEOKyungjin Kim

Location231, Hyeomnyeok-ro, Siheung-si, Gyeonggi-do, 15086 Korea

SpecialtyOligo APIs and New Drug Development, CMO(New Drug APIs & Intermediates), Generic APIs


Technology Transfer / LicensingSeohyun AhnNew Drug DevelopmentT. +82-2-527-6331E. [email protected]

Domestic SalesDong-Soo LeeGeneric APIsT. +82-2-527-6364E. [email protected]

Overseas SalesKris S. Choi Marketing & Business Development/Bio DivisionT. +82-2-527-6329E. [email protected]

CONTACT US

ST PHARM Co., Ltd.

52

Info

rmat

ion

of K

orea

n In

nova

tive

Ph

arm

aceu

tica

l Com

pany

www.taejoon.co.kr/en

For Happiness of Humanity and Respect for Life

CEOTae Young Lee

Location8 Daesagwan-ro 31 gil, Yongsan-gu, Seoul, Republic of Korea

Specialty1. Ophthalmic IMD 2. Contrast media IMD 3. GI IMD

Tel/Fax/E-mailT. +82-2-798-6601F. +82-2-798-6608

Technology Transfer/LicensingJun Hee LeeBusiness Development/DirectorT. +82-2-799-0072E. [email protected]

Overseas exportGa Ram ChoiBusiness Development/Assistant ManagerT. +82-2-799-0164E. [email protected]

CONTACT US

Taejoon Pharmaceutical Co., Ltd.

Established in 1978, Taejoon Pharmaceutical Co., Ltd. ("Taejoon") is one of the leading specialty pharmaceutical companies in ophthalmology, radiology, and GI. With a vision to become the best global pharmaceutical company in the specialized area, Taejoon has been building up company’s future growth by focusing its corporate resources; specialization, global marketing, and R&D innovation. In particular, Taejoon has acquired US and EU GMP certifications to secure global competitiveness and maintains state-of-the-art manufacturing facilities.

Main Products

Product (Ingredient/Formulation) Use Exporting Countries Remarks

Cyporin N Eye Drop 0.05% (Cyclosporin) Dry eye Launched

Xalost-S Ophthalmic Solution (Latanoprost) Glaucoma Launched

Xalost Ophthalmic Solution (Latanoprost) Glaucoma EU, China, Nigeria, Indonesia Launched

Xalostplus Ophthalmic Solution (Latanoprost, Timolol maleate) Glaucoma EU, Hong Kong Launched

Gadobirx Pre-filled Syringe Injection (Gadobutrol) Contrast enhancement of cranial and spinal MRI Launched

Iobrix INJ 240/300/350 (Iohexol) Contrast enhancement Thailand, Philippines Launched

CleanViewAL Powder (Polyethylene glycol3350) Bowel cleansing Launched

R&D Pipeline

Category Project IndicationDevelopment process

Discovery Preclinical PhaseⅠ PhaseⅡ PhaseⅢ Launch

IMD Undecided Eye disease



IMD Undecided Gastrointestinal disease

IMD Undecided Gastrointestinal disease

53


Pharmaceutical Com

pany

www.tegoscience.com/kor/main.do

WORLD LEADER IN CELL THERAPY

CEOSaewha Jeon

Location93, Magokjungang 8-ro, Gangseo-Gu, Seoul 07794, Korea

Specialty1. Dematological cell therapy2. Musculo-skeletal cell therapy3. Ophtamological cell therapy


Technology Transfer/Licensing/Overseas export/Overseas Office/etc Seungwun BaekBusiness Development/Team ManagerT. +82-2-818-2900E. [email protected]

CONTACT US

Tego Science, Inc.

A World Leader in Cell Therapy & Advanced Regenerative Medicine

Tego Science is a Seoul-based biopharmaceutical company specializing in regenerative skin cell therapy for wound healing. Tego’s chief strengths have been leading-edge technologies in cell culture, skin-graft manufacturing and cryopreservation. It is now evolving into wider regenerative medicine areas involving musculo-skeletal, ophtalmological and dematological targets, with plans for overseas expansion. Tego Science has been listed in KOSDAQ since 2014.

Main Products

Product(Ingredient/Formulation) Use Exporting Countries(E) Remark

Holoderm® (Autologous Keratinocytes) 3rd degree burn - Launched

Kaloderm® (Allogenic Keratinocytes) Deep 2rd degree burn, Diabet-ic Foot Ulcer Mongolia, Indonesia Launched

Rosmir® (Autologous Fibroblasts) Wrinkles Vietnam Launched

Neoderm® (3D Human Skin) Replacing animal testing Japan Launched

R&D Pipeline

R&D Pipeline

제품/성분명 적응증 초기

연구

비

임상

임상 NDA

Ⅰ Ⅱ Ⅲ TPX-114 / 자기유래 배양섬유아세포 회전근개 전층 파열

TPX-115 / 동종유래 배양섬유아세포 회전근개 부분층 파열

TPX-113 / 자기/동종유래 배양점막 구강점막결손

TPX-107 / 자기유래 배양각막 각막이식 연구자 임상

TPX-108 / 케모카인을 이용한 상처치유용 드레싱제 피부상처

TPX-109/ 케모카인을 이용한 상처치유용 드레싱제 연골재생

Project / Cell & Protein therapy Indications Discovery Pre-

Clinical

Clinical Trial NDA

Ⅰ Ⅱ Ⅲ TPX-114 / Dermal fibroblasts (auto) Full-thickness rotator-cuff tear

TPX-115 / Dermal fibroblasts (allo) Partial-thickness rotator-cuff tear

TPX-113 / Keratinocytes(auto/allo) Oral mucosal defects

TPX-107 / Mucosal keratinocytes (auto) Cutaneous wounds Investigator Initiated Trial (IIT)

TPX-108 / Chemokine Cartilage defects

TPX-109/ Chemokine Rotator-cuff tear

* Arrows indicate current progress with MFDS.

* Arrows indicate current progress with MFDS.

Holoderm®

Rosmir®

Kaloderm®

Neoderm®

54

Info

rmat

ion

of K

orea

n In

nova

tive

Ph

arm

aceu

tica

l Com

pany

eng.yuhan.co.kr

Great Yuhan, Global Yuhan

CEOWook Je Cho

Location74, Noryangjin-ro, Daebang-dong, Dongjak-gu, Seoul, Korea

Specialty1. Chemical/Biologics New drug2. Incrementally Modified Drugs

Tel/Fax/E-mailT. +82-2-828-0181F. +82-2-828-0300

Technology Transfer/LicensingJosephine ChoLicensing team/Team managerT. +82-2-828-0093E. [email protected]

Overseas exportSeungdoug parkOverseas Business/Team managerT. +82-2-828-0191E. [email protected]

CONTACT US

Yuhan Corporation

Yuhan Corporation continues to focus on innovation through breakthrough therapy R&D, new business opportunities and global network-building initiatives to grow into a leading global pharmaceutical company. Yuhan’s priority lies on targeting cancer, metabolic diseases and CNS diseases. Currently, our R&D pipeline consists of 30 new drugs and 22 incrementally modified drugs (IMDs). In pursuit of breakthrough therapies, we are developing 15 oncology programs including immunotherapies and next-generation targeted drugs to fight against cancer and the best example is the newly launched Leclaza® (Lazertinib). Yuhan has incorporated an IMD-developer AddPharma in 2017, which is expected to launch range of new products and contribute to the overall sales and profit growth. Within recent years, Yuhan signed out-license deals on disc degenerative disease treatment molecule with Spine Biopharma (2018), lazertinib with Janssen (2018), two NASH treatment programs with Gilead (2019), another NASH program with Boehringer Ingelheim (2019), and a GI mobility disorder treatment molecule with Processa Pharmaceuticals (2020). These five major deals add to total of KRW 4.0 trillion in value, repositioning us as a R&D-driven pharmaceutical company with the ultimate goal of developing standard of care treatment on a global level.

Main Products

Products Ingredients Indications Exporting Countries

Rebamipide SR Tablet Rebamipide 150mg Gastric ulcer, Improvement of Gastric mucosal lesion

Esomeprazole Combination Tablet

Esomeprazole, Precipitated Calci-um Carbonate

Gastroesophageal Reflux Dis-ease, Antacid

Pregabalin SR Tablet Pregabalin Neuropathic pain

Duowell Tablet Telmisartan,Rosuvastatin

Treatment for hypertension and hyperlipidemia Uzbekistan

Rosuampine Tablet Amlodipine, Rosuvastatin Treatment for hypertension and hyperlipidemia

Rosumet SR Tablet Metformin SR, Rosuvastatin Antidiabetic

Newfactan Bovine Lung Surfactant Treatment for respiratory distress syndrome of newborns Vietnam, Mongolia, Bolivia

Yucla Tablet Amoxicillin, Clavulanate Potassi-um Antibiotics

Almagate Suspension Almagate Antiacidic functions

Antiphlamine S Lotion Methyl Salicylate, L-menthol Anti-inflammatory agent Vietnam, Malaysia

Willogel Double Action Suspen-sion

Sodium alginate, Calcium carbonate,

Sodium bicarbonateAlleviation of heartburn and

indigest

Nazacare Nasal Spray Solution Momethasone FuroateNasal symptoms of allergic rhinitis, Nasal polyps, Acute

rhinosinusitis

R&D Pipeline

Copyright ⓒ 2021 by YUHAN. All rights reserved.

3

Discovery Lead Preclinical study Phase 1 Phase 2 Phase 3

YHC2118 (IO) YHC1108 (NASH) YHC1102 (NASH) YH25724 (NASH) YH14618 (DDD) LECLAZA (NSCLC)

YHC2115 (IO) YH34160 (Obesity) YH24931 (IO) YH35324 (CSU) YH12852 (FGID)

YHC2119 (IO) YHC1116 (Gaucher) YH29143 (IO)

YHC2122 (IO) YHC1104 (NSCLC) YH32367 (IO)

YHC2124 (IO) YHC1103 (IO)

YHC1128 (IO) YHC2120 (IO)

YHC1125 (CNS) YHC2126 (CNS)

YHC2127 (CNS)

YHC2129 (Obesity)

YHC1131 (NASH)

YHC1131 (NASH)

R&D 파이프라인_영문

IO : Immuno-oncology CNS : Central nerve system NASH : Non-alcoholic steatohepatitis NSCLC : Non-small cell lung cancer CSU : Chronic spontaneous urticaria DDD : Degenerative disk disease FGID : Functional gastrointestinal disorder

55


Pharmaceutical Com

pany

eng.yungjin.co.kr

The medicine for your life

BS BA 06 | 영진약품 Brand ArchitectureYUNGJIN PHARM CO.,LTD Identity Design Guide | Basic System

영진약품 브랜드 아키텍처

CEOChae Joon, Lee

Location13, Olympic-ro 35da-gil, Songpa-gu, Seoul, 05510, Korea

Specialty1. NCE (Targeted cancer therapy,

Cancer immunotherapy, Rare disease)

2. IMD & Generic (Cephalosporins, Antipyretic-analgesics & Anti-inflammatory, CNS, Rare disease)

3. API (Cephalosporins, Anti-hypertension, Anti-inflammatory, Analgesic)

Tel/Fax/E-mailT. +82-2-2041-8200F. +82-2-2041-8201

Technology Transfer/LicensingYeonhee PiBD&Licensing Division/DirectorT. +82-2-2041-8226E. [email protected]

Overseas exportSunyoung JungBD&Licensing division/ManagerT. +82-2-2041-8227E. [email protected]

Overseas OfficeYunhee, KimGlobal Business Department/Assistant ManagerT. +82-2-2041-8246E. [email protected]

CONTACT US

Yungjin Pharm. Co., Ltd.

Since its establishment in 1952, YUNGJIN PHARM. CO., LTD. has been a pioneer in the Korean domestic pharmaceutical industry for national economic development and improving public health with the lofty mission of saving humanity from disease and suffering through our medicines. As an affiliate of KT&G Group, YUNGJIN plays a pivotal role in the bio/pharmaceutical business within the group with outstanding drug production and R&D know-how, and has grown into a global pharmaceutical company by developing new products and expanding exports.

Main Products

Product(Ingredient/Formulation) Use Exporting Countries Remarks

Cefcapene Pivoxil(Cefcapene Pivoxil) Bacterial infections Worldwide API, Tab., Fine GranuleCefditoren Pivoxil(Cefditoren Pivoxil) Bacterial infections Worldwide API, Tab., Fine GranuleCefmetazole(Cefmetazole Sodium) Bacterial infections Worldwide API, Inj.

Cefotiam (Cefotiam HCl/HCl+Na2CO3) Bacterial infections Worldwide API, Inj.Ceftizoxime(Ceftizoxime Sodium) Bacterial infections Worldwide API, Inj.

Ceftriaxone inj.(Ceftriaxone sodium) Bacterial infections Worldwide Inj.Ceftazidime inj.(Ceftazidime hydrate) Bacterial infections Asia Inj.

Cefpodoxime Proxetil(Cefpodoxime Proxetil) Bacterial infections Asia API, Tab, Dry SyrupCefdinir(Cefdinir) Bacterial infections Asia API, Tab, Fine Granule

Linezolin tablet (Linezolid) Bacterial infections Asia TabMeicelin injection (Cefminox sodium hydrate) Bacterial infections Inj.

UK kit injection (Cefmetazole sodium / Cefotiam HCl / Cefo-tetan sodium / Cefoperazone sodium, Sulbactam sodium /

Ceftriaxone sodium / Vancomycin / Teicoplanin)Bacterial infections Inj.

Opast tablet (Limaprost alfadex) lumbar spinal canal stenosis Asia TabOmaron soft capsule (Omega-3 acids ethyl esters 90) Hypertriglyceridemia soft capsule

Candesartan Cilexetil (Candesartan Cilexetil) Hypertension Asia APIDenogan injection (Propacetamol HCl) Pain, fever Inj.

Loxoprofen(Loxoprofen) Anti-inflammatory, Analgesic Worldwide APIFybro tablet (Pirfenidone) Idiopathic pulmonary fibrosis Tab

Pancron tablet (Dimethicone, hemicellulose, ox bile extract, pancreatin) Indigestion Tab

Panprazol tablet (Pantoprazole) Gastroesophageal reflux disease, gastric duodenal ulcer Tab

Baroscon double action suspension (Sodium alginate, sodium bicarbonate, calcium carbonate) Indigestion Asia Oral liquids

Talimin tablet (Bepotastine nicotinate) Rhinitis, urticaria, itching TabHamonilan solution

(Protein, fat, carbohydrate, vitamin, mineral, fiber) Enteral nutrition Solution

R&D Pipeline

Project TherapeuticArea Target

Development Phase

Research Nonclinical Phase I Phase II Phase III Marketed

KL1333 MetabolicDisorder Mitochondrial

YPN-005 Oncology CDK7

YPN-006 Oncology Novel Target

YPN-007 CNS Novel Target

YPN-008 Oncology Novel Target

56

Info

rmat

ion

of K

orea

n In

nova

tive

Ph

arm

aceu

tica

l Com

pany

Supplement

1. Products Expected to Export2. Technology Transfer3. Certifications from Health Authorities

Supplement

company Product name Active Ingredient Indication Category ExpectedCountry note

AlteogenALT-B4 Hyaluronidase IVF Media Worldwide

ALT-L9 Aflibercept wetAMD Injection Worldwide

BCWORLD PHARM. CO.,

LTD.

Mepem inj. 500mg Meropenem Antibiotics Prescription Medicine Global

Mepem inj. 1g Meropenem Antibiotics Prescription Medicine Global

Sinraci inj. 500mg Imipenem/Cilastatin sodium Antibiotics Prescription Medicine Global

Ertapenem inj. Ertapenem inj. Antibiotics Prescription Medicine Global

Merogel Metronidazole Antibiotics Prescription Medicine Global

Quprin inj. Norepinephrine Cardiac stimulant Prescription Medicine Global

Fentanyl inj. Fentanyl Narcotics Prescription Medicine Global

Sufentanil inj. Sufentail Narcotics Prescription Medicine Global

Guthione inj. Glutathione Well-being product Prescription Medicine Global

Multipotent inj. Zn, Cu, Se, Cr, Mn, F, Fe, I, Mo Well-being product Prescription

Medicine Global

BMI Korea

Hitox Botulinum toxin improvement of facial wrinkles vialworldwide

(including USA, EU)

Hirax Hyaluronidase1) Edema, Pain reduction

2) Enhance drug permeation by subcutaneous injection

vial 1) Japan, Asia2) EU, USA

Hileukin Interleukin-21) * MRCC

2) Media ingredient for cell therapy drug development

vial 2) Japan, China

Boryung Phar-maceutical

co.,Ltd.

Kanarb® Fimasartan Hypertension Prescription Medicine

CHINA, BRAZIL, PERU, ECUADOR,

MENA, CIS

KanarbPlus® Fimasartan with HCTZ Hypertension Prescription

Medicine

Dukarb® Fimasartan with Amlodipine Hypertension Prescription Medicine

Tuvero® Fimasartan with Rosuvastatin Hypertension/Dyslipidemia Prescription

Medicine

Alimxid Inj. Pemetrexed Antineoplastic Prescription Medicine

MENA, LATAM,ASIA, CIS

Velkin Inj. Bortezomib Antineoplastic Prescription Medicine


Oxalitin Inj. Oxaliplatin Antineoplastic Prescription Medicine


Gelfos M® Colloidal Aluminum Phos-phate

HyperchlorhydriaHeartburn

Non-Prescription Medicine

HONGKONGTHAILANDINDONESIA

Bukwang Pharmaceuti-cal Co., Ltd.

Dexid® tab. R-thioctic acid trometh-amine Diabetic peripheral neuropathy Prescription

Medicine WorldwideAgreement reached in Southeast

Asia

Celltrion

Remsima SC InfliximabRheumatoidArthritis, Ankylsoing Spondy-litis, Ulcerative Colitis, Crohn's Disease,

Psoriasis, psoriatic arthritisBiobetter Global

Remsima InfliximabRheumatoidArthritis, Ankylsoing Spondy-litis, Ulcerative Colitis, Crohn's Disease,

Psoriasis, psoriatic arthritisBiosimilar Global

Truxima RituximabNon-Hodgkin's Lymphoma, Chronic-Lymphocytic Leukemia, Rheumatoid

Arthritis,Granulomatosis with Polyangii-tis, Microscopic Polyangiitis

Biosimilar Global

1. Product Expected to Export

58

Supplement


Celltrion

Herzuma TrastuzumabHER2-Positive Metastatic BreastCancer, Early Breast Cancer, Metastatic Gastric

CancerBiosimilar Global

Yuflyma Adalimumab Rheumatoid Arthritis ,IBD, Lymphoma Biosimilar Global

Temyxis Lamivudine, Tenofovir AIDS (Acquired ImmuneDeficiency Syndrome) IMD Global

Linezolid linezolidPneumonia, Skin and SkinStructure Infec-tions, Vancomycin-resistant Enterococcus

faeciumInfectionsGeneric Global

DiaTrust - COVID-19 IVD Test Kit Global

CKD Pharma-ceutical Corp.

Duvie Tab. Lobeglitazone sulfate Type 2 diabetes NCE(New Chemi-cal Entity) ASEAN Korea's 20th

new drug

Nesbell PFS Inj. Darbepoetin-α1. Anemia associated with chronic renal

failure 2. Anemia by cancer chemotherapy

Biologic drug / 2nd generation EPO Biosimilar

ASEAN

The world's first NESP biosimilar and the first bio

medicine of CKD

Pemecine liquid Inj. Pemetrexed disodium 2.5 hydrate

1. Non-small cell lung cancer2. Malignant pleural mesothelioma

Chemical generic drug US, Europe

EsoduoTab.

Omeprazole+Sodium bicarbonate Gastroesophageal reflux disease (GERD)

IMD(Incrementally Modified Drug)

US, Europe

The world'sfirst and

onlyIR-Esome-

prazole as an IMD

CorestemInc. Neuronata-R®

Autologous bone marrow derived mesenchymal stem

cellAmyotrophic lateral sclerosis (ALS,L Lou

Gehrig’s disease)Stem cell Thera-

py product Global

MFDS Approval (2014.07) Release (2015.01)

CrystalGe-nomics, Inc. Acelex 2mg Polmacoxib Osteoarthritis Small molecule

Worldwide(Except Turkey, MENA, Brazil,

EAEU countries)

Daehwa Phar-maceutical

Co., Ltd.

Liporaxel sol’n PaclitaxelAdvanced and metastatic or local recur-

rent gastric cancer and breast cancer (phase III ongoing)

IMD Global

Rivamensa patch RivastigmineMild to moderately serve dementia of the Alzheimer type dementia associated with

Parkinson’s disease Generic Global

Loxona plaster & cataplasma Loxoprofen sodium

External analgesics: Traumatic inflam-mation of muscles, strains and sprains. Relief of symptoms of muscular pain.

Generic Global

Flospan tab. & sol’n PhloroglucinolAntispasmodic: Renal and urinary colic

hepatic, gall bladder and spasmodic colic, intestinal colic and dysentery syndrome

Generic Global

Gastric cap. Roxatidine acetate HCl Gastric and duodenal ulcer, acute gastri-tis, relapse period of chronic gastritis Generic Global

Daewon Pharm.Co.,Ltd.

Pelubi CR pelubiprofen Osteoarthritis, Rheumatoid, Back pain, Originatior Global

Freefol MCT Propofol Anesthesia Generic Global

Renamezin oral adsorptive charcoal chronic renal failure Generic Global

TG-fenon Choline fenofibrate Hypertriglyceridemia IMD Global

DaewoongPharmaceuti-

cal

FEXUCLUE Fexuprazan Anti-Peptic Ulcer Originator Brazil, Mexico

Nabota Botulinum toxin Glabella lines Originator

US, Canada, MENA, LATAM,

EU, ASIA, Austra-lia, Philippines,

Thailand

TBD Enavogliflozin Type 2 Diabetes Originator

59

Supplement


DaewoongPharmaceuti-

cal

Olostar Olmesartan/Rosuvastatin Concomitant hypertension and dyslipid-emia Originator

Mexico,Bolivia, Ecuador,Central America, Malaysia, USA,

Canada, Australia, Jordan, Iraq

Easyef Recombinant human Epider-mal Growth Factor Diabetic foot ulcer Originator

EcuadorBolivia, CIS,

SriLanka, Jordan, Iraq, Myanmar,

Philippines, Thailand

Ursa Ursodeoxycholic acid Cholestasis (including PBC, PSC), viral hepatitis C, gallstone Originator

BoliviaCIS

MalaysiaEcuador, Sin-

gapore, Brunei, Philippines, China, Vietnam, Cambo-dia, Jordan, Iraq,

Myanmar

Eposis Recombinant human Eryth-ropoietin α Anemia in end stage renal disease (ESRD) Biosimilar

Indonesia, Thai-land, Philippines, Vietnam, Myan-

mar

Luphere Leuprorelin AcetateProstate cancer, endometriosis, uterine fibroid, postmenopausal breast cancer,

central precocious pubertyGeneric Japan, Malaysia,

Russia, Philippines

COVIBLOCK Camostat Mesilate COVID19 Generic UAE, Jordan, Egypt, Kuwait

DongKoo Bio&Pharma

AC Cure MLE Gel Hydrous Benzoyl Peroxide 33.3mg, Adapalene

Local treatment of acne, pustule, come-done in age 9yrs+ Dermatology Mongolia, Iran,

Azerbaijan

Cernilton Tablet Cernitin T60, Cernitin GBX 3mg BPH, CP/CPPS Urology Taiwan, Mongolia

Heparos Soft Cap-sule

L-cystine 250mg, Choline Bitrartate 250mg

Supportive treatment of liver disease, fatty liver Endocrine Vietnam

Caverlactine Tablet Cabergoline 0.5mgPrevention and

inhibition of lactationTreatment of

hyperprolactinemiaEndocrine Uzbekistan,

Georgia

SmartX SVF Isolation Kit Treatment for Diabetic Foot Ulcer, Sys-temic sclerosis, and Fat engraftment

Plastic Surgery, Aesthetics,

Chrinic diseases

Russia(Europe), Turkey, USA, Middle east

CELL BLOOM Stemcell, 8-Peptide Anti-aging, Brightening, and Regerating skin Cosmeceuticals

Vietnam, Hong-kong, Europe,

USA, Middle east

Dongkook Pharmaceuti-

cal

Pofol Injection Propofol General anesthetic, sedation Generic26 countries incl.

Japan, Brazil, UAE, Thailand

Lorelin Depot Injec-tion Leuprolide acetate

Endometriosis, prostate cancer, premeno-pausal breast cancer, central puberty

puberty Generic

9 countries incl. Mexico,

Uruguay Iran

Alostin Injection AlprostadilImprovement of limb ulcer and resting

pain in chronic arterial obstruction (Burg-er's disease, obstructive arteriosclerosis)

Generic Japan

Octrin LAR Injection Octreotide acetate Acromegaly, endocrine tumors Generic Peru

Teicon Injection Teicoplanin Antibiotics Generic Japan, Mongolia, Syeria

Bellast Hyaluronic acid Wrinkle reduction Generic Vietnam etc

Hyaron inection Sodium hyaluronate Osteoarthritis of the knee joint Generic Vietnam, etc

Teicoplanin (API) Teicoplanin Antibiotics Generic13 countries icl. Japan, Spain, Brazil, India

60

Supplement


DONGWHA PHARM

Zabolante Zabofloxacin AE COPD NCE MX

Whal Myung Su Gambir, Ginger etc. Anorexia, Indigestion etc. OTC US, AU, PH

Each Paste Myrrh, Rhatany, Chamomile Gum treatment/Toothpaste OTC

Pancold Acetaminophen etc. Relief of common cold symptoms OTC

- Ambroxol Hydrochloride Mucolytic agent API JP, ID, MX, PH

- Levosulpiride Antiemetic agent API ES, VN

GENUONE Sciences

Bacterocin Oint. Mupirocin Topical antibacterial treatment OinmentHongKong,

Vietnam, Peru, Philippines, Mongolia

Calmio Ointment & Gel

Calcipotriol Monohydrate Betamethasone Dipropio-

nate Complex psoriasis treatment Oinment/Gel HongKong, Mon-

golia

Munals double action

Sodium Alginate Calcium CarbonateSodium Bicarbonate

Treatment of symptoms resulting from the reflux of acid, bile and pepsin into the oesophagus such as acid regurgitation,

heartburn and indigestionOral Solution Philippines,

Cambodia

Entekim Tablet Entecavir Treatment for chronic hepatitis B virus infection Tablet HongKong

Handok Inc.

KETOTOP Plaster Ketoprofen

Degenerative arthritis (Osteoarthritis), Periarthritis, humeral epicondylitis (tennis

elbow etc.), Peritendinitis, tendinitis, tendovaginitis, myalgia, post-traumatic

swelling/pain

Drug Global

READY Q Drink Curcumin Use for Hangover remedies Food & Beverage Global

READY Q Chew Curcumin Use for Hangover remedies Food & Beverage Global

HANLIMPHARM.CO., LTD.

Nasaflex Nasal Spray

Mometasone furoate,Azelastine HCl Perennial allergic rhinitis Allergy & ENT Worldwide

T-SporinEye Drops Cyclosporin Increase tear production Ophthalmic Worldwide

HyaluronEye Drops

(Single dose)Sodium

HyaluronateEndogenic disease, dry

eye syndrome Ophthalmic Worldwide

Risenex Plus Tab.

Sodium Risedronate,Cholecalciferol Osteoporosis Endocrine Worldwide

Heparin Sodium Inj. Heparin Sodium Anticoagulant Anticoagulant Worldwide

Hanlim Vasopressin Inj. Vasopressin Pituitary hormone agent Endocrine Worldwide

HanmiPharm.Co.,Ltd

Amosratan Amlodipine + Losartan Hypertension CV CIS

Amosartan Q Amlodipine + Losartan + Rosuvastatin

Hypertension& Hyperlipidemia CV LATAM

Amosartan PlusAmlodipine +

Losartan +Chlortahlidone

Hypertension CV LATAM

AmosartanXQ

Amlodipine + Losartan + Rosuvastatin +

EzetimibeHypertension

& Dyslipidemia CV EU, LATAMAPAC, Etc.

Rosuzet Rosuvastatin +Ezetimibe

Primary Hypercholesterolemia& Hyperlipidemia CV LATAM, APAC,

AFRICA

Gugutams Tamsulosin +Tadalafil ED, BPH Urology CIS

LATAM

Monterizine Montelukast+Levocetirizine Asthma Rhinitis Respiratory

LATAMSEA

Hyalrheuma Hyaluronic acid Osteoarthritis OA EUMENA

Esomesol DR Esomeprazole Magnesium GERD, NSAID Gastric ulcer GI

NA, EUAPACEtc.

61

Supplement


HK inno.N

K-CAB Tab. Tegoprazan Gastroesophageal reflux disease (GERD) Antiulcer Worldwide

Ex-one A Tab. Amlodipine/ Valsartan/ Atorvastatin Hypertension with dyslipidemia Fixed Dose

Combination Worldwide

Ex-one RTab.

Amlodipine/Valsartan/ Rosuvastatin Hypertension with dyslipidemia Fixed Dose


Ex-oneTab. Amlodipine/Valsartan Hypertension Fixed Dose


Atomet XR Tab. Atorvastatin/Metformin Type2 Diabetes/Hyperlipidemia Diabetes/Antihypertensive Worldwide

Machkhan Tab. Candesartan/Amlodipine Hypertension Antihypertensive Worldwide

Rovazet Tab. Ezetimibe/Rosuvastatin HyperlipidemiaPrimary hypercholesterinemia

Fixed Dose Combination Worldwide

ClosoneCap. Clopidogrel + Aspirin Atherosclerosis, thromboembolism Fixed Dose


Moveloxin Inj. Moxifloxacin Infection Antibiotics Worldwide

Cinezolid Tab&Inj. Linezolid Infection Antibiotics Worldwide

Citopcin Inj. Ciprofloxacin Infection Antibiotics Worldwide

Tapocin Inj. Teicoplanin Infection Antibiotics Worldwide

Vancorin Inj. Vancomycin Infection Antibiotics Worldwide

Epokine Inj. Erythropoietin Anemia Biologicals Worldwide

Pemta RTU Inj. Pemetrexed Cancer Oncology Worldwide Ready-to-use

Calmtop Inj. Irinotecan Cancer Oncology Worldwide

OmapOne Lipid Inj.Soybean oil, Olive oil, Fish

oil, Medium-ChainTriglycerides

Parenteral Nutrition IV Solution(1-chamber bag) Worldwide Generic of

Smof Lipid®

OmapOnePeripheral Inj. Lipid, Amino acid, Glucose Total Parenteral Nutrition (TPN) IV Solution

(3-chamber bag) WorldwideGeneric of

Smof Kabiv-en Peri®

Enteone Tab. Entecavir Hepatitis B infection Antiviral Worldwide

HYUNDAI Pharm.

Levotuss Tab. /Syrup Levodropropizine Cough : acute and chronic bronchitisFirst MA (Mar-

keting authoriza-tion)

Global

Uremin Tab Desmopressin acetate Nocturnal enuresis Generic Global

Tamirin SR Tab Galantamine HBr Alzheimer’s diseaseFirst MA (Mar-

keting authoriza-tion)

Global

Mirap ER Tab. Pramipexole HCl Parkinson’s disease Generic Global

Minoxyl Gel / Sol. Minoxidil Alopecia Generic Global

ILDONG PHARMACEU-

TICAL CO., LTD.

BesivoTab. Besifovir Hepatitis B virus

(HBV) infection Antiviral SEA

AlgikInj. Pemetrexed Pleural mesothelioma, NSCLC(Non-small

cell lung cancer) AnticancerSEA, CIS, Latin

America,MENA

VicureTab. Entecavir Hepatitis B virus

(HBV) infection Antiviral SEA, Latin Ameri-ca, CIS

TBD Rivaroxaban Prevent blood clots Anticoagulant TBD

DroptopTab.

Rosuvastatin+Ezetimibe Hypercholesterolemia HMG-CoA reduc-

tase inhibitor SEA

MemantoTab. Memantine Moderate-to-severe Alzheimer's disease NMDA Receptor

Blocker SEA

Reyvow lasmiditan Acute Migraine Anti-migraine agent Southeast Asia

62

Supplement


ISU ABXIS

Abcertin® Imiglucerase Gaucher’s Disease InjectionWorldwide

(excluding Korea, Iran, Mexico)

Fabagal® Agalsidase beta Fabry’s Disease Injection Worldwide(excluding Korea)

Clotinab® Abciximab Anti-thrombotic InjectionWorldwide

(excluding Korea, Turkey)

JW Pharma-ceutical

Combiflex LipidRefined soybean oil, Glucose, Amino Acid,

ElectrolytesSupply of all Nutrition I.V Solution Global

Lipision Refined soybean oil Lipid based IV Solution I.V Solution Global

Freamine 15 amino acids Amino Acid IV Solution I.V Solution Global

Nephramine 8 amino acids & 4 electro-lytes Amino Acid IV Solution I.V Solution Global

Prepenem Imipenem, Cilastatin Carbapenem Antibiotics Antibiotics Global

Pospenem Meropenem Carbapenem Antibiotics Antibiotics Global

Ertapenem Ertapenem Carbapenem Antibiotics Antibiotics Global

Doripenem Doripenem Anhydrous Carbapenem Antibiotics Antibiotics Global

Levofloxacin Levofloxacin Quinolone Antibacterial Agent Antibacterial Global

Heparin Heparin thrombosis Anticoagulant Global

J-Dart tab. Dutasteride BPH, Alopecia Urological Global

Levetiram Premix Levetiracetam Epilepsy Premix Global

Acetamin Premix Acetaminophen Pain Premix Global

Korea United Pharm. INC.

Clanza®CR Tab. Aceclofenac 200mg inflammation, pain Prescription Medicine Global

Controlled Release

Formulation

Clavixin Duo Capsules

Clopidogrel+Aspirin Antiplatelet Prescription

Medicine Global New fixed dose

Cilostan®CR Tab. Cilostazol 200mg Ischemic symptoms, Thrombosis Prescription Medicine Global

Controlled Release

Formulation

Fenorics EH Tab. Fenofibric acid 11mg Dyslipidemia Prescription Medicine Global New fixed

dose


Gastine ®CR Tab. Mosapride 15mg Gastrointestinal symtoms Prescription Medicine Global

Controlled Release

Formulation

Losasc® CR Tab. Losartan+Amlodipine Antihypertensive Prescription


Omethyl Cutilet®Soft capsule

Omega-3 acid ethylester 90 2g Dyslipidmeia Prescription


ATMEG®

Combigel®Atorvastatin 1g+

Omega-3-acid ethyelster90 Dyslipidemia PrescriptionMedicine Global New fixed

Dose

63

Supplement


Medytox

Neuronox,Meditoxin,

Siax etc.

Clostridium botulinum toxin typeA (Hall strain)

1. benign essential blepharospasm 2. equinus foot deformity due to spastici-

ty 3. serious glabellar wrinkles ranging from moderate to severe associated with cor-rugator muscle and/or procerus muscle

activities 4. upper limb spasticity associated with

stroke 5. moderate to severe lateral canthal

lines (crow’s feet lines) associated with orbicularis muscle activities

6. cervical dystonia

Biologics Global

CoretoxClostridium botulinum toxin

typeA (150kDa) (Hall strain)

moderate to serious glabella wrinkles related to corrugators muscle and/or

procerus muscle activity Biologics Global

Neurakin Ibuprofen piconol

1. acute eczema, contact dermatitis,atopic dermatitis, chronic eczema, rosa-cea-like dermatitis, perioral dermatitis

2. herpes zoster3. acne vulgaris

Generic drugs Global

Levocontra Levonorgestrel Emergency contraceptive Generic drugs Global

Pharmicell Co., Ltd. Cellgram-AMI

Autologous Bone Mar-row-Derived Mesenchymal

Stem CellAcute Myocardial Infarction Cell Therapy

Product Global -

Samyang Holdings Cor-poation(Bio-pharmaceuti-cals Business)

Genexol® PM Paclitaxel Breast cancer, NSCLC, Ovarian cancer

Injection

South East Asia, India, CIS

Nanoxel® M DocetaxelBreast cancer, NSCLC, Esophageal can-cer, H&N cancer, Ovarian cancer, Gastric

cancer, Prostate cancer-

Genexol® Paclitaxel Ovarian cancer, Breast cancer, NSCLC, Gastric cancer

Europe, South East Asia, CIS

Docetaxel DocetaxelBreast cancer, NSCLC, Esophageal can-cer, Ovarian cancer, H&N cancer, Gastric

cancer, Prostate cancerEurope, CIS

Nexatin® Oxaliplatin Colorectal cancer, Gastric cancer Europe, Japan, CIS

Crabcitabine® GemcitabinePancreatic cancer, NSCLC, Ovarian can-

cer, Breast cancer, Bladder cancer, Biliary tract cancer

-

Pemed® S Pemetrexed NSCLC, Mesothelioma -

Azalid® Azacitidine MDS, AML, CMML CIS

Decilid® Decitabine MDS, AML -

Protezomib® Bortezomib MCL, MM CIS

Bendalid® Bendamustine MM -

Lenalid® Lenalidomide MM

Tablet

CIS

Everose® EverolimusBreast cancer, Renal cancer, Pancreatic

Neuroendocrine tumor, GI and Lung Neu-roendocrine tumor, TSC-Renal Angiomyo-

lipoma, TSC-SEGA-

Palonosetron Palonosetron Anti-emeticsInjection

-

Zolenic® Zoledronic Acid Hypercalcemia of malignancy, Bone metastasis CIS

Rheumastop® Diclofenac Rheumatoid arthritis Plaster -

Nicostop® Nicotine Smoking cessation Patch, Gum -

Fentaderm® Fentanyl Chronic pain

Patch

-

Demencure® Rivastigmine Dementia -

Tulobuterol Tulobuterol Bronchial asthma -

Angiderm® Nitroglycerin Angina -

64

Supplement


Samyang Holdings Cor-poation(Bio-pharmaceuti-cals Business)

Paclitaxel Ovarian cancer, Breast cancer, NSCLC, Gastric cancer

API

USA, Europe, Japan, South East Asia, India, North

America

DocetaxelBreast cancer, NSCLC, Esophageal can-cer, Ovarian cancer, H&N cancer, Gastric

cancer, Prostate cancerEurope, Japan,

Middle East

Pemetrexed NSCLC, Mesothelioma Middle East

Bortezomib MCL, MM Middle East

Cabazitaxel Prostate cancer -

Shin Poong Pharm. Co., Ltd.

Pyramax® Tablets Pyronaridine tetraphos-phate & Artesunate Malaria Prescription

Medicine Global

Pyramax® Granules Pyronaridine tetraphos-phate & Artesunate

Malaria(Pediatric formulation)

PrescriptionMedicine Global

CandeAmlo® Tablets Amlodipine & Candesartan Hypertension PrescriptionMedicine Global

EzeRosu® Tablets Rosuvastatin & Ezetimibe Hyperlipidemia PrescriptionMedicine Global

Hyalforte® Injection Sodium hyaluronate Osteoarthritis Prescription

Medicine Global

Medicurtain® Injec-tion Sodium hyaluronate & HES Anti-adhesion

(Surgery) Medical Device Global

SK Chemicals Co., Ltd.

Rivastigminepatch rivastigmine Symptomatic therapy for alzheimer De-

mentia or Parkinson’s disease Dementia PatchEurope, Columbia, New zealand etc.

(19 conturies)

Taejoon Phar-maceutical

Co., Ltd.

Cyporin N Cyclosporine Dry eye Prescription medicine EU, Asia

Xalost Preservative Free Latanoprost Anti-glaucoma Prescription

medicine US, EU, Asia

Xalost Latanoprost Anti-glaucoma Prescription medicine EU, Asia

Xalost Plus Latanoprost, Timolol Maleate Anti-glaucoma Prescription

medicine EU, Asia

Gadobrix Gadobutrol MRI contrast enhancement Prescription medicine US, EU, Asia

CleanViewAL Pow-der (Polyethylene

glycol3350)Polyethylene glycol3350 Bowel cleansing Prescription

medicine US, EU, Asia

TegoScience

Kaloderm® Allogeneic Keratinocytes -Deep 2nd degree burn -Diabetic Foot Ulcer

Cell Therapy Product

(Prescription Medicine)

Global

Rosmir® Autologous Fibroblasts Improvement of Nasojugal GroovesCell Therapy

Product(Prescription Medicine)

Global

Neoderm® Reconstituted 3DHuman Skin For cosmetics testing and drug discovery Tester Kit for

Research GlobalAlternative methods to animal testing

65

Supplement


Yuhan Corpo-ration

Rebamipide SR Rebamipide 150mg Gastric ulcer, Improvement of Gastric mucosal lesion ETC Medicine

Asia, Middle East, North Africa, CIS, Latin America, etc.

Esomeprazole +Precipitated Calcium

Carbonate Tab.Esomeprazole +

Precipitated Calcium Carbonate Tab.

Gastroesophageal Reflux Disease,Antacid

Raloxifene Raloxifene Osteoporosis ETC Medicine

Atorvastatin +Ezetimibe Tab.

Atorvastatin +Ezetimibe Tab. Hypercholesterolemia ETC Medicine

Fenofibrate 145mg Tab. Fenofibrate 145mg Tab. Hyperlipidemia ETC Medicine

Pregabalin SR Tablet Pregabalin Neuropathic pain ETC Medicine

Duowell Tablet Telmisartan,Rosuvastatin

Treatment for hypertension and hyperlip-idemia ETC Medicine

Rosuampine Tablet Amlodipine, Rosuvastatin Treatment for hypertension and hyperlip-idemia ETC Medicine

Rosumet SR Tablet Metformin SR, Rosuvastatin Antidiabetic ETC Medicine

Newfactan Bovine Lung Surfactant Treatment for respiratory distress syn-drome of newborns ETC Medicine

Yucla Tablet Amoxicillin, Clavulanate Potassium Antibiotics ETC Medicine

Almagate Suspen-sion Almagate Antiacidic functions OTC Medicine

Antiphlamine S Lotion

Methyl Salicylate, L-men-thol Anti-inflammatory agent OTC Medicine

Willogel Double Action Suspension

Sodium alginate, Calcium carbonate,

Sodium bicarbonateAlleviation of heartburn and indigest OTC Medicine

Nazacare Nasal Spray Solution Momethasone Furoate Nasal symptoms of allergic rhinitis, Nasal

polyps, Acute rhinosinusitis ETC Medicine

Cough-S Syrup

Ammonium Chloride, Chlorpheniramine Maleate, Dextromethorphan Hydro-

bromide Hydrate, DL-Meth-ylephedrine Hydrochloride

Cough, Sputum ETC Medicine

66

Supplement


Yungjin Pharm. Co.,

Ltd.

Cefcapene Pivoxil(API, Tab., Fine

Granule)Cefcapene Pivoxil Infection Antibiotics Worldwide

Cefditoren Pivoxil(API, Tab., Fine

Granule)Cefditoren Pivoxil Infection Antibiotics Worldwide

Cefmetazole(API, Inj.) Cefmetazole Sodium Infection Antibiotics Worldwide

Cefotiam (API, inj.) Cefotiam HCl/HCl+Na2CO3 Infection Antibiotics Worldwide

Ceftizoxime(API, inj.) Ceftizoxime Sodium Infection Antibiotics Worldwide

Loxoprofen (API) Loxoprofen Anti-inflammatory, Analgesic CNS Worldwide

Febuxostat (API) Febuxostat Hyperuricemia Cardiovascular Worldwide

OPAST tab. Limaprost alfadexAlprostadil(prostaglandin E1) analogue, and a vasodilator that increases blood flow and inhibits platelet aggregation

Cardiovascular Asia

DENOGAN inj. Propacetamol HCl Relieve mild to moderate pain, and reduce fever Antiinflammatory Asia

LINEZOLIN tab. Linezolid Treatment of certain serious bacterial infections Oxazolidinone Asia

Imipenem-cilastatin inj. Imipenem, cilastatin

Treatment of serious infections and is a potent broad spectrum antibacterial agent for intravenous administration

Antibiotics Asia

BAROSCON DOUBLE ACTION susp.

Sodim alginate, calcium carbonate, sodium bicar-

bonate

Treatment of symptoms of gastro-oe-sophageal reflux such as acid regurgita-tion, heartburn and indigestion, and for

symptoms of excess stomach acid(hyper-acidity)

Gastro-intestinal Asia

Ceftriaxone inj. Ceftriaxone sodiumBroad-spectrum cephalosporin antibiot-ics with high degree of stability in the

presence of beta-lactamasesAntibiotics Asia

Ceftazidime inj. Ceftazidime hydrate Infection Antibiotics Asia

Cefpodoxime Prox-etil

(API, Tab, Dry Syrup) Cefpodoxime

Proxetil Infection Antibiotics Asia

Cefdinir (API, Tab, Fine

Granule)Cefdinir Infection Antibiotics Asia

Candesartan Cilex-etil(API) Candesartan Cilexetil Hypertension Angiotensin

receptor blockers Asia

67

Supplement

Company Category IndicationDevelopment Status Targeted

Country noteKorea Overseas

ABL Bio, lnc.

ABL503 Solid Tumor Phase 1 (U.S.)

ABL111 Solid Tumor(Pancreatic, Gastric Cancer) Phase 1 (U.S.)

ABL501 Solid Tumor Phase 1 IND

ABL301 Parkinson’s Disease Preclinical

Alteogen

ALT-B4 Cancer Phase 1 - worldwide

ALT-P1 Growth hormone deficien-cy Phase 2 Phase 1 Brazil

ALT-P7 Breast cancer Phase 1 - USA, EU

BCWORLD PARM. CO., LTD.

BCWP_Y001 Anti-Cancer - - Global

BCWP_Y002 Anti-fungal - - Global

BCWP_Y007 Antibiotics - - Global

BoryungPharmaceutical

co.,Ltd.

New Chemical Entity(ARB: Fimasartan) Hypertension Launched N/A

Oncology Antineoplastic Launched N/A

CorestemInc.

Neuronata-R® Amyotrophic Lateral Sclerosis (ALS) Phase Ⅲ Phase Ⅲ Korea, United

States (Global) On-going

CS20AT04 systemic lupus erythema-tosus (SLE) Phase Ⅰ NA Global MFDS IND approval

(2015.05)

CrystalGenomics, Inc.

Ivaltinostat Pancreatic cancer, Myelo-dysplastic syndromes Phase II Worldwide

CG-650 Acute/Chronic pain Phase I Worldwide

CG-651 Neuropathic pain Phase I Worldwide

CG-549ABSSSI, Osteomyelitis and

other serious S. aureus infections including MRSA

Phase I Worldwide

Daehwa Pharmaceu-tical Co., Ltd.

DH-LASED platform - - - Global

Liporaxel sol’n Gastric & Breast cancer ◯ ◯ Globally except China

DHP23001(Oral Docetaxel) Anticancer agent Non-clinical - Global

DHP23003(Oral Irinotecan) Anticancer agent Non-clinical - Global

DHP23007(Oral Zanamivir) Influenza Non-clinical - Global

DHP33001(Oral GLP-1) Diabetes & Obesity Non-clinical - Global

DaewoongPharmaceutical

DWN12088 IPF Phase 1, AU TGA Global

DWP17061 OA pain Global PC

DWP212525 Autoimmune disease Global PC

DWP213388 Autoimmune disease Global PC

Dongkook Pharma-ceutical

DKF313 Benign prostatic hyperpla-sia Phase 3 Japan, EU

DKM412 Osteoarthritis of the knee joint Phase 3 China

DKF-5122 Fungal infection BE study Brazil, EU

DONGWHA PHARM

NCE(Zabolante) COPD Phase III Global

NCE COVID-19 Preclinical Global

NCE Cancer Lead optimization Global

2. Technology Transfer

68

Supplement



Genexine, Inc.

GX-I7(Long-acting IL-7)

Solid tumor Phase 1b - Global

Glioblastoma Phase 1b Phase 2 Global

TNBC(w/ KEYTRUDA®) Phase 1b/2 - Global

COVID-19Therapeutic Phase 1b Phase 2 Global

GX-188(HPV DNA therapeutic

vaccine)Cervical Cancer

(w/ KEYTRUDA®) Phase 1b/2 - Global

GX-H9(Long-acting hGH) AGHD & PGHD Completed Phase 2 Ongoing Phase 3 Global

GX-G3(Long-acting G-CSF) Neutropenia Completed

Phase 2Completed

Phase 2 Global

GX-E4(Long-acting EPO) CKD-induced Anemia Ongoing Phase 3 Ongoing Phase 3 Global

GX-G6(Long-acting GLP-1) Type 2 Diabetes - Phase 2 IND

Approval Global

GX-G8(Long-acting GLP-2) Short Bowel Syndrome - Phase 1 IND

Approval Global

GX-P1(Long-acting PD-L1)

Autoimmune Transplanta-tion Completed Phase 1 - Global

GX-19N COVID-19Preventive

OngoingPhase 1/2a

Expand to Phase 2/3 Global

Handok Inc.

Biologics Adult growth hormone deficiency (AGHD) Ph 2 completed Ph 2 completed USA/EU

Biologics Pediatric growth hormone deficiency (PGHD) Ph 2 completed Ph 2 completed USA/EU

HANLIMPHARM.CO., LTD.

HL217 AMD EU Phase II USA, EU

HL237 Rheumatoid arthritis Phase II USA, EU

HL237A Liver transplantation Phase II USA, EU

HL237B Sjogren’s Syndrome Phase II USA, EU

Stafen Cap. Mixed hyperlipidemia Marketed Japan, South-East Asia

Belion CR Tab. Allergic rhinitis, Pruritus Marketed Japan, South-East Asia

Lumino-mark Inj. Breast lesion surgery marker Phase III USA, EU

Jakfas Tab. Rheumatoid arthritis MFDS Approval Japan, South-East Asia

69

Supplement



HanmiPharm.Co.,Ltd

Amosratan Amlodipine + Losartan Hypertension CV CIS

Amosartan Q Amlodipine + Losartan + Rosuvastatin

Hypertension& Hyperlipidemia CV LATAM

Amosartan PlusAmlodipine +

Losartan +Chlortahlidone

Hypertension CV LATAM

AmosartanXQ

Amlodipine + Losartan + Rosuvastatin +

EzetimibeHypertension

& Dyslipidemia CVEU

LATAMAPACEtc.

Rosuzet Rosuvastatin +Ezetimibe

Primary Hypercho-lesterolemia

& HyperlipidemiaCV LATAM, APAC,

AFRICA

Gugutams Tamsulosin +Tadalafil ED, BPH Urology CIS

LATAM

Monterizine Montelukast+Levocetirizine Asthma Rhinitis Respiratory

LATAMSEA

Hyalrheuma Hyaluronic acid Osteoarthritis OA EUMENA

Esomesol DR Esomeprazole Magnesium GERD, NSAID

Gastric ulcer GINA, EUAPACEtc.

HK inno.N

K-CAB Tab. (Tego-prazan)

Gastroesophageal reflux disease (GERD) Launched Phase 1

(Completed) Worldwide NCE

IN-A002Rheumatoid Arthritis,

Atopy dermatitis, Crohn’s disease, Ulcerative colitis,

Alopecia areta

Phase I(ongoing) N/A Worldwide NCE

IN-A010 NASH, Glaucoma, Diabetic nephropathy NA Phase II Asia NCD

EX-one R (Amlodipine + Valsartan + Rosuvasta-

tin)Hypertension/Hyperlipid-

emia Launched N/A Worldwide IMD

EX-one A(Amlodipine + Valsar-

tan + Atorvastatin)Hypertension/Hyperlipid-

emia Launched N/A Worldwide IMD

IN-B001(Vaccine)

Prevention of Hand, Foot & Mouth Disease

Phase I(ongoing)

Phase II(Planned) Worldwide Vaccine

IN-B009(Vaccine) Prevention of COVID19 Pre-clinical N/A Worldwide Vaccine

HYUNDAI Pharm.

HD-6277 Diabetes -Phase 2 IND

approved(US FDA)

Global

BPDO-1603 Alzheimer’s disease Phase 3 - Global

HDDO-1728 Alzheimer’s disease Formulation - Global

HDDO-1756 Hyperlipidemia Phase 1 - Global

HDDO-1801 Respiratory disease Phase 1 - Global

HDDI-1914 Surgery (hardening soft tissue) Pre-clinical - Global

ILDONG PHARMA-CEUTICAL CO., LTD.

Ophthalmology Age-related Macular Degeneration (AMD) Preclinical Global

Anti-cancer / CNSChronic Lymphocytic

Leukemia (CLL) / Relapsing form of Multiple Sclerosis

(RMS)- P3 / P2 Southeast Asia

70

Supplement



ISUABXIS

ISU104 Head and Neck Cancer Phase 1 Worldwide Anti-ErbB3 antibody

ISU305 Paroxysmal Nocturnal Hemoglobinuria

Phase 1(Australia/ New

Zealand)

Worldwide(excluding Russia/

CIS)Biosimilar to eculizum-

ab (Soliris®)

Abcertin® Gaucher’s Disease Phase 1(Australia) Worldwide Biosimilar to imiglu-

cerase (Cerezyme®)

Fabagal® Fabry’s Disease Phase 3 WorldwidePhase 3 is planned to be initiated in 2021; launched in Korea in

2014

JW Pharmaceutical

CWP232291Acute Myeloid Leukemia,

Multiple Myeloma, Gastric Cancer

Phase 1b(ongoing) - Global

URC102 Gout Phase 2b(ongoing) -

GlobalexceptChina

CWL080061 Alopecia - - Global


Clavixin®Duo Capsule antiplatelet Launched Global

Kalomin®Tab. Upper respiratory tract infections Launched Global

Losasc®Tab 5/50 Hypertension Launched Global

Levotics®CR Upper, chronic respiratory tract infections Launched Global

Fenorics®EH Tab Hyperlipidemia Launched Global

LG Chem, Ltd

LR19055 Autoimmune disease N/A Phase 3 ROW Antibody biosimilar

LR19074 Gout N/A Phase 2 Worldwide XO inhibitor

LR19019 Ulcerative colitis N/A Phase 2 Worldwide S1P receptor modula-tor

LR19021 Obesity N/A Phase 1 Worldwide MC4R agonist

Medytox

MT912 Macular Degeneration TBD TBD Global Biobetter

MT927 Immune Disorder TBD TBD Global Immune cell therapeu-tics

MT971 Inflammatory Bowel Disease TBD TBD Global Live Biotherapeutic

Product

MT981 Solid cancers TBD TBD Global Antibody New Drug

MT921 Fat Reduction Phase 2 clinical trial in progress TBD Global New Chemical Entity

OliX Pharmaceuti-cals,Inc.

OLX101A Hypertrophic Scar Phase 20n-going

Phase 20n-going(US)

Global(Excl. Asia)

OLX104C Androgenic Alopecia Preclinical Preclinical Global

OLX301A Dry & Wet AMD Preclinical Preclinical Asia-Pacific

OLX301D Subretinal Fibrosis Preclinical Preclinical Asia-Pacific

OLX701 Liver Fibrosis Preclinical Preclinical Global

OLX702 Liver Disease (NASH, Diabetes etc.) Preclinical Preclinical Global

OLX703 HBV Preclinical Preclinical Global

Pharmicell Co., Ltd. Cellgram-AMI Acute Myocardial Infarc-tion Launched - Global -

71

Supplement



Samyang Holdings Corpoation(Bio-pharmaceuticals

Business)

Polymer-basedparenteral DDS

Tech.Renal cell carcinoma Preclinical - US, EU Solubility

enhancing

Polymer-basedparenteral DDS

Tech.Cancer Ph 1 - US, EU

Solubilityenhancing,Sustained

release

Absorption enhancing oral DDS Tech. Emesis Preclinical - US, EU Bioavailability enhanc-

ing tablet

Fast dissolving oral DDS Tech. Allergy, Emesis Ph 1 (BEQ complet-

ed) - US, EU Fast dissolving tablet

Colon specific oral DDS Tech. IBD, IBS Preclinical (com-

pleted) - US, EU Colon specific delivery system

Oncolytic virus, nucleic acid delivery Tech. Cancer / Vaccine Preclinical Preclinical US, EU Stability enhanced

nano shells


Otaplimastat(SP-8203) Acute Ischemic Stroke Phase 2b

(On-going) - Global Combination with tPA

SP-8008 Anti-platelet -Phase 1(Europe)

(On-going) Global Oral,

less bleeding

SP-8356 Cerebro-cardiovascular diseases -

Phase 1(Europe)

(On-going)Global

Oral,enhanced vessel

elasticity

SP-8416 Heart failure Lead compound(On-going) - Global -

SP5M001 Osteoarthritis Phase 3 IND(completed) - Global Long-lasting viscosup-

plement

SP5M002 Osteoarthritis Phase 1/2 IND(On-going) - Global Rapid pain relief

viscosupplement

SP1M002 Osteoarthritis Non-clinical(On-going) - Global Anti-inflammatory

viscosupplement

TegoScience Rosmir® Improvement of Nasojugal

GroovesPhase II complet-ed & Marketing

approvedGlobal

Yungjin Pharm. Co., Ltd.

Respiratory Chronic Obstructive Pulmo-nary Disease Phase 2 Worldwide

Metabolic Mitochondrial Respiratory Chain Disorder Phase 1 Japan Licensed out to Abliva

Oncology Solid cancers, Hematologi-cal cancers Nonclinical Worldwide

Immunology Rheumatoid arthritis Phase 2 Korea

72

Supplement

Company Product name Active Ingredient Dosageform Indication International certification note

BMI Korea

Hitox Botulinum toxin vial improvement of facial wrinkles1) GMP Certificate

(by KFDA)2) EU GMP, cGMP

to be applied in 2022

Hirax Hyaluronidase vial Enhance drug permeation by subcutaneous injection

EU GMP, cGMPto be applied in 2022

BoryungPharmaceutical

co.,Ltd.

CefonInj.

Cefoperazone, Sulbact-am FP Antibiotics PMDA

FosomycinInj.

FosfomycinSalt FP Antibiotics PMDA

RoxithromycinTab. Roxithromycin FP Antibiotics PMDA

Gelfos ALPO 4 FP Gastrointestinal Taiwan FDA

Kanarb Fimasartan FP Cardiovascular Approved in 19 countries

Oxalitin Inj. Oxaliplatin FP Antineoplastic EU GMP, Thailand, Malaysia, Philippine, Syria EU GMP scheduled

Neoplatin Inj. Carboplatin FP Antineoplastic Thailand, Syria

AD Mycin Inj. Doxorubicin FP Antineoplastic Thailand, Malaysia, Philip-pine, Syria

VCS Inj. Vincristine FP Antineoplastic Thailand, Vietnam, Syria, Iran

Effcil Inj. 5-FU FP Antineoplastic Thailand

Alacepril Alacepril API Cardiovascular PMDA

Pitavastatin Pitavastatin API Cardiovascular PMDA

Fexofenadine Fexofenadine API Antihistamine PMDA

Aripiprazole Aripiprazole API Schizophrenia PMDA

Tamsulosin Tamsulosin API Urology System PMDA, Russia

Celltrion

Remsima SC Infliximab SCRheumatoidArthritis, Ankylsoing Spondylitis, Ulcerative Colitis,

Crohn's Disease, Psoriasis, psoriatic arthritis

EMA

Remsima Infliximab IVRheumatoidArthritis, Ankylsoing Spondylitis, Ulcerative Colitis,

Crohn's Disease, Psoriasis, psoriatic arthritis

EMA, FDA

Truxima Rituximab IV

Non-Hodgkin's Lymphoma, ChronicLymphocytic Leukemia,

Rheumatoid Arthritis,Granuloma-tosis with Polyangiitis,

Microscopic Polyangiitis

EMA, FDA

Herzuma Trastuzumab IVHER2-Positive Metastatic Breast-

Cancer, Early Breast Cancer,Metastatic Gastric Cancer

EMA, FDA

Yuflyma Adalimumab SC Rheumatoid Arthritis ,IBD, Lymphoma EMA

Temyxis Lamivudine, Tenofovir Tab. AIDS (Acquired ImmuneDeficien-cy Syndrome) FDA

Linezolid Linezolid Tab.Pneumonia, Skin and SkinStruc-

ture Infections,Vancomycin-resistant Enterococ-

cus faeciumInfectionsFDA

3. Certification from Health Authorities

73

Supplement


CKD Pharmaceuti-cal Corp.

Tacrolimus Cap. Tacrolimus0.5, 1, 5mg Cap. Immunosuppressant GMP Japan/MHLW

Ceftriazone sodium inj.

Ceftriaxone sodium 0.5, 1mg Inj. Antibiotics GMP Japan/MHLW

Cefazolin sodium inj.

Cefazolin sodium0,5, 1, 2mg Inj. Antibiotics GMP Japan/MHLW

Pengood Bacampicillin hydro-chloride Tab. Antibiotics GMP Japan/MHLW

Plant certification(Sterile/Non-ster-

ile drug)GMP Japan/MHLW

Myrept Tab. Mycophenolate Mofetil 500mg Tab. Immunosuppresant GMP

Sudan/National Medicines and Poisons Board

Gemtan inj. Belloxa Inj.

Gemcitabin 200mg, 1g/Oxaliplatin 50, 100mg Inj. Anticancer GMP

Sudan/National Medicines and Poisons Board

Cypol Soft Cap, Cypol Oral Solu-

tionCyclosporin 25, 100mg,

100mg/mL Cap. Immunosuppresant GMPThailand/

Thailand Food and Drug Administration

Gemtan inj. Gemcitabin 1g Inj. Anticancer GMPKazakhstan

/Ministry of Health, Republic of Kazakh-

stan

Tacrobell Cap. Myrept tab.

Cypol Soft Cap.

Tacrolimus 0.5, 1.0mg/Mycophenolate

Mofetil 500mg/ Cyclo-sporin 25, 100mg

Cap./Tab. Immunosuppresant GMP

Philippine /Philip-pine Food and Drug

Administration

Tazoperan Inj. Tazobactam 0.5g, Piperacillin 4.0g Inj. Antibiotics GMP

Philippine /Philip-pine Food and Drug

Administration

Plant certification(Biologic drug) GMP Japan/MHLW

Daehwa Pharma-ceutical Co., Ltd.

Almetamin tab.Betamethasone,

Dexchlorpheniramine maleate

Tablet Acute urticaria and others Ethiopia and others / PICs

Kebanon plaster Ketoprofen Plaster Muscular pain Asian / PICs

Demacot creamBetametasone dipro-pionate, Clotrimazole,

Gentamicin sulfateCream

Allergic dermatitis, alopecia areata, first degree burn, derma-

tomycosisAsian and Africa / PICs

Protase tab. Crystalized trypsin, Bromelain Tablet

Fracture, sprain, internal, external and incarcerated hem-orrhoid after proctoptosis and a hemorrhoidal surgery, stagnant

breast, mammitis, hematoma and thrombosis

Asian / PICs

Top-rollsoft cap.

Ginseng powder and others

Soft capsule

Tonics and nutritional supple-mentation Qatar / PICs

Daewoong Phar-maceutical

Nabota Botulinum toxin Type A Injection Treatment of wrinkles between the eyebrows cGMP, EU-GMP, Canada GMP

Ursa Ursodeoxycholic acid Tablet, Capsule

Cholestasis (including PBC, PSC), viral hepatitis C, gallstone PIC/S GMP

Olostar Olmesartan/Rosuvas-tatin Tablet Concomitant hypertension and

dyslipidemia PIC/S GMP

Luphere Leuprorelin Acetate Depot Injection

Prostate cancer, endometriosis, uterine fibroid, postmenopausal breast cancer, central precocious

pubertyPIC/S GMP

EasyefRecombinant human Epidermal Growth

FactorSolution Diabetic foot ulcer PIC/S GMP

Caretropin Recombinant human growth hormone PFS Growth hormone deficiency and

Turner syndrome PIC/S GMP

Eposis Recombinant human Erythropoietin α PFS Anemia in end stage renal

disease (ESRD) PIC/S GMP

74

Supplement


DongKoo Bio&-Pharma

Pharmaceuticals -Tablets, Capsule, Cream,

Ointment- Taiwan GMP registered Certified

Feb. 2018

Pharmaceuticals -Tablets, Capsule, Cream,

Ointment- Vietnam GMP registered Certified

Nov. 2019

Pharmaceuticals -Gel,

Cream, Ointment

- Iran GMP registered CertifiedApril. 2020

Dongkook Pharma-ceutical

Pofol Injection Propofol Injection General anesthetic, sedation Brazil GMP, Ukraine GMP Japan(PMDA) GMP

Alostin Injection Alprostadil InjectionImprovement of limb ulcer and resting pain in chronic arterial obstruction (Burger's disease, obstructive arteriosclerosis)

Japan(PMDA) GMP

Teicon Injection Teicoplanin Injection Antibiotic Japan(PMDA) GMP

- Teicoplanin

Active Pharma-ceutical Ingredi-

ent

Antibiotic Japan(PMDA)

Accredited Foreign Manu-

facturers (Sterile/Non-sterile drug)

- - - Japan(PMDA)

Handok Inc.

Amaryl M SR2/500mg Glimepiride Metformin Tablet Type II diabetes ANVISA

Ukraine-PIC/S

Amaryl M 2/500mg Glimepiride Metformin Tablet Type II diabetes

Russia GMPINVIMA, ANVISA

MCC–PIC/SUkraine -PIC/STaiwan-PIC/S

Philippines-PIC/S

Amaryl M 1mg/250mg Glimepiride Metformin Tablet Type II diabetes

ANVISA,MCC–PIC/S

Ukraine -PIC/S

Esperson oint.0.25%

Desoxymethasone Semi-solid

Semi- solid

Corticosteroid-responsive derma-toses

Taiwan(PIC/S)

Daonil tab. Glibenclamide Tablet Type II diabetes

Lasix tab. Furosemide Tablet Edema., Hypertensionos

Surgam tab. 200mg Tiaprofenic acid Tablet

Rheumatoid Arthritis, Osteoar-thritis,

Ankylosing spondylitis, Backache

Roxan Capsule Roxatidine acetate HCl CapsuleStomach ulcer,Duodenal ulcer,

Reflux esophagitis

Frisium tab.10mg Clobazam Tablet Epilepsy

KETOTOP Plaster Ketoprofen Plaster

Degenerative arthritis (Osteo-arthritis), Periarthritis, humeral

epicondylitis (tennis elbow etc.), Peritendinitis, tendinitis, ten-

dovaginitis, myalgia, post-trau-matic swelling/pain

Russia GMPTaiwan(PIC/S)

Philippines(PIC/S)

75

Supplement


HanmiPharm. Co.,Ltd

Gugu Tadalafil Tab. Erectile Dysfunction PMDA (Japan) Global Smart Plant

Lozap AM Amlodipine +Losartan Tab, Hypertension Russia GMP Global Smart Plant

Hyalrheuma Hyaluronic acid Inj, Osteoarthritis US FDA(cGMP) Bioplant

Esomeprazole API GI US FDA(cGMP) Hanmi Fine Chem.

Cefotaxime API Antibiotics EU GMP Hanmi Fine Chem.

Ceftriaxone API Antibiotics EU GMP Hanmi Fine Chem.

Ceftazidime API Antibiotics EU GMP Hanmi Fine Chem.

Ceftizoxime API Antibiotics PMDA (Japan) Hanmi Fine Chem.

Raloxifene API Osteoporosis PMDA (Japan) Hanmi Fine Chem.

Losartan API CV PMDA (Japan) Hanmi Fine Chem.

HK inno.N

Best-Call® Cefmenoxime Hcl Inj. Infection Japan GMP Inspection

Supply APIs to a Japanese CompanyFirstcin® Cefozopran Hcl Inj. Infection Japan GMP Inspection

Pan-Sprorin® Cefotiam Hcl Inj. Infection Japan GMP Inspection

Banan® tab. Cefopodoxime Tab. Infection Japan GMP InspectionSupply bulk-prod-

ucts to a Japanese companyBanan®

dry syrup Cefopodoxime Syrup Infection Japan GMP Inspection

Ceftazidime inj. Ceftazidime Inj. Infection Japan DMF

Ceftriaxone inj. Ceftriaxone Inj. Infection Japan DMF

ILDONG PHAR-MACEUTICAL CO.,

LTD.

Biovita Probiotics & Vitamin Granule Probiotic Digestion and Vitamin Supplement for babies USA

Xelobig Capecitabine Tablet Breast cancer, colon cancer, rectal cancer

PAKISTAN,MYANMAR

Algik Pemetrexed Injection Pleural mesothelioma, Non-small cell lung cancer PAKISTAN

Vicure Entecavir Tablet Hepatitis B virus (HBV) infection

AZERBAIJANPERU

MONGOLIAHONG KONG

Memanto Memantine Tablet Moderate-to-severe Alzheimer's disease

PHILIPPINES MYANMAR

N/A Fursultiamine HCl API Vitamins JAPAN

N/A Topiramate API Anticonvulsant drug material JAPAN

ISU ABXIS

Abcertin® Imiglucerase Injection Gaucher’s Disease Iran GMPIran MOHME

20142015

Abcertin® Imiglucerase Injection Gaucher’s Disease Mexico GMPMexico MOH

20142015

Abcertin® Imiglucerase Injection Gaucher’s Disease Russian GMP 2019

76

Supplement


JW Pharmaceuti-cal

Prepenem Inj.Imipenem monohydrate

andCilastatin sodium

Injection Antibiotics PMDA

Pospenem Inj. Meropenem trihydrate Injection Antibiotics ANVISA

Itraconazole SD Itraconazole API Fungal Infection PMDA

Toracona tab Itraconazole Tablets Fungal Infection PMDA

ImipenemMixture

Imipenem monohydrate and Cilastatin sodium APi Antibiotics COFEPRIS

MeropenemMixture Meropenem trihydrate API Antibiotics COFEPRIS

Montelukasttab. Montelukast sodium Tablets

asthma symptoms and to relieve the symptoms of seasonal

allergiesPMDA

Bosentan tab. Bosentan API Treatment of pulmonary arterial hypertension PMDA

Olanzapine Tab. Olanzapine Tablet Treatment of schizophrenia PMDA

Finasteride Tab. Finasteride Tablet Treatment of male pattern alope-cia PMDA

Korea Otsuka Phar-maceutical Co.,

Ltd.

Rebamipide Rebamipide API gastritis, gastric ulcer PMDA

Cilostazol Cilostazol API cerebral infarction, etc. FDA, PMDA

Abilify OD tablet Aripiprazole OD tablet schizophrenia, etc. EMA, MHRA, TFDA, FDA Philippines

Abilify Oral solution Aripiprazole oral

solution schizophrenia, etc. EMA, MHRA, FDA Philip-pines

Abilify tablet Aripiprazole tablet schizophrenia, etc. FDA Philippines

Pletaal tablet Cilostazol tablet cerebral infarction, etc. FDA Philippines, NPCB

Pletaal SR cap-sule Cilostazol capsule cerebral infarction, etc. FDA Philippines

Mucosta Rebamipide tablet gastritis, gastric ulcer DRAP, NPCB, FDA Philippines

Samsca Tolvaptan tablet hyponatremia, ADPKD FDA Philippines, BPOM

Korea United Pharm. INC. Clanza®CR Aceclofenac Tab inflammation, pain RussiaGMP

MedytoxNeuronox,Meditoxin,

Siax etc.

Clostridium botulinum toxin typeA(Hall strain)

Biophar-maceu-

tical prod-

ucts(Lyo-philized powder

for injection,

Injec-tions)

1. benign essential blepharo-spasm

2. equinus foot deformity due to spasticity

3. serious glabellar wrinkles ranging from moderate to severe

associated with corrugator muscle and/or procerus muscle

activities 4. upper limb spasticity associat-

ed with stroke 5. moderate to severe lateral

canthal lines (crow’s feet lines) associated with orbicularis

muscle activities 6. cervical dystonia

Brazil GMP Colombia GMP

Iran GMPSaudi Arabia GMP

etc.

Samyang Holdings Corpoation(Bio-pharmaceuticals

Business)

Paclitaxel Inj. Paclitaxel Injection Ovarian cancer, Breast cancer, NSCLC, Gastric cancer EU GMP

Docetaxel Inij. Docetaxel InjectionBreast cancer, NSCLC, Esopha-

geal cancer, Ovarian cancer, H&N cancer, Gastric cancer, Prostate

cancerEU GMP

Pemetrexed Inj. Pemetrexed Injection NSCLC, Mesothelioma EU GMP

Oxaliplatin Inj. Oxaliplatin Injection Colorectal cancer, Gastric cancer EU GMP

Azacitidine Inj. Azacitidine Injection MDS, AML, CMML병 EU GMP

77

Supplement



Pyramax® Tablets Pyronaridine tetraphos-phate, Artesunate Tablets Anti-malarial EU GMP Certification

Pyramax® Gran-ules

Pyronaridine tetraphos-phate, Artesunate Granules Anti-malarial

(Pediatric formulation) EU GMP Certification

Medicurtain®

InjectionSodium hyaluronate,Hydroxyethyl starch Injection Anti-adhesion

(Surgery) CE Certification

Hyalforte®

Injection Sodium hyaluronate Injection Osteoarthritis CE Certification

API

Clopidogrel bisulfate API Anti-platelet PMDA

Celecoxib API NSAID PMDA

Loxoprofen sodium API NSAID PMDA

Telmisartan API Hypertension PMDA

Sulbactam sodium API Anti-biotic PMDA

Valsartan API Hypertension PMDA

Irbesartan API Hypertension PMDA

Fosfomycin API Anti-biotic PMDA

Cilostazol API Antithrombotic PMDA

SK Chemicals Co., Ltd.

Omed omeprazole Tablet Gastric Ulcer EU GMP

Wondron Patch rivastigmine Patch Alzheimer Dementia EU GMP

Taejoon Pharma-ceutical Co., Ltd.

Xalost Latanoprost Solution Anti-glaucoma EU GMP, ANVISA, NAFDAC certification

Xalost Plus Latanoprost, Timolol Maleate Solution Anti-glaucoma EU GMP certification

TegoScience

Holoderm® AutologousKeratinocytes

-Deep 2nd

degree burn over 30% of TBSA

Cell Therapy Product(Prescription Medicine) Global

Kaloderm® Allogeneic Keratino-cytes

-3nd degree

burn over 10% of TBSA


Rosmir® Autologous Fibroblasts

Improve-ment of Naso-jugal

Grooves


78

Supplement


Yuhan Corporation

API1 API1 - Antiviral USFDA, TGA, PMDA



API4 API4 - Antiviral USFDA



API7 API7 - Immunosuppressant USFDA

Piperacillin Monohydrate

Piperacillin Monohy-drate - Antibiotic USFDA, TGA, EDQM

Rosuvastatin Ca. Rosuvastatin Ca. - Antihyperlipidemic PMDA

Cilostazol Cilostazol - Antiplatelet PMDA

Levofloxacin Levofloxacin - Antibiotic PMDA

YungjinPharm.Co.,Ltd.

Cefaclor Cefaclor Monohydrate Capsule Infection PMDA

Cefmetazole Cefmetazole Sodium API Infection PMDA

Cefotiam Cefotiam HCl API Infection PMDA

Cefdinir Cefdinir API, Tablet Infection PMDA

Cefditoren Cefditoren Pivoxil API, Dry syrup Infection PMDA

Ceftriaxone Ceftriaxone Sodium Inj. Infection PMDA

Cefcapene Cefcapene Pivoxil HClAPI,

TabletFine

GranuleInfection PMDA

Caftazidime Caftazidime Pentahy-drate

API, Injection Infection PMDA

Cefpodoxime Cefpodoxime ProxetilAPI, Tab-let, Fine Granule

Infection PMDA

Candesartan Candesartan Cilexetil API Cardiovascular Agents PMDA

Loxoprofen Loxoprofen Sodium API Antipyretics and analgesics, anti-inflammatory agents PMDA

Rosuvastatin Rosuvastatin Calcium API Cardiovascular Agents PMDA

Febuxostat Febuxostat API Hyperuricemia TDMF

79

memo

80

2021

혁신형

제약기업

디렉토리북

Supported by

Korea Innovative Pharmaceutical Company

Documents

Korea Innovative PHARMACEUTICAL Company